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FAR-PL-01 Orthosteric and Allosteric Ligands Selectively 
Acting at Cholinergic Receptor Subtypes 
 
Marco De Amici, Clelia Dallanoce, Giovanni Grazioso, Carlo De Micheli 
 
Dipartimento di Scienze Farmaceutiche “Pietro Pratesi” dell’Università degli Studi  
di Milano, Via L. Mangiagalli 25, 20133 Milano, Italy  
marco.deamici@unimi.it 
 
The presentation will focus on the results recently achieved by our research 
group in the design, synthesis and pharmacological evaluation of selective ligands 
which target cholinergic receptor subtypes, belonging to both the nicotinic 
(nAChR) and the muscarinic (mAChR) acetylcholine receptor families. 
A set of spirocyclic derivatives will be illustrated, in which the simultaneous 
presence of the quinuclidinyl and 2-isoxazolinyl moieties, coupled with suitable 
stereoelectronic features of the substituent at position 3 of the spirocyclic ring, 
engendered a selective agonist profile at the homomeric neuronal 7 nAChRs [1]. 
The most promising compound in the series has been further investigated in 
preclinical studies and in in vivo models of CNS disorders and neuropathic pain. A 
group of novel hybrid peptides structurally related to natural -conotoxins MII and 
PIA will be also presented, which behave as competitive antagonists able to 
discriminate 62* and 32* nAChR subtypes [2]. 
The five mAChR subtypes bind their physiological transmitter in the highly 
conserved orthosteric site within the transmembrane domains of the receptors. 
Orthosteric muscarinic agonists have negligible binding selectivity and poor 
signaling specificity. A less conserved allosteric site has been also characterized at 
the extracellular entrance of the binding pocket of mAChRs. To gain subtype-
selective M2 receptor activation, we designed a group of putative bitopic 
compounds, i. e. hybrid derivatives fusing highly potent, unselective oxotremorine-
like orthosteric activators with M2-selective bis(ammonio)alkane-type allosteric 
fragments. The new ligands interacted simultaneously with both recognition areas 
of the receptor protein, thus allowing the exploitation of favorable features of the 
orthosteric and the allosteric site by a single ligand molecule. The orthosteric 
interaction provided high affinity binding and activation of M2 mAChRs. The 
allosteric interaction yielded receptor subtype-selectivity and, in addition, could 
modulate efficacy and activate pathway-specific intracellular signaling [3]. 
 
[1] C.Dallanoce, P.Magrone, C.Matera, F.Frigerio, G.Grazioso, M.De Amici, 
S.Fucile, V.Piccari, K.Frydenvang, L.Pucci, C.Gotti, F.Clementi, C.De 
Micheli, ChemMedChem, 6, 2011, 889-903. 
[2] M.De Amici, G.Grazioso, C.Dallanoce, C.De Micheli et al.,  submitted. 
[3] K.Mohr, C.Tränkle, E.Kostenis, E.Barocelli, M.De Amici, U.Holzgrabe, 
Br.J.Pharmacol., 159, 2010, 997-1008. 
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FAR-PL-02 Modulation of Hydrolysis of Fatty Acid 
Ethanolamides: Rational Drug Design for Novel Therapeutic 
Opportunities 
Marco	Mor		
Dipartimento Farmaceutico, Università degli Studi di Parma, Viale Usberti 27/a, 
43124 Parma, Italy 
marco.mor@unipr.it 
 
Fatty acid ethanolamides (FAEs) are a class of bioactive lipids, the effects and 
metabolism of which can be modulated by new compounds with potential 
application in different therapeutic areas, e.g. the treatment of pain and 
inflammation. Two relevant members of this family are anandamide, an 
endocannabinoid,  and palmitoylethanolamide 
(PEA), endowed with anti-inflammatory activity. 
Selective control of their levels may be achieved 
through the design of new compounds, either 
affecting FAE metabolism at different levels or 
having tissue-selective distribution. 
This lecture will focus on the development of 
carbamate-based inhibitors of Fatty acid amide 
hydrolase (FAAH), and of the first potent and 
selective inhibitors of N-acylethanolamine-
hydrolyzing acid amidase (NAAA). Starting from the well-known FAAH inhibitor 
URB597, through the study of its inhibition mechanism by molecular modelling [1] 
and of structure-reactivity relationships we developed p-hydroxy derivatives with 
improved in vivo properties. This class includes URB937, a peripherally-restricted 
FAAH inhibitor with remarkable analgesic activity [2]. 
NAAA is a lysosomal enzyme which preferentially hydrolyzes PEA. Homology-
based models, supported by mutagenesis studies, helped the discovery of a new 
class of NAAA inhibitors, including the stereoselective compound (S)-OOPP [3]. 
This compound showed remarkable anti-inflammatory activity and allowed a better 
characterization of the role of NAAA activity in inflammation. 
 
[1] A. Lodola, L. Capoferri, S. Rivara, E. Chudyk, J. Sirirak, E. Dyguda-
Kazimierowicz, W. Andrzej Sokalski, M. Mileni, G. Tarzia, D. Piomelli, M. Mor, 
A.J. Mulholland, Chem.Commun. 47, 2011, 2517-2519. 
[2] J.R. Clapper, G. Moreno-Sanz, R. Russo, A. Guijarro, F. Vacondio, A. Duranti, 
A. Tontini, S. Sanchini, N.R. Sciolino, J.M. Spradley, A.G. Hohmann, A. 
Calignano, M. Mor, G. Tarzia, D. Piomelli, Nature Neurosci. 13, 2010, 1265-1270. 
[3] C. Solorzano, C. Zhu, N. Battista, G. Astarita, A. Lodola, S. Rivara, M. Mor, R. 
Russo, M. Maccarrone, F. Antonietti, A. Duranti, A. Tontini, S. Cuzzocrea, G. 
Tarzia, D. Piomelli, Proc. Natl. Acad. Sci. U S A 106, 2009, 20966-20971 
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FAR-PL-03 Advances in the Characterization of New 
Challenging GPCRs 
 
Gloria Cristalli  
 
School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. 
Agostino 1, 62032 Camerino, Italy.  
gloria.cristalli@unicam.it 
 
Purinergic receptors are classified in P2X, a ligand-gated ion channel family, 
activated by ATP and ADP, and P1 and P2Y, two G protein-coupled receptor 
(GPCR) families, activated by adenosine and purine/pyrimidine nucleotides, 
respectively. They are widely distributed in the body and involved in several 
cellular functions, most of them still poorly understood, although in recent years a 
number of clinical applications of purinergic receptor ligands have been proposed 
and few compounds are already on the market or in clinical trials.  
Purinoceptor families include also purinergic-like receptors, which need to be 
better characterized and, between them, the recently deorphanized GPR17 seems to 
be dually activated by uracil nucleotides and cysteinyl-leukotrienes. GPR17 was 
found to be highly expressed in organs typically undergoing ischemic damage, thus 
representing a potential target for new therapeutic approaches to acute and chronic 
neurodegenerative diseases. 
Characterization of this receptor has been performed on transfected 1321N1 cells 
by using [35S]GTPγS binding assay. Known and newly synthesized nucleotides 
were screened and proved to behave as ligands for this receptor with a wide range 
of activity. Moreover, an innovative and non-radioactive functional cAMP assay 
was validated, which showed a strong correlation with the data obtained with 
[35S]GTPγS binding assay and confirmed that GPR17 is coupled with a Gαi [1]. 
Furthermore, specific binding sites for [3H]-guanosine, which are not recognized by 
other purinergic receptor ligands, were detected on membrane preparations from rat 
brain. These findings supported the hypothesis of the existence of a specific GPCR 
for guanosine that could account for the actions played by this naturally occurring 
purine nucleoside. An innovative assay was optimized for the characterization at rat 
brain membranes of the putative guanosine binding site by using a series of known 
and novel guanosine derivatives, prepared by modifying the purine and the sugar 
moiety of guanosine. Results of these experiments proved that guanosine, 6-
thioguanosine, and their derivatives activate a new GPCR, which is different from 
the well characterized adenosine receptors [2]. 
 
[1] M. Buccioni, G. Marucci, D. Dal Ben, D. Giacobbe, C. Lambertucci, L. Soverchia, A. 
Thomas, R. Volpini, G. Cristalli, Adv. Pharmacol. Sci., in press. 
[2] R. Volpini, G. Marucci, M. Buccioni, D. Dal Ben, C. Lambertucci, C. Lammi, R.C. Mishra, A. 
Thomas, G. Cristalli, ChemMedChem., DOI: 10.1002/cmdc.201100100, VIP (the paper was 
judged to be very important by the referees).  
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FAR-PL-04 Multidisciplinary and Multitarget Approaches in 
the Search for Novel Drugs in the Treatment of Neurodegenerative 
Diseases  
 
Angelo Carotti  
 
Department of Medicinal Chemistry, University of Bari “Aldo Moro”, Via 
Orabona 4, I-70125 Bari, Italy. E-mail: carotti@farmchim.uniba.it 
 
Research in medicinal chemistry has recently shifted towards the design of 
multitarget/multipotent agents that, interfering with different biological pathways 
critical for either the onset or the progression of a given disease, may have higher 
therapeutic benefits compared to  single-target–selective drugs [1,2]. Multitarget 
ligands would be simpler to develop in a clinical setting and present lower risks of 
drug-drug interactions compared to multicomponent drugs and drug combinations. 
On the other hand, the design and optimization of multiple ligands exhibiting high 
and, more importantly, well-balanced affinities at selected targets, is quite a 
daunting task. 
Within this challenging scenario, we developed new multitarget ligands 
which act as reversible, dual MAO-B and acetylcholinesterase (AChE) inhibitors 
[3,4] or as ChE inhibitors and beta-amyloid (A) anti-aggregating agents [5], with 
the potential for treating Alzheimer’s disease (AD) [6]. 
In a parallel research, we have been working along the amyloid hypothesis of AD 
that has led to a deeper understanding of the pathology of AD and has provided 
insight into the design of novel potential drugs [7]. According to this hypothesis, 
the increase of Aβ production and aggregation into low-molecular weight 
oligomers, fibrils and, ultimately, amyloid plaques are the leading cause of AD. 
The reduction of both Aβ formation (with β- and -secretase modulators) [8] and 
aggregation and the increase of Aβ clearance (with active and passive 
immunization) [9] are promising therapeutic strategies for AD. Pursuant to the 
development of a fast spectrofluorimetric method for the kinetic analysis of Aβ 
aggregation [10], a screening of medium-sized molecular libraries was carried out 
and several classes of novel anti-aggregating agents, including two anticancer 
drugs, have been discovered.[11,12] The optimization of the most interesting 
molecules afforded compounds  capable of blocking Aβ-fibril formation at a sub-
micromolar concentration. Spectroscopic, analytical and biophysical methods have 
been used to elucidate the inhibition mechanism of Aβ aggregation. Among them, 
capillary electrophoresis proved particularly efficient to detect the oligomeric 
species targeted by the compounds blocking A fibril formation.[12] Finally, 
molecular dynamics simulations on carefully conceived model systems have shed 
light on A fibril formation and on how small molecules may hinder the early 
phase of A aggregation.[13] 
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FAR-KN-01 Furthering the Understand of Polypharmacology 
in Nuclear Receptor Superfamily. 
 
Antonio Macchiarulo, Marco Cellanetti, Andrea Carotti, Roberto Pellicciari 
 
Dipartimento di Chimica e Tecnologia del Farmaco, Università degli Studi di 
Perugia, Via del Liceo 1, 06123, Perugia. 
Email: antonio@chimfarm.unipg.it 
 
Recent years have seen an increasing awareness that drugs often bind to more than 
one molecular target, exhibiting polypharmacology [1]. Although this aspect has 
commonly been considered as undesirable promiscuity being responsible for 
unwanted side effects, in many cases it is a key component to the therapeutic 
efficacy of drugs [2]. The knowledge on polypharmacology can therefore aid the 
explanation of why some drugs work better than expected, or why other drugs have 
diverse side effects, albeit acting on the same target. 
Polypharmacology is the result of poor ligand specificity that combines with 
protein promiscuity [3]. Accordingly, in order to further the understand of 
polypharmacology, both ligand-based and protein-based computational techniques 
are being developed that provide predictions of proteins to which ligands are likely 
to bind [4].  
In this communication, we investigate aspects of polypharmacology in the 
superfamily of human nuclear receptors (NRs). Human NRs comprise 48 members 
of ligand-dependent transcription factors that offer important druggable targets for 
therapeutic interventions in multiple disease areas [5]. Many NRs are promiscuous 
with respect to the wide range of ligands that act as modulators, and many NR 
modulators are not specific with respect to the number of NRs they bind.  
The construction of a target-centric chemical space [6, 7] and the application of 
integrative approaches are discussed as instrumental in charting key components 
and interactions of NR binding sites, with the aim of aiding the rationalization and 
optimization of selectivity and/or multi-target profile of selected NR ligands. 
 
 
[1] A.L. Hopkins, Nature. 462, 2009, 167. 
[2] M.J. Keiser MJ, J.J. Irwin, B.K. Shoichet, Biochemistry, 49, 2010, 10267. 
[3] A. Macchiarulo, I. Nobeli, J.M. Thornton, Nat. Biotechnol., 22, 2004, 1039. 
[4] A.D. Boran, R. Iyengar, Curr. Opin. Drug Discov. Devel. 13, 2010, 297. 
[5] A. Aranda, A. Pascual, Physiol. Rev. 81, 2001, 1269. 
[6] A. Macchiarulo, R. Pellicciari, J. Mol. Graph. Model. 26, 2007, 728.  
[7]     A. Macchiarulo, R. Nuti, G. Eren, R. Pellicciari, J. Chem. Inf. Model. 49, 
2009, 900.  
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antagonists 
Spalluto Giampiero,a Stephanie Federico,a Giorgia Pastorin,b Barbara 
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Ferrara; dInstitut für Pharmakologie, Universität of Würzburg, D-97078 Würzburg, 
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Padova 
e-mail: spalluto@units.it 
 
Blokade of adenosine receptors (ARs) is largely responsible for the broad variety of 
effects in several organ systems permitting to consider that regulation of ARs has 
substantial therapeutic potential. In antagonists field several classes of heterocyclic 
derivatives have been reported as ARs antagonists with high levels of both affinity 
and selectivity. In particular our group in the last years deeply investigated the 
nucleus of triazolo-pyrazolo-pyrimidine as ARs antagonists. Modulating the 
substitution at the N5, N7 and N8 positions potent and selective A2A (1) and A3 (2) 
ARs antagonists have been synthesized.[1] Nevertheless this class of compounds, 
such as other tricyclic structures, showed several problems such as poor water 
solubility and most importantly tangled synthetic preparation. 
On these bases we focused our attention versus the optimization and a 
simplifications of this nucleus in order to avoid the problems related to this 
structure. All the obtained results will be summarized. [2,3] 
 
[1] Moro, S.; Gao, Z.G.; Jacobson, K.A.; Spalluto, G. Med. Res. Rev. 2006, 26, 131-159. 
[2] Cheong, S.L.; Dolzhenko, A.; Kachler, S.; Paoletta, S.; Federico, S. et al. J. Med. Chem. 
2010, 53, 3361-3375. 
[3] Federico, S.; Paoletta, S.; Cheong, S.W:; Pastorin, G. et al. J. Med: Chem. 2011, 54, 877-
889. 
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discovery 
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Immobilised enzyme reactors (IMERs) have proven to be a useful and economic 
alternative to conventional in-solution methods, when increased reliability, 
automation and fast data output are required. In particular, considering the high 
cost and difficulty in over-expression, isolation and purification of recombinant 
enzymes, this analytical technique represents an extremely useful approach to 
preserve the activity when a small amount of enzyme is available. In the IMER 
format, enzymes are ready to be reused and can be coupled to chromatographic 
systems and appropriate detectors (UV-Vis, MS, FL). This coupling generally 
increases automation, reproducibility and analyses accuracy and reduces sample 
handling and operator time consumption. 
In the field of drug discovery, IMERs can be reliably applied to different phases of 
the drug discovery pathway, i.e., to rapidly screen for potential drugs candidates 
(lead selection), to characterize the mode of action at specific targets and perform 
SAR studies (lead optimization), and to determine ADMET parameters (early 
ADMET studies). In fact, in a second stage following the screening step, selected 
hits need to be further characterized in terms of mechanism of action and kinetic 
parameters.  
In this talk, a few IMERs applications will be presented, useful in all the steps of 
drug discovery and development. At this regard, acetyl-, butyryl-cholinesterase and 
BACE-1 (beta secretase) immobilized reactors were validated for the screening and 
determination of the mechanism of action and inhibitory constants of new leads for 
the treatment of Alzheimer’s disease in a highly reliable and automated mode. 
Remarkably, besides representing valid tools to screen new reversible inhibitors, 
immobilized reactors were also used to characterize pseudo-irreversible inhibitors. 
In drug development stage, the monolithic disk-shaped mini-columns (2 mm x 6 
mm I.D.) containing immobilized 2D6 and 3A4 isoforms of cytochrome  P450 
were developed as tools for phase I drug metabolism studies, for the early estimates 
of the drug metabolism, toxicity and possible drug-drug interactions. 
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FAR-KN-04 From the central benzodiazepine receptor to the 
adenosine receptors exploiting the 3-diketoindole moiety. 
 
Barbara Cosimelli 
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The first non-xantinic antagonists at the adenosine receptors (ARs) were 
reverse agonists at the benzodiazepine receptor (BzR) showing SNC stimulating 
properties [1]. 
Some time ago our research group disclosed 3-aryl[1,2,4]triazino[4,3-
a]benzimidazol-4-(10H)-ones as A1 AR antagonists designed by modifying 
analogous compounds binding to the BzR [2]. 
Following a similar approach, we have more recently investigated indol-3-
ylglyoxylyamides as potential AR antagonists starting from previously reported 
chemically analogous BzR ligands. As a reference compound we selected the high 
affinity indol-3-ylglioxylylbenzylamide (1) which was modified taking into 
account pharmacophore-based and modelling studies (Fig. 1) [2]. 
In this lecture, the design, synthesis and biological activity of a number of 
new compounds featuring the 3-diketoindole moiety will be presented. 
 
 
 
[1] J. E. Francis, W.D. Cash, S. Psychoyos, G. Ghai, P. Wenk, R.C. Friedmann, C. 
Atkins, V. Warren, and P. Furness, J.Med.Chem., 31, 1988, 1014. 
[2] F. Da Settimo, G. Primofiore, S. Taliani, A.M. Marini, C. La Motta, E. 
Novellino, G. Greco, A. Lavecchia, M.L: Trincavelli, and C. Martini, 
J.Med.Chem., 44, 2001, 316. 
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Contino, Carmela Inglese, Mauro Niso, Roberto Perrone 
 
Dipartimento Farmacochimico, Universitá degli Studi di Bari, via 
Orabona,4, 70125, Bari, Italy 
colabufo@farmchim.uniba.it 
 
ABC transporters, in particular P-gp, BCRP, and MRPs are highly expressed 
in various physiological barriers such as blood-brain barrier, blood-testis 
barrier, blood-tumor barrier [1]. They modulate the accumulation of various 
drugs by active efflux transport. It has been demonstrated that changes in 
ABC transporter expression and function are involved in various 
neurodegenerative pathologies such as Alzheimer’s and Parkinson’s disease 
as well as epilepsy [2]. Moreover, the overexpression of these transporters in 
tumour cells causes Multidrug Resistance. PET radiotracers allow a noninvasive 
in vivo imaging of transporter function and expression. Recently 
several probes have been developed but their unfavorable pharmacodynamic 
and pharmacokinetic properties limited the in vivo investigation [3]. The 
design of new imaging probes to visualize efflux transporters is complicated 
by the overlapping substrate recognition pattern of different ABC 
transporter types. Three probes for PET analysis displaying favorable 
preclinical studies will be presented: 
- [11C]MC266, a P-gp substrate, to image the pump activity; 
- [11C]MC18, a P-gp inhibitor, to detect the pump expression; 
- [11C]MC113, a P-gp substrate, to identify chemosensitive and chemoresistant 
tumors [4] 
 
 [1] W. Löscher, H. Potschka, Prog. Neurobiol. 76, 2005, 22. 
[2] N.A. Colabufo, F. Berardi, M. Cantore, M. Contino, C. Inglese, M. Niso, 
R. Perrone, J. Med. Chem. 53, 2010, 1883. 
[3] F. Bauer, C. Kuntner, J.P. Bankstahl, T. Wanek, M. Bankstahl, J. Stanek, 
S. Mairinger, B. Dörner, W. Löscher, M. Müller, T. Erker, O. Langer O. 
Bioorg Med Chem. 18, 2010, 5489. 
[4] A. Van Waarde, N.K. Ramakrishnan, A.A. Rybczynska, P.H. Elsinga, F. 
Berardi, J.R. de Jong, C. Kwizera, R. Perrone, M. Cantore, J.W.A. Sijbesma, 
R.A. Dierckx, N.A. Colabufo, J. Med. Chem. 523, 2009, 4524 
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potent and selective non-hydroxamic matrix metalloproteinases 
inhibitors 
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In the last 20 years, a great variety of synthetic, low molecular weight MMP 
inhibitors (MMPIs) have been synthesized and tested, and some of them entered 
phase III clinical trials as anticancer drugs, although none has reached clinical 
utility. A general structure for an effective MMP inhibitor includes a zinc-binding 
group (ZBG) capable to bind the catalytic zinc (II) ion of these proteinases, at least 
one functional group that provides crucial H-bonding interactions with the enzyme 
backbone and one or more side chains giving rise to effective van der Waals 
interactions with the enzyme subsites.  
The hydroxamic acid group is by far the most commonly 
used ZBG in inhibitor design and has generally been 
found to be the most effective. Hydroxamate binds the 
catalytic zinc (II) ion in a bidentate fashion, blocking 
substrate access to the active site and rendering the metal 
incapable of peptide hydrolysis. The failure of 
hydroxamic acid-based MMPIs in vivo may stem from 
poor pharmacokinetics (low oral bioavailability and short 
half-life), from the ability to bind other metal ions, and 
from the lack of specificity due to very strong binding to 
the catalytic zinc ion. As a consequence, it has been 
pointed out that the design of selective inhibitors should involve weaker ZBGs to 
effectively modulate affinity by variation of substituents on the molecule scaffold. 
With a single coordinate bond to the metal center, inhibitors with monodentate 
ZBGs (such as carboxylic acids or phosphonic acids) are generally weaker 
inhibitors. We have been studying non-hydroxamic MMPIs for a long time, with a 
particular attention towards phosphonic derivatives.1-3 
In this lecture, the design, synthesis, structure-activity relationship and in vitro 
pharmacological evaluation of new phosphonic MMPIs will be presented. 
 
[1] G. Pochetti, E. Gavuzzo, C. Campestre, M. Agamennone, P. Tortorella, V. Consalvi, C. Gallina, 
O. Hiller, H. Tschesche, P. A. Tucker, F. Mazza, J Med Chem 49(3), 2006, 923. 
[2] A. R. Folgueras, A. Fueyo, O. Garcia-Suarez, J. Cox, A. Astudillo, P. Tortorella, C. Campestre, 
A. Gutierrez-Fernandez, M. Fanjul-Fernandez, C. J. Pennington, D. R. Edwards, C. M. Overall, 
C. Lopez-Otin, The Journal of biological chemistry 283(14), 2008, 9465. 
[3] M. T. Rubino, M. Agamennone, C. Campestre, G. Fracchiolla, A. Laghezza, F. Loiodice, E. 
Nuti, A. Rossello, P. Tortorella, ChemMedChem 4(3), 2009, 352. 
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useful ligands to define the stereochemical requirements for MT2-
selective melatonin receptor antagonists 
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Understanding the therapeutic potential of melatonin (N-acetyl-5-
methoxytryptamine, MLT) has become an interesting topic in medicinal chemistry 
research, and MT1 and MT2 receptors are emerging as possible therapeutic targets 
for sleep disorders and depression. Three therapeutic agents (Circadin®, 
Rozerem®, and Valdoxan®) are already in use, and other compounds are currently 
under study for the treatment of sleep disturbances or depression.[1] Consistent 
information is available for non-selective MT1/MT2 ligands, and several molecular 
models, both ligand- and receptor-based, have been proposed to rationalize their 
SARs.[2] On the contrary, only limited data on MT1 or MT2 subtype-selective 
compounds are available up to now, and a clear definition of the structural 
requirements for subtype selectivity is still lacking. During the present decade, 
SAR investigations on melatonin receptor ligands were therefore aimed at both the 
discovery of new chemical classes and the definition of structural requirements for 
subtype selectivity.  
Conformational restriction of bioactive molecules is a valuable tool for 
investigating the topographical and chemical features of small-molecule ligands. 
For instance, the -aminotetralin skeleton has been successfully used as a rigid 
template for the synthesis of non-indolic melatonin-like agents, and several other 
substances possessing important biological activities. 4-Phenyl-2-
propionamidotetralin (4-P-PDOT) [3] is a prototypical MT2-selective ligand 
employed in pharmacological tests to discriminate the role of MT1 and MT2 
receptors in MLT mediated effects. Despite its pharmacological application, the 
SARs for its derivatives have been poorly explored.  
In this lecture the design, synthesis [4] and pharmacological 
characterization of 4-phenyl-2-amidotetralin derivatives will be described, focusing 
on their SAR, active conformation and configuration. A convenient protocol 
providing access to all four 4-P-PDOT enantiomers (ee >99%), and the 
determination of  their absolute configuration will also be described. Binding data 
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on each single stereoisomer, conformational analysis and pharmacophore-based 
superpositions led to a new chiral pharmacophore model which can be applied to 
both melatonin receptor agonists and MT2-selective antagonists. Validation of this 
pharmacophore model has been achieved synthesizing conformationally 
constrained tetrahydronaphthalene derivatives.            
 
 
 
 
 
 
 
 
 
Superposition of  (2S,4S)- and (2R,4S)-4-P-PDOT 
 
[1] G. Spadoni, A. Bedini, S. Rivara,  and M. Mor, CNS Neurosci. Ther., (2010), 
DOI: 10.1111/j.1755-5949.2010.00197.x. 
[2] S. Rivara, M. Mor, A. Bedini, G. Spadoni, and G. Tarzia, Curr. Top. Med. 
Chem., 8, 2008, 954. 
[3] M.L. Dubocovich, M.I.  Masana, S. Iacob, and D.M. Sauri, Naunyn-
Schmiedeberg's Arch. Pharmacol. 355, 1997, 365. 
[4] S. Lucarini, A. Bedini, G. Spadoni, and G. Piersanti, Org. Biomol. Chem. 6, 
2008, 147 
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tool for the treatment of localized infections 
Donata Dei 
Molteni Therapeutics, Via Fiorentina 1, Siena; Via Barontini 8, Scandicci (FI) 
d.dei@moltenitherapeutics.it 
The pandemic diffusion of new microbial infections, as well as the onset of 
resistance toward antibiotic treatment of many pathogens, urge the development of 
new antimicrobial therapies as an alternative to the use of classical drugs.[1] 
In this area, and particularly for the treatment of localized infectious diseases, the 
use PhotoDynamic Therapy (PDT) could represent a new appealing strategy to 
combact pathogens, help the wounds healing, reduce the risk of systemic infections 
and limit the spread of resistance.[2] 
Molteni Therapeutics (MT) is involved since many years in the synthesis, 
analytical characterization and pharmaco-biological testing of new photosensitizers 
belonging to several classes of derivatives (Zinc and Silicon phthalocyanines [3], 
as well as porphyrins [4]), with the aim to discover new PDT agents and to 
elucidate the structure-activity relationships of these active compounds. 
Up to now, very good results in the photoinactivation of yeasts and bacteria have 
been obtained with many of the synthesized compounds. In particular, the use of 
Zn(II)-phthalocyanines bearing quaternary ammonium groups has been extensively 
studied, starting from Discovery  to Development for a restricted number of 
selected molecules. RLP068, the lead compound of MT  pipeline, is currently being 
evaluated in a  Phase IIa Clinical Trial.   
In this presentation a brief introduction on PDT principles and an overview of 
the work done by MT on photosensitizers, spanning from synthetic and analytical 
data to in vitro and in vivo biological results, will be given. 
 
 
 
 
[1] European Centre for Disease Prevention and Control “Annual epidemiological 
report on communicable diseases in Europe 2008”; Center for Global 
Development’s Drug Resistance Working Group “The race against drug 
resistance”, 2010. 
[2]  Wainwright Journal of Antimicrobial Chemotherapy 1998, 42, 13-28; Garland et 
al. Future Med. Chem. 2009, 1(4), 667-691. 
[3] Roncucci et al. EP0906758 (2011), EP1164135 (2004), EP1381611 (2005), 
EP1356813 (2005), EP1444236 (2007), EP1883641 (2008), EP1883640 (2009). 
[4]  Roncucci  et al  EP1558616 (2008). 
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Laura Mercolini1, Roberto Mandrioli1, Chiara Marcheselli1,  
Giovanni Serpelloni2, Maria Augusta Raggi1 
 
1 Laboratory of Pharmaco-Toxicological Analysis, Department of Pharmaceutical 
Sciences, Faculty of Pharmacy, University of Bologna, Via Belmeloro 6,  
40126 Bologna, Italy 
2  Department of Antidrug Policies, Presidency of the Council of Ministers, 
Via Po 16/a, 00198 Roma, Italy        
laura.mercolini3@unibo.it 
 
Driving under the influence (DUI) of psychotropic substances, such as drugs 
of abuse (DoA) and/or alcohol, is one of the leading causes of traffic collisions. 
Furthermore, car accidents are the first cause of death (and of acquired disability) 
for young people under the age of 35. As a consequence, roadside controls are 
routinely performed by law enforcement agencies as part of prevention/dissuasion 
policies. Within this framework, the correct and timely sampling of a significant 
biological matrix, followed by a reliable qualitative/quantitative analysis, is the 
cornerstone of a fair assessment of the DUI state. For alcohol intake, the use of 
breathalizers has reached a satisfactory level of reliability and speed. However, 
assessing the actual state of drug intoxication is much more complicated. It is 
important to have at disposal fast and reliable analytical methods, able to provide 
good results for the identification and the quantitation of the most important DoA. 
The Laboratory of Pharmaco-Toxicological Analysis develops advanced 
methods for the analysis of DoA in different biological fluids and tissues, in 
particular in an innovative matrix: Dried Blood Spots (DBS) [1]. DBS are obtained 
from blood drops collected on filter paper from a simple finger prick; the technique 
represents a very attractive and feasible alternative to the traditional blood 
sampling. It is especially useful “on street”, because is minimally invasive and 
allows sample collection, transport and storage, granting good stability without 
requiring refrigeration nor other pre-treatments. A few original analytical methods 
are  for the analysis of different DoA in human DBS, for the purpose of reliable 
“on street” drug testing.The methods are based on LC-ESI-MS/MS (triple 
quadrupole) and samples are directly injected into the system, after a very fast 
solvent extraction. The results obtained until now on cocaine, cannabinoids and 
their main metabolites are promising, in terms of extraction yields, sensitivity and 
selectivity. Assays are in progress in order to fully validate the methods. 
 
[1] L. Mercolini, R. Mandrioli, G. Gerra and M.A. Raggi, Analysis of cocaine 
and two metabolites in dried blood spots by liquid chromatography with 
fluorescence detection: A novel test for cocaine and alcohol intake,  
J. Chromatogr. A, 46, 2010, 7242. 
 352 
 
FAR-OR-02 Selective serotonergic 5-HT7 receptor agonists as 
a new therapeutic venue for treatment of  cognitive disorders: 
focus on Fragile X syndrome. 
Enza Lacivita,a Paola De Giorgio,a Lucia Ciranna,b Lara Costa,b Francesco 
Berardi,a Roberto Perrone,a Marcello Leopoldo.a 
aDipartimento Farmaco-Chimico, Via Orabona, 4; 70125, Bari, Italy 
bDipartimento di Scienze Bio-Mediche, Sezione di Fisiologia, Viale Andrea Doria, 6; 95125, 
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Serotonin (5-HT) affects the excitability of hippocampal neurons and hippocampal-
dependent cognitive functions. We have recently shown that 5-HT7 receptor 
activation modulates glutamate AMPA receptor-mediated basal transmission [1] 
and metabotropic glutamate receptor-induced long-term depression (mGluR-LTD) 
in the CA3-CA1 synapse of mouse hippocampus. Activation of 5-HT7 receptors is 
able to reverse mGluR-LTD also in the Fmr1 knockout (KO) mice model of Fragile 
X syndrome (FXS) [2], the most common form of hereditary intellectual disability, 
in which hippocampal mGluR-LTD is abnormally enhanced [3], suggesting that a 
pharmacological treatment selectively targeting 5-HT7 receptors might be 
considered in the therapy of FXS. 
LP-211, a selective 5-HT7 receptor agonist [4], is able to modulate AMPA-
mediated synaptic currents and to reverse mGluR-LTD in the CA3-CA1 
hippocampal synapse similarly to 8-OH-DPAT, the standard 5-HT7 non selective 
agonist. 
HN
O
N( )5
N
NC
LP-211
5-HT7 Ki: 0.58 nM; 5-HT1A Ki: 188 nM 
 
On the basis of these results, we have undertaken a new project for the 
identification of new selective 5-HT7 receptor agonists endowed with 
pharmacodynamic and pharmakocinetic properties suitable for in vivo use. This 
will allow to clarify the therapeutic potential of 5-HT7 receptor agonists in the 
pharmacological treatment of cognitive disorders. 
[1] L.Costa, C.Trovato, S.A.Musumeci, M.V.Catania, L. Ciranna Hippocampus, 2011, in press; 
doi: 10.1002/hipo.20940. 
[2] L. Costa, M. Spatuzza, C. Trovato, C.M.Bonaccorso, S.A. Musumeci, M.V. Catania, L. 
Ciranna, article submitted; presented in abstract form (757.25/M18 Neuroscience Meeting 
Planner. San Diego, CA: Society for Neuroscience, 2010). 
[3] M.F.Bear, K.M.Huber, S.T.Warren Trend Neurosci. 27, 2004, 370. 
[4] M.Leopoldo, E.Lacivita, P.De Giorgio, C.Fracasso, S.Guzzetti, S.Caccia, M.Contino, 
N.A.Colabufo, F.Berardi, R.Perrone, J. Med. Chem. 51, 2008, 5813. 
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In the last few years, the synergistic relationship between organic chemistry, 
molecular modeling and biology has played a growing role in the identification of 
new potential drug candidates. A key contribution to this successful 
multidisciplinary approach has been given by modern instruments/techniques 
which have significantly accelerated the 
drug-discovery process. Despite molecular 
modeling approaches have significantly 
speed-up the identification of potential hits 
from large libraries of compounds, synthetic 
chemistry still play a key role in producing 
new chemical entities both for the discovery 
and optimization phase.  
Within the medicinal chemist’s “toolbox”, 
high-speed chemical techniques have become 
an important device for the rapid 
identification of new biologically active 
compounds. Parallel synthesis, microwave 
assisted techniques, click-chemistry and 
multicomponent reactions represent 
nowadays commonly used techniques for rapid identification of novel hit 
compounds and for the hit-to-lead optimization of promising inhibitors. An 
overview on the application of these modern techniques to the synthesis of 
different heterocyclic scaffold with antiviral, antitumor and antitubercular activities 
will be given [1]. 
 
 
[1] a) M. Radi, et al. J.Comb.Chem., 7, 2005, 117. b) D. Castagnolo, et al. 
Tetrahedron-Asymmetry, 18, 2007, 1345. c) M. Radi, et al. Bioorg. Med. Chem. 
Lett., 18, 2008, 1207. d) M. Radi, et al. Tetrahedron Lett., 49, 2008, 4464. e) 
M. Radi, et al. Nucleosides, Nucleotides & Nucleic Acids, 28, 2009, 504. f) M. 
Radi, et al. Tetrahedron Lett., 50, 2009, 6572. 
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Giuseppe Fracchiolla, Luca Piemontese, Antonio Laghezza, Mariagiovanna 
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Loiodice. 
 
Dipartimento Farmaco Chimico dell’Università degli Studi di Bari “Aldo Moro”, 
Via E. Orabona 4, 70126, Bari, Italy. (e-mail: fracchiolla@farmchim.uniba.it) 
 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors that govern lipid and glucose homeostasis, therefore they play 
a central role in cardiovascular disease, obesity and diabetes. Recently, novel 
PPAR ligands have been identified that are claimed as potentially superior 
therapeutic agents for human metabolic disorders. These include dual PPAR 
agonists and PPAR partial agonists or selective modulators (SPPARMs) with 
concomitant hypolipidemic and hypoglycaemic activity and fewer adverse effects 
than currently available agonists.[1,2] Here, we present the synthesis and the 
preliminary biological evaluation on the PPAR/ isoforms of some new 
(oxy)iminomethyl analogs obtained by the bioisosteric substitution of the distal 
phenyl ring of the novel lead compound LT175, recently synthesized and tested in 
our laboratories (Figure 1).[3–5] 
 
O COOH O COOH
H
N
O
R
LT175 R = H, alkyl chain, alkylaryl chain  
Figure 1 
 
Different substituents on the hydroxyl group of the (oxy)iminomethyl moiety have 
been introduced and the preparation of the eutomers of the most active derivatives 
has been achieved. Docking experiments were performed to provide a molecular 
explanation for their different activity. The preliminary biological results revealed 
some interesting compounds with mixed PPAR agonist activity which can be 
further explored to assess their pharmacological properties in in vitro and in vivo 
studies. 
 
[1] Willson T.M., et al. J. Med. Chem. 2000, 43, 527. 
[2] Shearer B. G., et al. Biochim. Biophys. Acta 2007, 1771,1082. 
[3] Pinelli A., et al. J. Med. Chem 2005, 48, 5509.  
[4] Fracchiolla G., et al. ChemMedChem 2007, 2, 641. 
[5] Montanari R. et al. J. Med. Chem. 2008, 51, 7768. 
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FAR-OR-05 Avicholic Acid: A Primary Bile Acid from Birds 
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G.;b Adorini, L.;b Roda, A.;c Pellicciari R.a 
aDipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, 06123 
Perugia, Italy. bIntercept Pharmaceuticals Italia, 06073 Corciano (PG), Italy. 
cDipartimento di Scienze Farmaceutiche, Università di Bologna, 40126 Bologna, 
Italy. 
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Bile acid (BA) activated receptors are widely recognized as relevant targets for 
drug discovery efforts. The key members of this family, namely FXR and TGR5, 
are implicated in a number of liver and metabolic diseases such as cholestasis, non-
alcoholic steatohepatitis (NASH), obesity and type II diabetes.[1] In this 
framework, we have developed a small library of BA derivatives which was 
instrumental to defined the SAR of BAs as FXR/TGR5 agonists and to disclose 
selective and potent ligands for both receptors (Figure 1).[2] As a continuation of 
our efforts aimed at finding novel potent and selective chemical tools to probe the 
functions of BA related receptors in different tissues, we have been engaged in the 
further chemical elaborations of the BA scaffold. Our attention, in particular, was 
attracted by the peculiar structure of avicholic acid, a natural BA isolated from 
avian species (Shoebill stork and herons) and characterized by a hydroxy group at 
the C16-position (Figure 1). Polar groups at this position were indeed suggested 
by our QSAR model as favoring the activity to the TGR5 receptor.[3] Starting from 
this observation, we report the synthesis, the biological and PK appraisals, and 
structure activity relationships of novel avicholic acid derivatives as TGR5 ligands. 
Avicholic Acid
OHHO
CO2H
H
OH
Obeticholic Acid (INT-747)
FXR Agonist, Phase II/III Clinical Trials
OHHO
CO2H
H
S-EMCA (INT-777)
TGR5 Agonist, Preclinical Trials
OHHO
CO2H
H
OH
6 6
23(S)
16
 
Figure 1. Bile acid derivatives as potent and selective FXR/TGR5 ligands. 
 
[1] Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Nat. Rev. Drug 
Discov. 2008, 7, 678. [2] a) Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; 
Costantino, G. et al. J. Med. Chem. 2002, 45, 3569. b) Pellicciari, R.; Gioiello, A.; 
Macchiarulo, A.; Thomas, C.; Rosatelli, E.; Natalini, B.; Sardella, R.; Pruzanski, M.; Roda, 
A. et al. J. Med. Chem. 2009, 52, 7958. [3] Macchiarulo, A.; Gioiello, A.; Thomas, C.; 
Massarotti, A.; Nuti, R.; Rosatelli, E.; Sabbatini, P.; Schoonjans, K.; Auwerx, J.; 
Pellicciari, R. J. Chem. Inf. Model. 2008, 48, 1792. 
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Mitochondria play a central role in the control of both necrotic and apoptotic cell 
death. A key mitochondrial mechanism promoting cell death is the opening of the 
permeability transition pore (mPTP), a high conductance channel of the inner 
mitochondrial membrane. The role of mitochondria-mediated cell death in the 
aetiology of many diseases is well established and inhibitors of PTP are regarded as 
potential therapeutic agents, particularly for the prevention and/or treatment of 
diseases and conditions characterized by ischemia/reperfusion, oxidative or 
degenerative tissue damage. 
In this report we describe the synthesis, 
structure−activity relationships (SAR) for 
inhibition of  mPTP opening induced by 
Calcium overload, and preliminary biological 
characterization of acrylamido derivatives (I), a 
novel series of potent inhibitors of mPTP. 
(E)-3-(4-Fluoro-3-hydroxy-phenyl)-N-naphthalen-1-yl-acrylamide, one of the most 
interesting compounds in this series, was effective in an in vivo Rabbit model of 
heart ischemia/reperfusion injury. 
 
 
 
 
 
 
 
 
( I ) 
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One of the most interesting technological novelties in the field of 
radiochemistry is the use of microfluidic devices to perform efficient, rapid, cost 
effective reactions in a user-friendly environment. Microreactors have considerable 
advantages in radiochemistry where short-life positron-emitters are used to produce 
radiotracers for molecular imaging with positron emission tomography (PET) 1-3.  
A lots of advantages may be expected from this technology, such as the use 
of smaller amounts of radioactive precursors for saving precious materials, the 
possibility to work in safer conditions, to accurately control the reaction parameters 
and to use cheap, interchangeable, disposable and quality-assured radiochemistry 
processors4. 
This work provides an overview of materials and microfluidic networks 
suitable for radiochemistry at microscale. Several micro devices are realized to 
perform on-chip reactions and separations. Preliminary results demonstrate the 
effectiveness of the proposed microfluidic platforms for radiopharmaceutical 
applications.   
 
 
[1] Lee CC, Sui GD, Elizarov A, Shu CYJ, Shin YS,Dooley AN, et al. Science 
310:1793–1796 (2005) 
[2] Lu SY, Watts P, Chin FT, Hong J, Musachio JL, Briard E, et al. LabChip 
4:523–525 (2004) 
[3] Lu S, Giamis AM and Pike Vw, Current Radiopharmaceuticals, 2, 49-55, 
(2009). 
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FAR-OR-08 Design of Novel Dual and Selective Allosteric 
Inhibitors Acting on C5a/CXCR1: Lead Likeness Strategy of a 
Series of Innovative Aryltrifluoromethanesulfonates Reparixin 
Analogues 
Andrea Aramini*, Alessio Moriconi, Candida M. Cesta, Laura Brandolini,  
and Marcello Allegretti 
Dompé Research Centre, Dompé pha.r.ma S.p.A. Via Campo di Pile, I- 67100 
L’Aquila, Italy. 
e-mail: andrea.aramini@dompe.it 
Among the chemokine family, CXCL8 and CXCL1 play a key role in the activation and 
recruitment of neutrophils at the site of inflammation. CXCL8 binds two membrane 
receptors, CXCR1 and CXCR2, whereas CXCL1 is a selective agonist for CXCR2[1-2]. A 
novel class of small molecular weight allosteric CXCR1 inhibitors was previously 
identified in our laboratories and reparixin (I)[3-4], the first drug candidate, is currently 
under clinical investigation in Pancreatic islet -cell transplant. 
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Starting from the derived binding model, a rational design program has been undertaken 
with the aim to identify novel potent inhibitors with comparable inhibitory efficacy for 
both CXCR1/C5aR.  
The replacement of the isobutyl group with the trifluoromethanesulfonyl (triflate) group, 
led to a significant potency increase on C5a strongly enhanced the affinity at CXCR1 and 
C5a. The sulfonate spacer was confirmed as optimal from a spatial point of view for the 
correct orientation in the hydrophobic pocket of the receptors and by a retro-inversion of 
the amide bond was able to obtain a selective C5aR inhibitors. Among these, the 
C5aR selective inhibitor DF2593A(II) and the dual CXCR1/C5aR inhibitor 
DF2297A (III) were selected as promising candidates for in vitro and in vivo 
pharmacological characterization. Both DF2593A and DF2297A potently inhibited 
C5a-induced human (IC50 of 510-9M and 810-9M, respectively) and murine (IC50 
of 110-9M and 810-9M, respectively) PMN migration.  
[1] Vann Damme, J. The Cytokine Handbook; Academic Press: New York, 1994; pp 185-205. 
[2] Petersen, F.; Flad, H. D.; Brandt, E. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites 
on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and 
biologic effects. J. Immunol., 1994, 152(5), 2467-2478. 
[3] Allegretti, M.; Bertini, R.; Cesta, M. C.; Bizzarri, C.; Di Bitonto, R.; Di Cioccio, V.; Galliera, E.; Berdini, 
V.; Topai, A.; Zampella, G.; Russo, V.; Di Bello, N.; Nano, G.; Nicolini, L.; Locati, M.; Fantucci, P.; Florio, 
S.; Colotta, F. 2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive 
CXCL8 Inhibitors. J. Med. Chem. 2005, 48, 4312-4331. 
[4] Aramini A., Moriconi A., Bertini, R.; Beccari A. R.; Cesta, M. C.; Bizzarri, C.; Locati M.; Allegretti, M.; 
Design of Non-Competitive Interleukin-8 inhibitors acting on CXCR1 and CXCR2. J. Med. Chem. 2007, 50, 
3984-4002. 
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A new generation of selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) was 
developed to circumvent the major side effects of cyclooxygenase-1 (COX-1) and 
COX-2 inhibitors (stomach ulceration and nephrotoxicity). 
A series of previously patented 1,5-Diarylpyrrol-3-acetic esters and 1,5-
Diarylpyrrole-3-alkoxyethyl ethers proved to be potent and selective COX-2 
inhibitors in in vitro cell culture assay.ref The potential anti-inflammatory and 
antinociceptive activities of  these compounds were evaluated in vivo, where they 
showed a very good activity against both carrageenan-induced hyperalgesia and 
edema in the rat paw test. 1,2,3 
These classes of compounds (International Patent: PCT/EP2006/065011 and WO 
2008/014821 A1) were at the basis of the development of new compounds, the 
COX-2 inhibiting nitric oxide (NO) donors (CINODs). 
CINODs are a new class of anti-inflammatory and analgesic drugs that may 
minimize gastrointestinal toxicity compared with standard non-steroidal anti-
inflammatory drugs (NSAIDs) along with reduced cardiovascular risks associated 
with the Coxibs (celecoxib, valdecoxib, etc.) by virtue of their nitric oxide 
donation.  
This project was based on the synthesis of NO-donor’s compounds characterized 
by modifications of the side chain at position 3 of 1,5 diarylpirrole derivatives in 
which the 1,5-diarylpyrrole scaffold is linked to a nitric oxide moiety. In particular, 
the aim of the project is the extended functionalization of position 3 by means of 
“linkers” with different stereo-electronics properties in order to obtain “hybrid 
molecules” that after releasing NO are able to show elevated selective COX-2 
activity in vitro along with  elevated anti-inflammatory and anti-nociceptive 
activity in in vivo animal  models.4 
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[1]Cappelli, A.; Anzini, M.; Caselli, G.; Giordani, A.; Makovec, F.; Rovati, L.C.; Biava, M. 3-Substituted-1,5-
diarly-2-alkyl-pyrroles Highly Selective and Orally Effective COX-2 Inhibitors. WO/2008/014821 
[2]Biava, M. et al. Cyclooxygenase-2 Inhibitors. 1,5-Diarylpyrrol-3-acetic Esters with Enhanced Inhibitory 
Activity toward Cyclooxygenase-2 and Improved Cyclooxygenase-2/Cyclooxygenase-1 Selectivity J. Med. 
Chem. 2007, 50, 5403-5411  
[3]Anzini, M. Biava, M. et al. Synthesis, Biological Evaluation, and Enzyme Docking Simulations of 1,5-
Diaryl pyrrole-3-alcoxyethyl Ethers as Highly Selective COX-2 Inhibitors Endowed with Anti-inflammatory 
and AntinociceptiveActivity J. Med. Chem., 2008, 51, 4476-4481. 
[4]Anzini M. et al. Nitroesteri di 1,5-diaril-2-alchilpirroli-3-sostituiti, inibitori selettivi di COX-2 e donatori di 
Ossido Nitrico., TA2010A000739 
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 MPS1 (Monopolar Spindle-1 kinase), also known as TTK, plays critical 
roles in the proper execution of mitosis, is frequently over-expressed in human 
tumors, and is required for tumour cell proliferation. Selective inhibitors of this 
target may provide an innovative therapy for the treatment of tumors and spindle 
assembly checkpoint inhibition could be a way to selectively target aneuploid 
tumor proliferation.  
 In this poster we report the synthesis and SAR of a series of novel pyrazolo-
quinazolines as potent and selective MPS1 inhibitors. We describe the optimization 
of the initial hit, identified by screening the internal library collection, into an 
orally available, potent and selective MPS1 inhibitor (NMS-P715).  
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[1] R. Colombo, M. Caldarelli, M. Mennecozzi, M.L. Giorgini, F. Sola, P. 
Cappella, C. Perrera, S. Re Depaolini, L. Rusconi, U. Cucchi, N. Avanzi, J.A. 
Bertrand, R. Bossi, E. Pesenti, A. Galvani, A. Isacchi, F. Colotta, D. Donati, J. 
Moll, Cancer Res. 2010, 70, 10255. 
 
[2] M. Caldarelli, M. Angiolini, T. Disingrini, D. Donati, M. Guanci, S. Nuvoloni, 
H. Posteri, F. Quartieri, M. Silvagni, R. Colombo, Bioorg. Med. Chem. Lett. 
submitted 
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Click chemistry has recently made an outstanding contribution to medicinal 
chemistry research [1]. This term, coined by K. B. Sharpless, refers to a new 
synthetic approach which exploits nearly perfect reactions. Among them, the 
copper-catalyzed Huisgen cycloaddition between azides and alkynes plays a 
prominent role. 
Over the past few years, we have exploited this reaction in the discovery of 
resveratrol [2] and estrogenic analogues [3], HDAC inhibitors [4], and, lately, PI3K 
inhibitors. Phosphatidylinositol-3-kinases (PI3Ks), a class of lipid kinases, are an 
emerging target in antitumoral therapy as they play a major role in proliferation and 
survival in a wide variety of human cancers [5]. 
Our approach in the discovery of potent and selective PI3 kinase inhibitors 
involved the functionalisation of TGX-155, a micromolar PI3 kinase inhibitor, in 
the 8-position with differently substituted triazole rings  (Figure 1). 
Figure 1: TGX-155 
 
Three lead compounds have been identified, which display inhibitor activity 
at the nanomolar level, having a clear selectivity against  and  isoforms [6]. In 
this communication, design, synthesis, and biological evaluation of this promising 
class of PI3K inhibitors will be illustrated. 
[1] G.C. Tron, T. Pirali, R.A. Billington, P.L. Canonico, G. Sorba, A.A. Genazzani, Med. Res. Rev.  
2008, 28, 278 
[2] F. Pagliai, T. Pirali, E. Del Grosso, R. Di Brisco, G.C. Tron, G. Sorba, A.A. Genazzani, J. Med. 
Chem. 2006, 49, 467 
[3] T. Pirali, S. Gatti, R. Di Brisco, S. Tacchi, R. Zaninetti, E. Brunelli, A. Massarotti, G. Sorba, 
P.L. Canonico, L. Moro, A.A. Genazzani, G.C. Tron, ChemMedChem 2007, 2, 437 
[4] T. Pirali, F. Pagliai, C. Mercurio, R. Boggio, P.L. Canonico, G. Sorba, G.C. Tron, A.A. 
Genazzani, J. Comb.  Chem. 2008, 10, 624 
[5] E. Hirsch, L. Braccini, E. Ciraolo, F. Morello, A. Perino, TIBS  2009,  34,  244 
[6] G. Sorba, G.C. Tron, T. Pirali, U. Galli, A. Massarotti, E. Hirsch, E. Ciraolo, BIT13714-CF: 
TO2010A000956 
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Reversible post-translational modifications of histones such as 
acetylation/deacetylation play an important role in chromatin structure and control 
of gene expression. The histone acetylation status is regulated by two enzyme 
families: histone acetyltransferases (HATs) and histone deacetylases (HDACs)[1]. 
HDACs have emerged as an attractive target for the development of new 
anticancer agents, and several compounds are currently in clinical studies for solid 
and hematological tumor therapy[2]. Two inhibitors, vorinostat (SAHA) and 
romidepsin (FK228), have been recently approved by the FDA for the treatment of 
cutaneous T-cell lymphoma. Despite these recent successes, there remains 
significant interest in identifying new HDAC inhibitors with a superior 
pharmacokinetic profile, improved efficacy, and good tolerability[3]. 
With the objective to find new HDAC inhibitors we had synthesized a 
series of spiro[chromane-2,4'-piperidine]hydroxamic acid derivatives[4] by 
combining privileged structures with minimal structures able to inhibit histone 
deacetylase enzymes[5]. Herein, we wish to describe the identification of 4-
oxospirochromane-N-hydroxyacrylamides, leading to highly potent compounds in 
biochemical and antiproliferation assays as well as with a good in vitro ADME 
profile. 
[1] E.I. Campos, D. Reinberg Annual Review of Genetics, 43, 2009, 559-599. 
[2] F. Thaler, S. Minucci Expert Opinion on Drug Discovery, 6, 2011, 393-404. 
[3] A.A. Lane, B.A. Chabner, J. Clin. Oncol. 27, 2009, 5459-5468. 
[4] M. Varasi, F. Thaler, A. Abate, C. Bigogno, R. Boggio, G. Carenzi, T. Cataudella, R. Dal 
Zuffo, M.C. Fulco, M.G. Rozio, A. Mai, G. Dondio, S. Minucci, C. Mercurio J. Med. 
Chem., 54, 2011, 3051-3064. 
[5] F. Thaler, A. Colombo, A. Mai, R. Amici, C. Bigogno, R. Boggio, A. Cappa, S. Carrara, T. 
Cataudella, F. Fusar, E. Gianti, S.J. di Ventimiglia, M. Moroni, D. Munari, G. Pain, N. 
Regalia, L. Sartori, S. Vultaggio, G. Dondio, S. Gagliardi, S. Minucci, C. Mercurio, M. 
Varasi, M. J. Med. Chem. 53, 2010, 822-839. 
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Second generation, irreversible inhibitors of Epidermal Growth Factor Receptor 
(EGFR) are characterized by a recognition scaffold, resembling those of clinically-
employed reversible inhibitors, and by a cysteine-reactive warhead, able to 
covalently interact with a conserved cysteine residue in the kinase domain of the 
ErbB family members (C797 in EGFR) [1]. Cysteine-trapping groups reported in 
literature so far (acrylamides, -chloroacetamides) are endowed with high intrinsic 
reactivity. This could cause rapid metabolic deactivation of the inhibitor or, at 
worst, enhanced in vivo toxicity, due to the aspecific reactivity towards off-target 
thiol-containing nucleophiles.  
We have recently started systematic exploration on the role and reactivity of 
warheads for irreversible EGFR inhibition, introducing different cysteine-trapping 
groups on the 4-anilinoquinazoline scaffold [2]. In the present work, our attention 
is focused on a new set of inhibitors, in which a -aminocarbonyl group (Mannich 
base) is linked to different scaffolds through an amide bond. These derivatives 
proved to be as efficient as the irreversible acrylamide derivative PD168393 in 
inhibiting EGFR-TK activity in different cell lines. For both acrylamide and 
Mannich-base derivatives, inhibition persisted for 8 hours after the wash-out of the 
compound from cell medium. However, their in vitro reactivity profile markedly 
diverged, with Mannich bases being stable in the presence of low MW thiols (GSH, 
cysteine, cysteamine), compared to the highly reactive acrylamide. A combined 
approach, employing: i. fluorimetric analysis of inhibitors incubated with cell-free 
EGFR, ii. quantification by HPLC-MS of inhibitors and their metabolites in A549 
cell lines and in cell lysates, showed that Mannich bases can act as prodrugs, 
partially releasing acrylamide in the cellular environment.  
 
 
[1] C.P. Belani, Cancer Invest. 28, 2010, 413-23. 
[2] C. Carmi, A. Cavazzoni, S. Vezzosi, F. Bordi, F. Vacondio, C. Silva, S. Rivara, 
A. Lodola, R. R. Alfieri, S. La Monica, M. Galetti, A. Ardizzoni, P. G. Petronini, 
M. Mor, J. Med. Chem., 53, 2010, 2038-2050. 
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The transient receptor potential (TRP) superfamily is a large group of ion channels 
that has received increased attention in recent years. TRPM8, on which this study is 
focused, belongs to the subfamily of thermo-TRP channels which are triggered by 
diverse chemical and physical stimuli and whose precise activation mechanism is 
still unknown. Specifically, TRPM8 is activated by cold temperature, ligands such 
as menthol and icilin (a synthetic derivative), positive membrane potential and the 
endogenous signaling lipid, PIP2. Therefore, TRPM8 could find therapeutic 
applications in several pathological conditions, including neurogenic inflammation, 
neuropathic pain, overactive bladder and prostate cancer. [1] An homology model 
of the TRPM8 tetramer was recently generated using a fragmental strategy by some 
of us. [2] Beside the global architecture of the TRPM8 channel, such a model 
revealed the key residues involved in ligand recognition and suggested that the 
agonist binding is able to induce a cascade of conformational shifts which globally 
may orchestrate the channel opening (at least partially). Such a mechanism was 
then confirmed by classic all-atoms MD simulations which evidenced how agonists 
are able to trigger such structural changes whereas agonists block the channel in its 
starting conformations. Considering the rather nonspecific nature of TRPM8 
binding site and the resulting difficulty of predicting ligand bioactivity by docking 
calculations, adaptive biasing force (ABF) MD simulations [3] were exploited to 
derive the free energies involved in TRPM8 activation and the obtained energy 
values are in line with the activity of a representative set of TRPM8 ligands. These 
results emphasize that suitably targeted MD runs can be fast enough to be 
systematically applied to predict the bioactivity of rather large ligand datasets. 
[1] Jordt SE, Ehrlich BE., Subcell Biochem. 2007, 45, 253-71 
[2] Pedretti A, Marconi C, Bettinelli I, Vistoli G., Biochim Biophys Acta. 2009, 
1788, 973-82 
[3] Darve E., Pohorille A. J. Chem. Phys. 2001, 115, 9169-9183. 
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GABA is the main inhibiting neurotransmitter in the CNS. It modulates the 
neuronal activity by mediating its action via GABAA, GABAB and GABAC 
receptors The GABAB receptor belongs to the family 3 of the G-protein coupled 
receptors and it is an heterodimer made of two similar but distinct subunits. 
Although drugs activating the GABAB receptor were found to have a number of 
possible therapeutic actions, these were limited because of tolerance and undesired 
side effects which include sedation, myorelaxing activity and hypothermia.1 
Allosteric modulators are molecules that bind to a site on a receptor which is 
topographically distinct from the orthosteric-binding pocket. They have little or no 
intrinsic agonistic activity of their own but induce conformational changes in the 
receptor protein, which affect its interaction with the endogenous neurotransmitter. 
Thus, positive allosteric modulators (PAMs) of GABAB receptor appear as a better 
alternative to GABAB agonists, allowing the specific enhancement of receptor 
activity when and where needed, and as such, are less prone to tolerance in contrast 
to the pure agonists (such as baclofen) that constantly activate the receptor in any 
region where it is expressed. These compounds are valuable anxiolytics and 
effectively reduce craving for drugs of abuse such as alcohol, nicotine and 
cocaine.2 Four companies have invested substantial resources into the search of 
PAMs of GABAB receptors (Novartis, Roche, AstraZeneca and Addex) with 
significant differences in the target indications. These medicinal chemistry efforts 
have enlarged the number of scaffolds, which lead to potent compounds and thus 
expanded our knowledge on structure-activity relationships significantly. 
Nevertheless, substantial efforts are still needed in order to optimize drugs for a 
given indication to get all the ADMET parameters right as well, such as metabolic 
stability, brain penetration for the CNS indications (or no brain penetration for the 
peripheral indications), sufficient water solubility, no alerts in Ames and 
genotoxicity tests, and several other parameters. 
Our research in the area started from a structure-based computational approach 
which allowed, through a virtual screening, the identification of a number of 
possible PAMs of GABAB receptor. Among those selected, one molecule gave 
interesting results both in vitro and in vivo studies. 
[1] Froestl, W. Future Med. Chem. 2011, 3, 163-175 
[2] Pin, J.-P.; Prézeau, L. Curr. Neuropharm. 2007, 5, 195-201 
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Among the ligand gated ionotropic P2X receptors activated by ATP, the P2X3 
subtype plays an important role in neuropathic and chronic pain pathways [1]. 
Hence, ligands blocking this receptor could be useful for the treatment of chronic 
pain conditions and migraine [1]. Recently, a number of purine acyclic-nucleotides 
have been synthesized and proved to behave as partial agonists of P2X3 receptors 
[2]. Furthermore, since non-nucleotide benzylic diamino-pyrimidine derivatives 
were reported to block P2X3 receptors with high potency [3], a new series of purine 
derivatives bearing a substituted benzyl chain in 9-position (Figure 1) was designed 
and synthesized in the search for new P2X3 antagonists. 
  
 
Figure 1. 
The compounds were evaluated on recombinant murine and human P2X3 receptors 
using patch clamp technique. Furthermore, an assay on native P2X3 receptors 
expressed by trigeminal ganglion sensory neurons in culture has been performed. 
The new compounds resulted to behave as P2X3 receptor antagonists with IC50 in 
the low micromolar range.  
 
[1] G. Burnstock, Pharmacol. Rev., 58, 2006, 58.  
[2] R. Volpini, R.C. Mishra, D.D. Kachare, D. Dal Ben, C. Lambertucci, I. Antonini, S. 
Vittori, G. Marucci, E. Sokolova, A. Nistri, and G. Cristalli, J. Med. Chem., 52, 2009, 
4596. 
[3] D.S. Carter, M. Alam, H. Cai, M.P. Dillon, A.P.D.W. Ford, J.R. Gever, A. Jahangir, C. 
Lin, A.G. Moore, P.J. Wagner, and Y. Zhai, Bioorg. Med. Chem. Lett., 19, 2009, 1628. 
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We have previously described a synthetic glycopeptide, termed CSF114(Glc), 
able to detect specific auto-antibodies in sera of patient affected by Multiple 
Sclerosis (MS), an inflammatory, demyelinating disease of the central nervous 
system [1]. The pathogenesis of MS involves an autoimmune mechanism against 
myelin auto-antigens, even if the target antigens remain elusive. Accordingly, we 
focused our attention on both the characterization of the antigenic properties of 
CSF114(Glc) and the identification of the native auto-antigen(s) recognized by 
anti-CSF114(Glc) auto-antibodies. 
In this context, we have recently used the glycopeptide CSF114(Glc), coated 
on magnetic beads, to select by phage display specific human domain antibodies 
(dAb) from a domain antibodies library [2]. Purified dAbs (15 kDa) were 
characterized by Biacore for binding specificity to CSF114(Glc) versus 
unglycosylated CSF114, showing a good specificity and affinity. 
 Subsequent Biacore experiments demonstrated that these recombinant dAbs 
cross-react with anti-CSF114(Glc) auto-antibodies isolated from MS patients’ sera 
by immuno-affinity chromatography. Accordingly, the new recombinant dAb may 
be used for the characterization of the native auto-antigens in human tissues or as a 
positive control in an in vitro diagnostic assay based on CSF114(Glc).  
 
[1] F.Lolli, B.Mulinacci, A.Carotenuto, B.Bonetti, G.Sabatino, B.Mazzanti, 
A.M.D'Ursi, E.Novellino, M.Pazzagli, L.Lovato, M.C.Alcaro, E.Peroni, 
M.C.Pozo-Carrero, F.Nuti, L.Battistini, G.Borsellino, M.Chelli, P.Rovero, 
A.M.Papini, Proc. Natl. Acad. Sci. 102, 2005, 10273. 
[2] C.M.Lee, N.Iorno, F.Sierro, D.Christ, Nature Protoc. 2, 2007, 3001. 
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Experimental evidence confirmed that reactive carbonyl species (RCS) are 
involved in the pathogenesis of several human diseases including diabetes related 
disorders and distress metabolic syndrome. Hence RCS, beside to be considered 
biomarkers of oxidative damage, can be also seen as potential targets for the 
development of bioactive compounds acting as detoxifying agents of RCS 
(carbonyl quenching compounds). We found that the endogenous dipeptide 
carnosine (-alanyl-L-histidine) is a selective and potent RCS sequestering agent, 
even though its clinical application is limited due to the rapid hydrolysis in blood 
by a specific dipeptidase (carnosinase). With a view to finding stable and effective 
agents, several carnosine derivatives were recently proposed in literature and some 
of these compounds proved promising in vivo in suitable animal models. Despite 
the mentioned variety of carnosine analogues, the chemical space of the 
proteinogenic histidine containing dipeptides was never exhaustively investigated. 
On these grounds, the study is focused on the synthesis, physicochemical profiling, 
in silico analysis and biological evaluation of a set of diastereoisomeric pairs of 
histidine containing dipeptides suitably chosen to cover a large part of the 
accessible chemical space. In detail, the examined peptides were designed as 
diastereoisomeric pairs in order to delve the configurational effects on the activity 
which could shed additional light on the quenching mechanism. Finally, some 
relevant physicochemical properties (namely pKi, log P and log D7.4) were 
experimentally determined to clarify the main factors governing the quenching 
activity and their relationships with in silico determined descriptors were also 
investigated. 
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Human serum albumin (HSA) has been successfully used as chiral selector in 
enantioselective HPLC. These HSA-based columns usually present the problem of 
a significant variation of the chromatographic performances depending not only on 
the immobilization procedure, but also on the origin of the anchored protein from 
different sera. This makes difficult the application of developed and validated 
HPLC methods. Recombinant human albumin, rHA (RECOMBUMIN®, 
Novozymes Biopharma UK Limited) can overcome the problem, because of the 
high homogeneity of the structure and binding properties of the protein samples.  
RECOMBUMIN®, produced from Novozymes’ Saccaromyces cerevisiae was 
purified and defatted before use. The protein was then characterized for its 
conformation and its binding properties by circular dichroism (CD). In particular 
the analysis of the CD at high energy showed substantially the same secondary 
structure for the recombinant albumin with respect to the serum albumin. In 
addition the binding of selected markers for the most important binding sites (i.e. 
phenylbutazone for site I, diazepam for site II, and bilirubin for site III) was proved 
to be stereoselective. A sample of RECOMBUMIN® was then anchored in situ to 
an epoxy silica matrix of a HPLC column. The anchoring method was validated by 
checking the binding parameters of known ligands on the immobilized protein. The 
RECOMBUMIN® -based column was efficiently used for the enantioselective 
analysis of a variety of chiral drugs and amino acid derivatives. As an example 
enantiomeric resolution was obtained for rac-warfarin ( =  2.1), rac-lorazepam 
hemisuccinate ( =  5.3), N-benzoyl-DL-leucine (=2.8), using 1-
propanol/phosphate buffer (pH 7.5) 15/85, 0.6 ml/min flow rate. The obtained 
values of enantioselectivity are comparable or higher with respect to those obtained 
with the corresponding HSA-based columns, under the same experimental 
conditions. The rHA based column has also a great potential for its use as affinity 
support for characterizing the binding of new active compounds in terms of KD and 
location of primary binding site. 
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Fluorazone (9H-pyrrolo[1,2-a]indol-9-one) I and its analogs represent valuable 
intermediates in the synthesis of biologically active compounds. They have been 
extensively studied in relation to a variety of activities showed by many of their 
functionalized derivatives. In particular, we found that some N’-heteroacyl-
hydrazone derivatives (es. cpd II) possess noticeable cytotoxic activity against a 
colon cancer cell line [1], while thienopyrrolizinone III, belonging to the 
tripentones family, has been shown to act as a microtubule polymerization inhibitor 
[2]. 
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IC50  7 µ M   (SKBr3 cell line) 
  
    IC  50  0.015 µM 
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A number of synthetic strategies have been therefore developed for the preparation 
of (un)substituted-fluorazones and analogs. Amongst the known synthetic methods,  
the most appealing appear those starting from ortho-(1H-pyrrol-1-yl)aryl and 
heteroaryl carboxylic acids, in turn obtained by pyrrolation of ortho-aminoaryl 
(anthranilic) and ortho-aminoheteroaryl carboxylic acids, respectively [3]. We 
herein investigated the possibility of directly converting anthranilic acids  into 
fluorazones, through a sequential one-pot pyrrole formation/cyclization, by using 
DMTHF and 4-chloropyridine hydrochloride as the acid catalyst. This allows the 
preparation of fluorazone based derivatives from ortho-aminoaryl and heteroaryl 
carboxylic acids in generally good yield and after a simple work-up, avoiding any 
intermediate manipulation. A further advantage of the procedure lies in the easy 
availability of the starting aminoacids, most of which are commercial reagents.  
 
[1] Grande, G.; Yamada, R.; Cao, X.; Aiello, F.; Garofalo, A.; Neamati, N. Expert 
Opin. Investig. Drugs 2009, 18, 555. 
[2] Lisowski, V.; Enguehard, C.; Lancelot, J. C.; Caignard, D.-H.; Lambel, S.;   
Leonce, S.; Pierrè, A.; Atassi, G.; Renard, P.; Rault, S. Bioorg. Med. Chem. Lett. 
2001, 11, 2205. 
[3] Aiello, F.; Garofalo, A.; Grande, F. Tetrahedron 2010, 66, 274. 
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Adenosine receptors (AR) belong to the superfamily of G-protein-coupled 
receptors (GPCRs). They are divided into four subtypes (A1, A2A, A2B, and A3) 
[1], and can be distinguished on the basis of their distinct molecular structures, 
distinct tissues distribution, and selectivity for adenosine analogs [2,3]. The hA3R, 
the most recently identified adenosine receptor, is involved in a variety of 
intracellular signaling pathways and physiological functions [4]. Expression of 
A3R was reported to be elevated in cancerous tissues [5], and A3 antagonists have 
been proposed for therapeutic treatments of 
cancer. The recent literature availability of 
crystal structure of hA2A adenosine receptor 
(PDB code: 3EML) provided us a new 
template for A3R homology modeling. The 
validation of the obtained structure model was 
performed by inspecting the Ramachandran 
plot (Fig. 1). The modeled protein was 
optimized using nanosecond scale molecular 
dynamics simulation. One hundred twenty two 
active and selective compounds were docked into the obtained model using 
Induced Fit Docking [6] and used as training set to generate pharmacophore models 
by means PHASE [7]. Energy-optimized pharmacophore mapping was performed; 
to each pharmacophore feature site was assigned an energetic value as the sum of 
the GLIDE XP contributions of the atoms included in the site. This pharmacophore 
model addresses the prevalent features to be used for the search of new inhibitors. 
Therefore it was employed as template to screen the ZINC database in the attempt 
to find new potent and selective human A3R antagonists. 
[1] B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, K.N. Klotz, J. Linden, Pharmacol. Rev., 53, 
2001, 527. 
[2] P.G. Baraldi, R. Romagnoli, D. Preti, F. Fruttarolo, M.D. Carrion, M.A. Tabrizi, Curr. Med. 
Chem., 13, 2006, 3467. 
[3] M.D.Okusa, Am. J. Physiol. Renal Physiol., 282, 2002, F10. 
[4] A.Ochaion, S. Bar Yehuda, S. Cohen, F. Barer, R. Patoka, L. Del-Valle, G. Perez-Liz, J. Ophir, 
R. Galili-Mosberg, T. Reitblat, H. Amital, P. Fishman, Ann. Rheum. Dis., 66, 2007, 446. 
[5] L.Madi, A. Ochaion, L. Rath-Wolfson, S. Bar-Yehuda, A. Erlanger, G. Ohana, A. Harish, O. 
Merimski, F. Barer, P. Fishman, Clin. Cancer Res., 10, 2004, 4472. 
[6] Schrödinger Suite 2009 Induced Fit Docking protocol; Glide version 5.5, Schrödinger, LLC, 
New York, NY, 2009; Prime version 2.1, Schrödinger, LLC, New York, NY, 2009. 
[7] Phase, version 3.1, Schrödinger, LLC, New York, NY, 2009. 
Figure 1 
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Nitric oxide (NO) is an important mediator involved in the regulation of many 
physiological and pathological processes.[1] The formation of NO is catalyzed by 
the enzyme nitric oxide synthase (NOS) via the NADPH- and O2-dependent 
oxidation of L-arginine. Three distinct isoforms of NOS have been identified: the 
constitutive endothelial (eNOS) and neuronal (nNOS), and the inducible (iNOS). 
The overproduction of NO by iNOS may have detrimental consequences, and 
seems to be involved in the pathophysiology of several human diseases, such as 
asthma, arthritis, multiple sclerosis, colitis, psoriasis, neurodegenerative diseases, 
tumor development, transplant rejection or septic shock. In the last years, 
considerable effort has been directed toward the selective inhibition of iNOS as a 
strategy for the prevention of excessive NO production, while maintaining the 
basal formation of NO from constitutive NOS that is required for normal 
physiological function. Selective inhibition of iNOS would be a useful therapy for 
inflammatory diseases.[2] 
Recently we have reported the synthesis of acetamidines 2 and 3, differing from 
known inhibitor W1400 (1) by the amino substitution at the 3-aminomethyl group 
with one or two benzylic groups. We have evaluated their iNOS inhibitory effect in 
vitro by an enzymatic assay. Here we will report the biological evaluation of the 
same molecules on H9C2 cells, spontaneously immortalized ventricular myoblasts 
from the rat embryo.  
 
  
[1] Zhou, L.; Zhu, D.-Y. Nitric Oxide - Biology and Chemistry 2009, 20, 223-230. 
[2] Domenico, R. Current Pharmaceutical Design 2004, 10, 1667-1676. 
[3] Fantacuzzi, M. et al. ChemMedChem 2011, in press. 
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Follicle Stimulating Hormone (FSH) is a glycoprotein, member of the 
gonadotropins family, which also includes luteinizing hormone (LH), chorionic 
gonadotropin (CG) and thyroid stimulating hormone (TSH). FSH is secreted from 
the pituitary gland and regulates reproduction in mammals. In females, FSH targets 
a receptor (FSHR) expressed only on granulosa cells, and induces the maturation of 
ovarian follicles. In males, FSH stimulates Sertoli cell proliferation in testes and 
supports spermatogenesis [1]. FSH and the other members of the gonadotropin 
family have closely related structures, composed of two non covalently linked - 
and -subunits. Both subunits are glycosylated. The glycosylation state plays a key 
role in determining and modulating biological functions in vivo; therefore, 
glycoproteins intended for pharmaceutical use in humans need to be carefully 
characterized, both in terms of their amino acid sequence and oligosaccharide 
structure. As a consequence, it is essential to develop methodologies for a fast and 
accurate monitoring of gonadotropin glycosylation. 
Due to their extensive structural heterogeneity, the elucidation of 
glycosylation patterns in glycoproteins, such as the FSH, remains one of the most 
challenging problems in the proteomic analysis of post-translational modifications. 
The glycosylation state is usually studied after decomposition of the intact proteins 
to the proteolytic peptide level [2], or after glycan release by hydrazinolysis [3]. 
These approaches are often laborious, and give no information on the whole protein 
[4]. Here we report the oligosaccharide profile of commercial FSH preparations, as 
obtained by intact molecular mass analysis and bioinformatic tools. The results 
obtained by RP-HPLC/IT-TOF mass spectrometry show a predominance of highly 
sialylated, highly branched glycans in human urinary FSH if compared to the 
recombinant FSH expressed in rodent cell lines.  
[1] K.M.Fox, J.A.Dias, and P.Van Roey, Mol.Endocrinol., 15, 2001, 378. 
[2] A.Amoresano, R.Siciliano, S.Orrù, R.Napoleoni, V.Altarocca, E.De Luca, 
A.Sirna, and P.Pucci, Eur.J.Biochem., 242, 1996, 608. 
[3] A.Gervais, Y.A.Hammel, S.Pelloux, P.Lepage, G.Baer, N.Carte, 
O.Sorokine, J.M.Strub, R.Koerner, E.Leize, and A.Van Dorsselaer, 
Glycobiology, 13, 2003, 179. 
H.Toll, P.Berger, A.Hofmann, A.Hildebrandt, H.Oberacher, H.P.Lenhof and 
C.G.Huber, Electrophoresis, 27, 2006, 2734. 
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The aim  of the LIBRA project is to collect small organic molecules, produced 
within scientific institutions in Italy, and distribute them in a format suitable for 
biochemical screening. The idea of building such a collection arose out of the 
observation that the Italian organic and medicinal chemistry communities annually 
produce a wealth of interesting novel small molecules. Often, these molecules 
undergo just one or very few tests, whereas with an appropriate organization and 
logistics up to 100 different biochemical or phenotype tests might be feasible with 
only 3-5 mg of a typical compound (MW < 500). One of the objectives of LIBRA 
is to offer new opportunities of screening, thus encouraging public-public and 
public-private collaborations.  
The Drug Discovery and Development unit of the Italian Institute of Technology 
decided to share part of its storage facility in favor of this initiative and to develop 
a procedure comprising several automated steps for the preparation of solutions, 
physico-chemical characterization, storage, cherry-picking and distribution on 
microplates of the LIBRA’s chemical collection. Details of the whole process will 
be illustrated, including methods and validation on the first experimental sets. 
Specifically: storage as DMSO solutions (10 mM), frozen and under nitrogen, will 
follow a well-established practice of modern screening centers;  distribution (the 
smallest quantities compatible with screening needs) will occur in 96-well 
microplates with appropriate liquid handling work stations. 
The collection will be limited to molecules with published or patented structure, in 
order to limit intellectual property issues, but is a must of LIBRA to protect the 
interest of the provider while keeping the collection appealing for the screening 
needs of all users. The construction of a web site to advertise and display the 
available molecular structures is part of the project, such as to offer a “One Stop 
Showcase” for biochemists and pharmacologists with specific screening initiatives 
ready to start. A highly requested option, delivery of selected portions of the 
collection (cherry picking), will be possible. 
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gDipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Polo 
scientifico. Miniato,  Via A. Moro, snc, I-53100 Siena. 
 
The development of COX-inhibiting nitric oxide donors (CINODs) has been 
driven by the pursuit for the search of novel analgesic/anti-inflammatory agents 
devoid of adverse side effects, especially those related to traditional Non Steroidal 
Anti-inflammatory Drugs (t-NSAIDs)[1]. Starting from new diarylpyrrole-based 
selective COX-2 inhibitors previously individuated by some of us [2,3] and taking 
into account all the structural features that were responsible for COX-2 inhibition 
and selectivity, we planned the synthesis of novel COX-2 selective CINODs, in 
which the nitric oxide (NO) release aims at cutting down the side effects displayed 
by COX-2-like structures [4]. Thus, for improving the biological profile of these 
class of compounds, we synthesized new derivatives introducing a nitrated amidic 
side chain. All compounds were evaluated to assess their inhibition towards both 
COX-1 and COX-2 through a cell-based assay, NO-dependent vasorelaxing effect 
and in vivo analgesic and anti-inflammatory profiles.  
 
[1] Fiorucci S. Science direct, Digestive and Liver Disease , 2007 , 39, 1043-1051.  
[2] Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Manetti, F.; Botta, M.; Forli, S.; Sautebin, 
L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; 
Patrignani, P.; Anzini, M. J. Med. Chem. 2010, 53, 723–33.  
[3] Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Botta, M.; Manetti, F.; Rovini, M.; 
Cappelli, A.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.;  Makovec, F.; 
Giordani, A.; Anzellotti, P.; Tacconelli,  S.;  Patrignani, P.; Anzini, M. Curr. Med. Chem. 18(10), 
1540-1554, 2011.  
[4] Biava, M.; Porretta, G.C.; Poce, G.; Battilocchio, C.; Alfonso, S.; Rovini, M.; Giorgi, G.; 
Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Papa, G.; Ghelardini, C.; Di Cesare 
Mannelli, L.; Giordani, A.;  Anzellotti, P.; Bruno, A.; Patrignani, P.; Anzini, M. J. Med. Chem. 
Submitted for publication. 
 
 
 377 
 
 
FAR-PO-07 GN8 Fluorescent Analogues as Chemical 
Probes for Prion Diseases  
 
Matteo Staderini,a Arletta Nowodworska,b Hoang Ngoc Ai Tran,b Nieves 
Cabezas,a Lucia Morelli,a Alice D’Onofrio,a Salvatore Bongarzone,c,d Paolo 
Carloni,e J. Carlos Menéndez,a Giuseppe Legname,b,d and Maria Laura 
Bolognesif 
 
aDepartamento de Quimica Organica y Farmaceutica, Facultad de Farmacia, 
Universidad Complutense, 28040 Madrid, Spain 
bPrion Biology Laboratory, Neurobiology Sector, Scuola Internazionale Superiore 
di Studi Avanzati (SISSA), via Bonomea 265, 34151 Trieste, Italy 
cStatistical and Biological Physics Sector, Scuola Internazionale Superiore di Studi 
Avanzati (SISSA), via Bonomea 265, 34151 Trieste, Italy 
dItalian Institute of Technology, SISSA Unit, via Bonomea 265, 34151 Trieste, 
Italy 
eGerman Research School for Simulation Sciences GmbH, Forschungzentrum 
Jülich GmbH - RWTH Aachen University 
fDepartment of Pharmaceutical Sciences, Alma Mater Studiorum, University of 
Bologna, Via Belmeloro 6, 40126 Bologna, Italy 
marialaura.bolognesi@unibo.it 
 
Prion diseases, or transmissible spongiform encephalopathies (TSEs) are a family 
of invariably fatal neurodegenerative disorders for which no effective curative 
therapy currently exists. A common feature of TSEs is the deposition of insoluble 
aggregates of disease-associated prion protein (PrPSc), the post-translationally 
refolded and partially protease-resistant isoform of normal cellular prion protein 
(PrPC). These observed deposits of PrPSc are thought to be the cause of neuronal 
cell death in TSEs, a process that leads to the spongiform degeneration of brain 
tissue [1]. 
A potential therapeutic approach for inhibiting the accumulation of PrPSc is to 
stabilize PrPC through the direct binding of a small organic molecules to make 
PrPC→PrPSc conversion less energetically favourable. Recently, GN8 (see 
Scheme), an antiprion compound that specifically binds PrPC, has been discovered. 
Interestingly, GN8 was found to inhibit PrPSc production in vitro on a mouse 
neuronal cell culture infected with TSE and to prolong the survival time of prion-
infected mice [2]. 
From our computational study dedicated to analyze GN8-PrPC interactions and 
from structure-activity relationship studies [3,4], we argued to modify the 
diphenylmethane core of GN8. By the introduction of an additional bond linking 
the two phenyl rings, we ended up with the fluorene derivative 1 (see Scheme). The 
fluorescent property of fluorene ring offers a unique opportunity to obtain chemical 
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probes which may elucidate the mechanism of action of GN8 derivatives in vitro 
and in vivo.  
Herein, we report the synthesis of a small library of fluorene-based analogues of 
GN8 and the evaluation of their antiprion activity in TSE infected cells. 
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[1]  Prusiner, S. B. Science 1991, 252, 1515. 
[2]  Kuwata, K.; Nishida, N.; Matsumoto, T.; Kamatari, Y. O.; Hosokawa-Muto, J.; 
Kodama, K.; Nakamura, H. K.; Kimura, K.; Kawasaki, M.; Takakura, Y.; 
Shirabe, S.; Takata, J.; Kataoka, Y.; Katamine, S. Proc. Natl. Acad. Sci. USA 
104, 2007, 11921. 
[3]  Kimura, T.; Hosokawa-Muto, J.; Kamatari, Y. O.; Kuwata, K. Bioorg. Med. 
Chem. Lett. 21, 2011, 1502. 
[4]  Kranjc, A.; Bongarzone, S.; Rossetti, G.; Biarnés, X.; Cavalli, A.; Bolognesi, 
M. L.; Roberti, M.; Legname, G.; Carloni, P. J. Chem. Theory Comput. 5, 2009, 
2565.  
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Strategies designed to enhance cerebral cAMP by phosphodiesterases 
inhibition have been proposed as symptomatic treatments to counteract cognitive 
deficits. We have recently reported a series of new 3-cyclopentyloxy-4-
methoxybenzaldehyde derivatives endowed with selective inhibitory activity 
toward the long-form PDE4D3 [1]. In a recent pharmacological study GEBR-7b, 
the most active of them, increased hippocampal cAMP and did not influence A 
levels; furthermore, in the object recognition test it improved spatial as well as 
object memory performance, at doses that did not cause emesis-like behaviour in 
rodents [2]. Therefore, our results further support the hypothesis that specific 
PDE4D isoforms play a critical role in the mediation of memory processes, as 
recently reported by other researchers [3-4]. It is well known that rolipram, a PDE4 
inhibitor lacking in isoforms selectivity, combines pro-cognitive properties with 
undesirable sedative effects, decreasing both locomotion and rearing in rodents [5]. 
Recently, Li et al. observed no changes in locomotor activity between PDE4D 
knock out and wild type mice, suggesting that PDE4D inhibition couldn’t induce 
sedation [4]. With the aim to develop PDE4 inhibitors endowed with a better 
tolerability, we synthesized a new series of analogues of previous compounds and 
evaluated “in vitro” their inhibitory activity on different PDE4 isoforms as well as 
their ability to affect spontaneous locomotor activity. Some of them (compounds 
4a, 5b, 7b, selective toward PDE4D isoforms and compounds 6b and 9b, inactive 
toward all PDE4 isoforms), when studied in open field test in mice, did not affect 
locomotor activity at doses comparable with those of rolipram able to decrease 
locomotor activity and prolong immobility time. Compound 11, having a non-
selective rolipram-like enzymatic profile, caused a similar even if not significant 
reduction in spontaneous motor activity.  
In conclusion, these findings further support the idea that selective PDE4D 
inhibition may represent an innovative cognitive-enhancing pharmacological 
strategy lacking side-effects such as emesis and sedation.  
 
[1] O. Bruno, et al. J. Med. Chem. 52, 2009, 6546. 
[2] O. Bruno, et al., Br. J. Pharm. 2011 DOI: 10.1111/j.1476-5381.2011.01524.x 
[3] A.B. Burgin, et al. Nat. Biotechnol, 28, 2010, 63.  
[4] Y.F. Li, et al. J. Neurosci. 31, 2011, 172. 
[5] J.S. Silvestre, et al. Pharmacol., Biochem. Behav. 64, 1999, 1. 
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NAD kinase (NADK) is a key enzyme that regulates supply of NADP in the 
cell. At this time no other pathway of NADP biosynthesis has been found in 
prokaryotic or eukaryotic cells. Human NAD kinase catalyzes a magnesium-
dependent phosphorylation of the 2’-hydroxyl group of the adenosine ribose moiety 
of NAD using ATP as phosphoryl donor to give NADP. Bacterial enzymes can use 
inorganic polyphosphates as phosphoryl donors in addition to ATP. Significant 
differences between the human and the mycobacterium enzyme were found that 
might allow for construction of inhibitors with selectivity against these proteins. 
Therefore, M. tubercolosis NADK has became an appealing new target for the 
development of potential drugs against multi-drug resistant (MDR) and extensively 
drug resistant (XDR) tubercolosis (TB). 
Recently, we have reported that dinucleoside disulfide NAD mimics, such as 
diadenosine disulfide (DTA), were found to be moderate inhibitors of M. 
tubercolosis and human NADKs. A restriction of the conformation of adenine 
moiety to syn by substitution with a bulky bromine atom at the C8 of one or two 
adenine rings of DTA, furnished the most potent inhibitors of both human and 
mycobacterium NADK reported so far. On the contrary, fixing the sugar 
conformation in the “North” or “South” conformation by introduction of a methyl 
group at the 2’- or 3’-position of the ribose ring was detrimental for NADK 
inhibitory activity [1].  
To further investigate the structural features of the ribose moiety, herein we 
report the synthesis and the NADK inhibitory activity of 2’-deoxy-, 3’-deoxy-, and 
2’,3’-dideoxy-DTA. The results of this study will be presented. 
 
[1]  R. Petrelli, Y.Y. Sham, L. Chen, K. Felczak, E. Bennett, D. Wilson, C. 
Aldrich, J.S. Yu, L. Cappellacci, P. Franchetti, M. Grifantini, F. Mazzola, M. Di 
Stefano, G. Magni, and K. Pankiewicz, Bioorg. Med. Chem., 17, 2009, 5656. 
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The oxidative stress plays an important role in the pathogenesis of many diseases 
such as cardiovascular and neurodegenerative disorders, accounting for the great 
interest in the identification and development of better and more effective 
antioxidants. Mexiletine (Mex), a well-known voltage-gated sodium channel 
blocker, can also act as an antioxidant by inhibiting hydroxyl radical-mediated lipid 
peroxidation in brain membranes.[1] Mex has also been reported to protect the 
neuronal tissues against diabetic oxidative and ischemia-reperfusion damages.[2] 
Moreover, a pyrroline derivative of Mex (R=CH3, X=CH2) has been demonstrated 
to be capable of providing marked protection against ischemia-reperfusion 
myocardial injury.[3] In the last ten years we have prepared several Mex analogues, 
most of which act more potently than Mex in blocking skeletal muscle voltage-
gated sodium channels.[4] Thus, looking for a synergism between sodium channel 
blocking activity and antioxidant properties, we have coupled our most potent and 
selective compounds with a pyrroline moiety in order to obtain potential dual-
acting drugs.  
X = CO, CH2O
N
H
R
X
N
H
R = CH3, iPr, tBu, Ph, Bn
 
Results obtained on skeletal muscle voltage-gated sodium channels for the 
pyrroline derivative of Mex (R=CH3, X=CO) and its isopropyl analogue (R=iPr, 
X=CO) revealed that both compounds show improved potency compared to Mex as 
use-dependent sodium channel blockers. Herein we report on the activity of 
pyrroline derivatives as scavengers of hydroxyl radicals. 
 
[1] E. Demirpence, H. Caner, M. Bavbek, K. Kilinc, Jpn. J. Pharmacol., 81, 1999, 7. 
[2] O. Ates, S.R. Cayli, E. Altinoz, N. Yucel, A. Kocak, O. Tarim, A. Durak, Y. Turkoz, S. Yologlu, 
Mol. Cell Biochem., 286, 2006, 125.  
[3] Y.-P. Li, R.J. Schwartz, I.D. Waddell, B.R. Holloway, M.B. Reid, FASEB J., 12, 1998, 87 
[4] C. Franchini, A. Carocci, A. Catalano, M. M. Cavalluzzi, F. Corbo, G. Lentini, A. Scilimati, P. 
Tortorella, D. Conte Camerino, A. De Luca, J. Med. Chem., 46, 2003, 5238. 
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The tremendous challenge of inhibiting therapeutically important protein-protein 
interactions has created the opportunity to extend traditional medicinal chemistry to 
a new class of targets and to explore nontraditional strategies. Holak and co. have 
recently described a two-dimensional 15N-HSQC based NMR assay for studying 
the effect of antagonists on protein-protein interactions [1]. The method, named 
AIDA (for antagonist induced dissociation assay), provides information on whether 
an antagonist of a protein-protein interaction is strong enough to dissociate the 
complex and whether its action is through denaturation, precipitation, or release of 
a protein in its functional folded state. AIDA requires the use of a large protein 
fragment (larger than 30 kDa) to bind to a small reporter protein (less than 20 kDa). 
In appropriate conditions (flexible residues), 1D proton NMR spectra may suffice 
for monitoring the states of proteins in complexes upon treatment with ligands. 
Because of the highly flexible nature of the N-terminal domain of p53, p53-MDM2 
complex is suitable for 1D proton NMR application. In particular, the NHε side 
chains of W23 and W53 produce sharp lines in the free p53 1D proton spectrum. 
On formation of the complex with MDM2, W23 signal disappears, since W23, 
together with the p53 residues 17-26, comprises the primary binding site for 
MDM2. Hence it is possible to determine the activity of potential p53-MDM2 
antagonists acquiring the 1H NMR spectrum of the protein complex. We have 
recently applied this method to a series of spiro(oxindole-3,3’-thiazolidine) 
derivatives thus discriminating the compounds able to block the p53-MDM2 
interaction [2]. The method is now applied to new series of peptide and small 
molecule compounds to screen their p53-MDM2 antagonist properties. 
 
[1] L. D’Silva, P. Ozdowy, M. Krajewski, U. Rothweiler, M. Singh, and T. A. 
Holak, J. Am. Chem. Soc., 127, 2005, 13220. 
[2] I. Gomez-Monterrey, A. Bertamino, A. Porta, A. Carotenuto, S. Musella, C. 
Aquino, I. Granata, M. Sala, D. Brancaccio, D. Picone, C. Ercole, P. Stiuso, P. 
Campiglia, P. Grieco, P. Ianelli, B. Maresca, and E. Novellino, J. Med. Chem., 53, 
2010, 8319. 
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Farnesoid X Receptor (FXR) belongs to a family of nuclear receptors that 
are ligand-inducible transcription factors. FXR is highly expressed in the liver and 
intestine and is activated by bile acids, such as chenodeoxycholic acid (CDCA) and 
cholic acid (CA), and their corresponding conjugates at physiological 
concentrations. FXR functions as a bile acid sensor in enterohepatic tissues, 
regulating several target genes associated with bile acid synthesis and transport [1]. 
Activation of FXR by bile acids or synthetic agonists results in transcriptional 
repression of cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme in 
the bile acid biosynthesis pathway, induction of the small heterodimer partner 
(SHP), a transcriptional repressor found in the liver and intestine, an induction of 
genes encoding for some bile acid transport proteins, such as intestinal bile acid-
binding protein (IBABP) [2] and bile salt export pump (BSEP) [3]. Furthermore, 
bile acid-mediated FXR activation is recently recognized as a major underlying 
pathway for energy homeostasis and glucose as well as lipid metabolism.  
FXR has also been suggested to counteract pro-inflammatory and pro-
atherogenic responses in cardiovascular diseases.  
All these evidences make FXR a promising potential target for the treatment 
of a variety of metabolic disorders, including hyperlipidemia, cholelithiasis, 
cholestasis, and diabetes mellitus. 
Over the past few years, many efforts have been dedicated to the search of 
highly potent steroidal- and nonsteroidal FXR modulators. With the aim of 
discovering novel classes of nonsteroidal FXR ligands, we initiated a virtual 
screening protocol based on the information retrieved by the crystal structures of 
FXR in complex with agonists. A multistep approach using ligand and structure-
based techniques will be presented. 
                                                 
[1] T.T.Lu, M.Makishima, J.J.Repa, K.Schoonjans, T.A.Kerr, J.Auwerx, and 
D.J.Mangelsdorf, Mol. Cell, 6, 2000, 507. 
[2] J.Li, P.C.Pircher, I.G.Schulman, and S.K.Westin, J. Biol. Chem., 280, 2005, 
7427. 
[3]  T.M.Willson, S.A.Jones, J.T.Moore, and S.A.Kliewer, Med. Res. Rev., 21, 
2001, 513. 
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Monoamine oxidases are flavoenzymes which exist in two isoforms: 
MAO-A and MAO-B. They catalyze the oxidative deamination of endogenous and 
exogenous monoamines, and are involved in the pathogenesis of mental disorders, 
particularly depression (hMAO-A), and neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s (hMAO-B). 
In previous studies conducted by our research group, several 1-(4-substituted-
thiazol-2-yl)-2-(alkyl/cycloalkyl/aryl)hydrazines have been studied as potent and 
selective hMAO inhibitors.1-4 A large number of new (hetero)arylidene-(4-
substituted-thiazol-2-yl)hydrazine derivatives were synthesized in high yields 
(Scheme 1) and tested for their in vitro ability of inhibiting hMAOs. All 
compounds showed weak or absent inhibitory activity against hMAO-A, while they 
were able to inhibit hMAO-B at micromolar or nanomolar concentration. The anti-
hMAO activity and selectivity are associated with the presence of small 
heterocyclic moieties on the hydrazonic nitrogen and electron withdrawing 
substituents at the para position of the phenyl ring, in particular fluorine, which is 
oriented towards the FAD coenzyme. 
 
[1] F.Chimenti, et al. Med. Chem. Comm. 1, 2010, 61. 
[2] F.Chimenti, et al. Bioorg. Med. Chem. 18, 2010, 5063. 
[3] F.Chimenti, et al. Bioorg. Med. Chem. 18, 2010, 5715. 
[4] F.Chimenti, et al. J. Med. Chem. 53, 2010, 6516. 
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Presently, the most promising and successful strategy in fighting malaria is the 
artemisinin-based combination therapy (ACT). Recent reports of ACT treatment 
failure in southeast Asia and the potential emergence of artemisinin resistance 
indicate that the search of new drugs or new combinations is still highly necessary. 
In order to develop new classes of antimalarial agents, we recently demonstrated 
that the replacement of the phenolic ring of amodiaquine and tebuquine with a 
pyrrole nucleus, still linked to the quinoline moiety through the usual NH, is 
associated with a good activity against both chloroquine sensitive (CQ-S) and  
chloroquine-resistant (CQ-R) strains of P. falciparum [1-2]. 
With the aim to investigate the effect of other different heterocyclic rings linked to 
the 4-aminoquinoline nucleus on the antimalarial activity, a set of 7-chloro-N-
(heteroaryl)-methyl-4-aminoquinoline and 7-chloro-N-(heteroaryl)-4-
aminoquinoline was synthesized and tested. All compounds exhibited from 
moderate to high antiplasmodial activities, and the most potent molecules inhibited 
the growth of both CQ-S and CQ-R strains of P. falciparum with IC50<30 nM.  The 
activity was strongly influenced both by the presence of a methylenic group, as a 
spacer between the 4-aminoquinoline and the heterocyclic ring, and by the presence 
of a basic head. Moreover, preliminary data indicate that the new compounds 
exhibit low toxicity against a human endothelial cell line (HMEC-1). All these 
results confirm that the presence of an heteroaryl moiety in the side chain of 7-
chloro-4-aminoquinoline is useful for the design and development of new powerful 
antimalarial agents. 
NCl
HN S
R
n
NCl
HN X
N
R1
R2
n= 0,1 x= S, O, NH  
 
[1] M. Casagrande et al., Bioorg. Med. Chem., 16, 2008, 6813.  
[2] M. Casagrande et al., Bioorg. Med. Chem., 18, 2010, 6625. 
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Mexiletine, 1-(2,6-dimethylphenoxy)-2-propanamine (Mex, Fig. 1), a class IB 
antiarrhythmic drug, represents the standard therapy for myotonic patients because 
of its ability to use-dependently block hNav1.4 skeletal muscle voltage gated 
sodium channel [1]. In Italy it has been withdrawn because of CNS and cardiac 
toxicity.  
We recently reported the first synthesis 
of meta-hydroxymexiletine (MHM, Fig. 1), a 
minor metabolite of Mex, more polar than 
the parent compound, and thus probably 
endowed with less side effects than Mex. 
MHM had been already isolated and partially 
characterized, in 1991, from urine of rats [2] 
but it had never been synthesized. 
A new synthetic route to both racemic and homochiral MHM will be 
presented. Moreover, results from pharmacological tests run on MHM will be 
reported. In particular, unlike other Mex metabolites (para-hydroxymexiletine and 
hydroxymethylmexiletine) [3–5], which were significantly less active than Mex, 
MHM does retain skeletal muscle sodium channel blocking activity being even 
more potent than Mex. 
[1] Kwiecinski, H., Ryniewicz, B., Ostrzycki, A. Acta Neurol. Scand. 1992, 86, 
371–375. 
[2] Grech-Bélanger, O., Turgeon, J., Lalande, M., Bélanger, P.M. Drug. Metab. 
Dispos. 1991, 19, 458–461. 
[3] Catalano A., Carocci A., Fracchiolla G., Franchini C., Lentini G., Tortorella 
V., De Luca A., De Bellis M., Desaphy J.-F., Conte Camerino D. Chirality, 
2004, 16, 72–78. 
[4] Cavalluzzi M.M., Catalano A., Bruno C., Lovece A., Carocci A., Corbo F., 
Franchini C., Lentini G., Tortorella V. Tetrahedron: Asymmetry 2007, 18, 
2409–2417. 
[5] Catalano A., Carocci A., Cavalluzzi M.M., Di Mola A., Lentini G, Lovece A., 
Dipalma A., Costanza T., Desaphy J.-F., Conte Camerino D., Franchini C. 
Arch. Pharm. Chem. Life Sci. 2010, 343, 325–332. 
MHM
O
NH2
OH
O
NH2
Mex
Figure 1. Structures of Mex and MHM
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Adenosine is an endogenous purine nucleoside that modulates many physiological 
processes by interacting with four G-protein coupled receptors termed A1, A2A, 
A2B, and A3. There is concrete evidence that adenosine receptors (ARs) could be 
promising therapeutic targets in a wide range of pathological conditions [1]. 
Recently, the involvement of A3 ARs in neuroprotection has been proposed [2], 
thus suggesting the investigation of A3 antagonists as neuroprotective in stroke [3]. 
This promising therapeutic application has produced a growing interest for this 
research field. In fact, also in our laboratory, much effort has been directed toward 
the study of human (h) A3 AR antagonists belonging to different classes of 
heteroaromatic systems. The  present research project takes its place into this 
scenario. Structural simplification of our previously reported tricyclic AR 
antagonists [3-5], has led to the design of some suitably substituted 2-
phenylpyrazolo[1,2-a]pyrazines (Series A) as  hA3 AR antagonists. Preliminary 
results are encouraging. In fact, 
thought the 8-amino-2-phenyl-
imidazo[1,2-a]pyrazine was 
inactive at all four ARs, 
introduction of a benzoyl 
substituent on the 8-amino group 
moved the affinity towards the 
hA3 AR. To improve hA3 affinity 
and selectivity, the synthesis of some new 8-acylamino derivatives of Series A are 
in progress.  Molecular docking studies will be performed to interpret the observed 
affinities of the new AR antagonists.  
 
[1] Baraldi, P.G. Tabrizi, M.A.; Gessi, S.; Borea P.A. Chem. Rev. 108, 2008, 238. 
[2] Pedata, F. et al. Immunol. Endocr. Metab. Agents Med. Chem. 7, 2007, 304. 
[3] Colotta, V. , Catarzi, D., Varano, F. et al. J. Med. Chem. 50, 2007, 4061. 
[4] Lenzi, O., Colotta, V., Catarzi, D. et al. J. Med. Chem. 49, 2006, 3916. 
[5] Catarzi, D. Colotta, V., Varano, F. et al. Bioorg. Med. Chem. 13, 2005, 705. 
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Amanita fungi are the main lethal toadstool among the 1000 poisonous mushrooms 
known in the world.    Thrombin is the key serine proteinase of the coagulation 
cascade and therefore a suitable target for inhibition of blood coagulation. An 
extract of Amanita virosa considerably inhibited thrombin (48%) and showed no 
inhibitory activity on trypsin. On the basis of inhibition selectivity between 
thrombin and trypsin and potency of thrombin inhibition,  Amanita virosa 
constituted a good starting material for isolation of further compounds that are 
active against thrombin.  
 In a preliminary study, 95 selected 
mushroom species have been screened in order 
to find novel specific non-peptidic thrombin 
inhibitors. The extract of Amanita virosa 
considerably inhibited thrombin (48% at 
concentration of 120 µg/mL).[1] 
A bioassay oriented fractionation of the extract 
of Amanita virosa has led to the isolation of 
active compounds. On the basis of spectroscopic data, chemical reactions and GC-
MS analysis, complex mixtures of triglycerides, monoacylglycerols, free fatty acids 
and ergosterol have been isolated and identified. 
 
 
References 
[1] B. Doljak, M. Stegnar, U. Urleb, S. Kreft, A. Umek, M. Ciglaric, B. Strukelj, T. 
Popovic. 'Screening for selective thrombin inhibitors in mushrooms' Blood Coagul. 
Fibrinolysis 2001, 12, 123-128. 
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A first report of what was later named “Alzheimer’s disease” (AD) was 
made by Alois Alzheimer in 1907, where he described a 51-year old women with 
rapid memory degeneration. Although the disease was once considered rare, it is 
now established as the leading cause of dementia which involve more than 20 
millions of persons in the world with enormous social and affective costs [1]. 
Despite major research efforts AD is still not curable. The difficulty for developing 
satisfactory therapy of AD lies in the complex pathophysiology of disease which 
involves numerous pathways. These include deficiency in cholinergic 
neurotransmission, defective -amyloid protein metabolism, accumulation of 
aggregated -proteins within neuronal cell, abnormalities of glutamatergic, 
adrenergic, serotonergic and dopaminergic neurotransmission, and involvement of 
inflammatory, oxidative and hormonal pathway [2, 3]. Although the exact 
aetiology of AD is still unclear an increasing amount of experimental data suggests 
that AD is a cerebral microvascular disorder with neurodegenerative consequences. 
Microvascular disorders occurring in advanced ageing or in the presence of 
increased oxidative stress are consequent to the endothelial dysfunction, namely 
reduced endothelial cell capacity to produce nitric oxide (NO) [4]. 
Due to the multy-
pathogenesis of AD, and 
considering the statement 
that there is a link between 
endothelial dysfunction and 
AD, we designed new multitarget drugs, potentially useful in modifying the 
development and the progress of the disease (figure 1). The products were obtained 
by combining a carbocyanine dye substructure, endowed with inhibitory properties 
of - and -protein aggregation, as well as antioxidant activity [5], with NO-donor 
moieties. Synthesis, inhibitory properties of -amyloid protein aggregation and 
vasodilator properties, due to activation of cGMP-dependent protein kinase (PKG) 
pathway of these products are reported and discussed. 
[1] C.P. Ferri, M. Prince, C. Brayne et. al., Lancet, 366, 2005, 2112.  
[2] P.M. Doraiswamy, CNS Drugs, 12, 2002, 811. 
[3] C. Ballatore, V.M. Lee, J.Q. Trojanowski, Nat. Rev. Neurosc., 8, 2007, 663. 
[4] J.C. de la Torre, G.B. Stefano, in Biomedical Significance of Nitric Oxide. 
G.B. Stefano, Ed. Medical Science International: Warsaw-New York, 2003, 
213. 
C.N. Chirita, M. Necula, J. Kuret, Biochemistry, 43, 2004, 2879. 
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Glutamate (Glu) plays pivotal roles in regulating many physiological 
processes by activation of metabotrobic and ionotropic receptors (iGluRs), these 
latter being classified as NMDA, AMPA and Kainate (KA) receptors. Excessive 
glutamatergic transmission is involved in several neurological disorders, including 
hypoxia/ischemia brain damage and epilepsy, thus the blockade of iGluRs could be 
employed for the treatment of these pathologies [1].  
In our laboratory, some research has been 
devoted to the study of iGluR antagonists such as 
the 3-hydroxyquinazoline-2,4-dione derivatives of 
series 1, in which the 7-chloro substituent was 
combined with various groups at position 6 (R6). 
Structure-affinity relationship (SAR) studies showed 
that the nature of R6 was critical for the selectivity 
toward the different iGluRs (Figure 1) [2,3]. 
Recently, we planned the synthesis of new 6-
substituted 3-hydroxyquinazoline-2,4-diones (series 2) bearing a 7-trifluoromethyl 
residue, since this group was thought to increase AMPA and KA receptor 
selectivity. Preliminary binding results showed that the new compounds possess 
increased AMPA receptor affinity and selectivity, with respect to the previously 
reported 7-chloro derivatives. Selected compounds exhibited good protective effect 
in an in vitro rat model of cerebral ischemia. To interpret the observed SAR, 
molecular modeling studies are in progress by docking compounds to models of the 
target receptors. 
 
[1] Traynelis S. F., Wollmuth, L.P. et al Pharmacol. Rev. 62, 2010, 405. 
[2] V. Colotta, D. Catarzi, F. Varano et al, Bioorg. Med. Chem. Lett. 14, 2004, 
2345. 
[3] V. Colotta, D. Catarzi, F. Varano et al, J. Med. Chem. 49, 2006, 6015. 
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New indolylarylsulfone (IAS) [1,2] derivatives bearing cyclic substituents 
at the indole-2-carboxamide linked through a methylene/ethylene spacer are potent 
inhibitors of the HIV-1 WT replication with inhibitory concentrations in the low 
nanomolar range.  
We report the results of docking and molecular dynamics experiments on 
this family of compounds. Analysis of the proposed binding pose into the WT and 
mutated RTs for the highly active compounds 5-chloro-3-((3,5-
dimethylphenyl)sulfonyl)-N-(pyrroldin-1-yl)-1H-indole-2-carboxamide (1), it is 
possible to highlight a series of crucial interactions: (i) a H-bond between the 
indole NH and Lys101; (ii) the 3,5-dimethylphenyl moiety forms hydrophobic 
interactions in an aromatic cleft formed by Tyr181, Tyr188, and Trp229; (iii) a H-
bond between the nitrogen atom of the heterocycle and the Glu138:B. 
The model proposed is in good agreement with the biological results: 1 
EC50 3.3 nM; IC50wt 12nM; IC50L100I 26nM, IC50K103N 93nM  
 
 
[1]  G. La Regina, A. Coluccia, A. Brancale, F. Piscitelli, V. Gatti, G. Maga, J. 
Balzarini, E. Novellino, R. Silvestri. J. Med. Chem., 54, 2011, 1587. 
[2]  F. Piscitelli, A. Coluccia, A. Brancale, G. La Regina, C. Giordano, J. 
Balzarini, G. Maga, E. Novellino, R. Silvestri. J. Med. Chem., 52, 2009, 1922. 
 392 
 
FAR-PO-21 Synthesis and Carbonic Anhydrase Inhibitory 
Activity of New 2-Aminochromenone Derivatives 
 
Congiu, C.,1 Onnis, V.,1 Balboni, G.,1 Innocenti, A.,2  Supuran, C. T.2 
 
1Dipartimento Farmaco Chimico Tecnologico, University of Cagliari, Via 
Ospedale , 72, I-09124, Cagliari, Italy 
2Dipartimento di Chimica, Laboratorio di Chimica Bioinorganica, University of 
Florence, Via della Lastruccia 3, Rm 188, Polo Scientifico, 50019-Sesto Fiorentino 
(Firenze), Italy 
E-mail: ccongiu@unica.it 
 
Carbonic anhydrase (EC 4.2.1.1, CA) is a family of metalloenzymes that catalyze 
the conversion of CO2 to HCO3- and H+, being involved in many physiologic 
processes [1]. CA isoforms are found in a variety of tissues where they participate 
in several important biological processes such as acid–base balance homeostasy, 
respiration, carbon dioxide and ion transport, bone resorption, ureagenesis, 
gluconeogenesis, lipogenesis, electrolyte secretion, and tumorigenesis among 
others [2]. Among the various natural antioxidants, phenolic compounds are 
reported to be active, quenching oxygen-derived free radicals by donating 
hydrogen atom or an electron to the free radical. Resveratrol, catechin, silymarin, 
and curcumin are natural compounds which are potent drugs, and dobutamine is a 
cardiac drug used after operations. Resveratrol (trans 3,4,5-trihydroxystilbene) is 
one such polyphenolic compound; it is found in red wine and is reported to have a 
variety of beneficial health effects, including protection against cardiovascular 
diseases [3]. We are now interested in evaluating of a new series of 2-
aminochromenone derivatives 1 strictly related to the above-mentioned natural 
phenols in order to study their inhibitory activity towards CA isoforms.  
 
1   
 
Here, we reported synthetic route to this family of compounds, and preliminary 
results of biological in vitro assays on carbonic anhydrase, using the esterase 
activity of hCA I and II, with 4-nitrophenyl acetate as substrate. 
 
[1]  C.T. Supuran Nature Rev Drug Discov, 7, 2008, 168. 
[2] Pastorekova S., Parkkila S., Pastorek J., Supuran C.T. J Enzyme Inhib Med 
Chem, 19, 2004, 199. 
[3] Gulcin I. Amino Acids, 32, 2007, 431. 
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Bacterial resistance to antibiotics has become an increasingly serious problem in 
recent years. Drug-resistant pathogens have evolved the MRSA and the VRSA 
phenotype. Unfortunately, bacterial resistance has also emerged against newer 
agents such as linezolid and daptomycin shortly after their use in clinic1 . Therefore 
the development of new and different antimicrobial drugs is very important goal 
and most of the research program efforts in this field are directed towards the 
design  of new agents.  
It is well documented that benzothiazine template is generally recognized as a 
privileged structure in medicinal chemistry to investigate both potentially 
anticancer2 and antibacterial molecules3. Looking at the importance of 
benzothiazine nucleus, in the recent past, we reported several examples of 
benzothiazine derivatives bearing substituents on the heterocyclic ring able to 
exhibit both antibacterial and antifungal activity (Figure 1). 
Here in, in continuation to extend our research on the 
synthesis and biological behaviour of 4H-1,4-benzothiazine 
analogues as potential drugs for antimicrobial management, 
we have been interested in the preparation and in SAR 
studies of new compounds containing modified 
benzothiazines.  
In order to enhance selectivity and potency, the MIC 
(Minimal Inhibitory Concentration) of the 
benzothiazine derivative, recorded on different Gram 
positive, Gram negative and Fungi strains belonging 
to American Type Colture Collection (ATCC) was 
reported. Docking studies carried out on the most 
active compound suggested a plausible binding mode 
for this class of antimicrobial agents. 
 
[1]. Davis, J. M.; Tsou, L. K.; Hamilton, A. D. Chem. Soc. Rev. 2007, 36, 326-334. (rif 58 
Chem. med chem.). 
[2]. F. Samizo, Y. Kamikawa, H. Katai, Y. Horiuchi, (Sumitomo Pharmaceuticals Co., 
Ltd., Japan) 2002. Patent. 
[3] D. Armenise, N. De Laurentis, A. Rosato, F. Morlacchi, J.Heterocyclic Chem. 2006, 
43, 1371-1378. 
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Nociceptin or orphanin FQ neuropeptide (N/OFQ) was identified in 1995 as the 
endogenous ligand for the NOP receptor, formerly known as ORL-1, a fourth 
member of the classical μ, δ and κ opioid receptors family [1]. N/OFQ-NOP system 
is found in central and peripheral nervous tissue, where it plays a key role in the 
nociception modulation, among other biological phenomena. Therefore, NOP 
receptor may provide a target for novel therapeutics against acute cancer pain [2]. 
On the basis of the confirmed affinity towards NOP receptor of the 2 adrenergic 
and 5-HT1A partial agonist spiroxatrine (Ki= 127 nM) [3], we focused our attention 
on the design, synthesis and characterization of novel NOP receptor ligands with a 
spiropiperidine core. At first, we studied the replacement of 1,4-benzodioxanyl 
moiety of spiroxatrine with 2-phenyl-, 2,2-diphenyl-1,3-dioxolanyl and 1,4-
spirodioxolanyl moiety, as in derivatives 1-3 (Fig.1). These compounds were 
evaluated in Chinese Hamster Ovary cells co-expressing the human recombinant 
NOP receptor and the C-terminally modified Gαqi5 protein (CHOhNOP cells). The 
bioassays showed that derivative 3 behaves as weak NOP receptor agonists (pEC50 
6.29), with potencies ~1000 fold lower than N/OFQ (pEC50 9.39). From the most 
promising lead candidate 3, we synthesized a series of 1,4-spirodioxolan-1,3,8-
triazaspirodecanones (derivatives 4-13, Fig.1). Biological assay results showed that 
the most interesting compounds of this series are 6 and 7, with pEC50 values 
comparable to that of spiroxatrine (pEC50 5.81, 6.33 and 6.10 respectively), but 
still ~1000 fold lower than N/OFQ. 
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The key reaction to obtain derivatives 1-13 is the nucleophilic substitution between 
1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-one and the toluensulfonate- or 2-
chloromethyl-intermediates resulting from the appropriate ketone or aldehyde, in 
the presence of Na2CO3 and dimethylformamide as solvent [4].  
 
[1] Zaveri N. Life Science, 2003, 73, 663-678; [2] Lambert D. Nature reviews, 
2008, 7, 694-710; [3] Calo’ G., Bigoni R., Rizzi A., Guerrini R., Salvadori S., 
Regoli D. Peptides, 2000, 21(7), 935-947; 
[4] Heine H. G. et al. Unites States Patent 6060482, 2000. 
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mechanism of action of new benzamido derivatives 
 
Demetrio Raffa, Benedetta Maggio, Fabiana Plescia, Stella Cascioferro, Maria 
Valeria Raimondi, Maria Grazia Cusimano, Giuseppe Daidone 
 
Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari dell’Università di 
Palermo, Via Archirafi 32, 90123-Palermo, Italy. 
gdaidone@unipa.it 
 
The cinnamoyl anthranilamides represent a class of biological active substances of great 
importance in medicinal chemistry [1,2]. Moreover, despite their wide range of biological 
activities, a review of the literature revealed that no anticancer activity is described for this 
kind of substances. Starting from the 2-cinnamamido-5-iodobenzamide, resulted able to 
inhibit the leukemic cell line K-562 proliferation with a percent of inhibition of 74% at 
10M concentration [3], we undertake the following structural modifications on 
cinnamamidobenzamide skeleton: the introduction of various substituents both on the 
benzamido and the cinnamamido moieties, the substitution of olefinic bond with the 
ethane, ethyne, cyclopropane and 
phenyl groups as reported in the 
scheme. 
Compounds 4, bearing an ethylene 
bond, caused growth inhibition against 
many tumor cell lines at low 
micromolar and submicromolar 
concentrations against every tumor cell 
line investigated The best activity was 
obtained when the 5 position of the 
benzamido moiety was substituted with 
an iodine moiety. COMPARE analysis, 
effects on tubulin polymerization and 
cell cycle distribution (G2-M phase 
block), including induction of 
apoptosis, indicate that these new 
antiproliferative compounds act as antitubulin agents [3]. Preliminary biological data on 2-
(3-phenylpropiolamido)benzamides 4, bearing an ethyne bond, showed a different 
mechanism of action considering that they caused a G0-G1 block of the cell cycle on K526 
cell line. 
 
[1] Gray N.S., Wodicka L., Thunnisen A.M.W.H., Norman T.C., Kwon S., Espinoza F.H., 
Morgan D.O., Barnes G., LeClerc S., Meijer L.M., Science, 281, 1998, 533. 
[2] Ogita, H.; Isobe Y.; Takaku, H.; Sekine, R.; Goto, Y.; Misawa, S.; Hayashi, H. Bioorg. 
Med. Chem. Lett., 11, 2001, 549 
[3] Raffa D., Maggio B., Plescia F., Cascioferro S., Plescia S., Raimondi M.V., Daidone 
G., Tolomeo M., Grimaudo S., Di Cristina A., Pipitone R.M., Bai R., Hamel E. Eur. J. 
Med. Chem., 46; 2011, 2786. 
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A3 adenosine receptor (A3AR) subtype is highly expressed in lungs, liver, and 
immune cells, and at lower densities in heart and brain and it is involved in a 
variety of key physiological processes such as release of inflammatory mediators 
and inhibition of tumor necrosis factor-α production. Agonists of this receptor have 
been recently analysed for pharmaceutical development based on their anti-
inflammatory, anticancer, and cardioprotective effects [1,2]. On this basis, the 
design and synthesis of potent and selective A3AR agonists could be helpful to 
provide tools for further characterization and evaluation of the physio-pathological 
role of this receptor and for the development of new drugs.  
Some years ago, we have reported the synthesis and binding affinity of a number of 
adenosine (Ado) derivatives bearing in 2-position (ar)-alkynyl chains, endowed 
with good affinity and different degrees of selectivity for the human A3AR [3]. The 
replacement in these compounds of the hydroxymethyl group in 4’-position of the 
sugar moiety with an ethylcarboxamido function or the introduction in N6-position 
of small alkyl groups enhanced A3AR affinity and selectivity, leading to 
compounds with A3AR Ki values at low nanomolar level.  
These molecules were tested for their ability to inhibit forskolin-stimulated 
adenylyl cyclase activity. Results showed that all the 5’-N-ethylcarboxamidoAdo 
(NECA) derivatives behave as full agonists of A3AR, while the 4’-unmodified Ado 
derivatives present a partial agonist profile at the same receptor. The N6-
substituents do not change the partial agonist activity observed for Ado derivatives 
unsubstituted at N6-position. 
Molecular modeling analyses, carried out by using the recently solved A2AAR 
crystal structure as template for homology modeling studies, helped to get a 
rationalization of the different pharmacological profile of the presented molecules 
at the human A3AR.  
 
[1] G. Cristalli, R. Volpini, Curr. Top. Med. Chem., 3, 2003, 355.  
[2] K.A. Jacobson, Z.G. Gao, Nat. Rev. Drug Dis., 5, 2006, 247. 
[3] R. Volpini, S. Costanzi, C. Lambertucci, S. Taffi, S. Vittori, K.-N. Klotz, G.  Cristalli, J. 
Med. Chem., 45, 2002, 3271. 
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Cytotoxicity and Topoisomerases Inhibition Properties. 
 
S. Salernoa, A. M. Marinia, F. Da Settimoa, G.Fornaciaria, S. Taliania, F. 
Simorinia, C. La Mottaa, O. Giab and L. Dalla Viab. 
aDipartimento di Scienze Farmaceutiche, Via Bonanno 6, 56126 Pisa; 
bDipartimento di Scienze Farmaceutiche, Via Marzolo 5, 35131 Padova.   
fsettimo@farm.unipi.it 
 
DNA topoisomerases (Topo I and Topo II) are essential enzymes that 
regulate the topological state of DNA during cellular processes such as replication, 
transcription, recombination, and chromatin remodelling, by catalyzing the 
relaxation of superhelical DNA through cycles of cleavage and religation. Under 
normal conditions, the covalent Topo I or II cleaved DNA intermediates are 
constitutively transient and, since the DNA relegation step is much faster than the 
cleavage one, they are tolerated by the cell. On the contrary, conditions that 
significantly alter the physiological concentration or lifetime of these breaks are 
responsible for DNA alterations that play a crucial role in inhibiting cell cycle 
progression. In this connection, the ability to interfere with the enzymes or generate 
enzyme-mediated damages is an effective strategy for cancer therapy; therefore 
DNA Topos (I and II) proved to be the excellent targets of clinically significant 
classes of anti-cancer drugs, forming the basis of widely used chemotherapy 
combinations. As a part of our extensive studies in this field [1,2], we describe the 
new series of Benzothiopyranoindoles 1 and Pyridothiopyranoindoles 2, which 
were functionalized with basic side chains on the indole nitrogen atom. 
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The novel derivatives, evaluated in vitro for their antiproliferative activity on 
human tumour cell lines (HeLa, A-431 and MSTO-211H), showed a significant 
ability to inhibit cell growth with IC50 values in the low micromolar range. Linear 
dichroism measurements showed that the compounds behave as DNA-intercalating 
agents. Moreover, relaxation assays evidenced a dose-dependent inhibition of Topo 
I and/or II activity.  
 
[1] S. Salerno, F. Da Settimo, S. Taliani, F. Simorini, C. La Motta, G. 
Fornaciari, A.M. Marini, Curr. Med. Chem., 2010, 17, 4270. 
[2] L. Dalla Via, S. Marciani Magno, O. Gia, A. M. Marini, F. Da Settimo, S. 
Salerno, C. La Motta, F. Simorini, S. Taliani, A. Lavecchia, C. Di Giovanni, G. 
Brancato, V. Barone, E. Novellino, J. Med. Chem., 2009, 52, 5429. 
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The Translocator Protein (18 kDa) (TSPO), is widely expressed in glial cells and in 
peripheral tissues, and is involved in a variety of biological processes 
(steroidogenesis, cell growth and differentiation, apoptosis induction...) [1,2] TSPO 
basal expression is alterated in several disorders, including a variety of tumours, 
neuropathologies and neuroinflammation, anxiety and mood disorders. [1,2] 
In last years, we have described potent and selective TSPO ligands, the N,N-
dialkyl-(2-phenylindol-3-yl)glyoxylamides I, [3,4] which allowed the development 
of newfluorescent or radio-labeled probes targeting this protein [5-7]. In this study, 
we reported a novel series of indolglyoxylamides, designed to investigate the 
binding role of the lipophilic pocket L1 of the hypothesized 
pharmacophore/receptor model.[1,2] Specifically, compounds featuring a bulky 
biphenyl II or 2-napthyl III group, phenyl with hydrophilic substituents IV, and 
fur-2-yl or thien-3-yl rings V at the 2-position of the indole nucleus, were 
synthesized and biologically evaluated. 
 
[1] Papadopoulos, V. et al. Trends Pharmacol. Sci., 27, 2006, 402.  
[2] Casellas, P. et al. Neurochem. Int., 40, 2002, 475.  
[3] Primofiore, G. et al. J. Med. Chem., 47, 2004, 1852.  
[4] Da Settimo. F. et al. J. Med. Chem., 51, 2008, 5798.  
[5] Taliani, S. et al. J. Med. Chem., 50, 2007, 404. 
[6] Taliani, S. et al. J. Med. Chem., 53, 2010, 4085.  
[7] Pike, V.W. et al. J. Med. Chem., 54, 2011, 366. 
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Ex vivo aPTT prolongation in mice at 1 h and 2 h after 
oral administration (100 mg/kg dose). 
FAR-PO-28 Lead optimization studies, synthesis and 
biological evaluation of new isonipecotamide-based orally active 
thrombin inhibitors 
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aDipartimento Farmaco Chimico and bDipartimento Farmaco Biologico, Università 
degli Studi di Bari “Aldo Moro”, Via Orabona 4, I-70125, Bari, Italy. 
decandia@farmchim.uniba.it 
 
Current anticoagulant therapy of venous thromboembolism (VTE) is based on 
parenterally administered heparins and orally administered vitamin K antagonists 
(e.g., warfarin), but narrow therapeutic window and side effects, such as bleeding, 
diet and genetic makeup influence, are associated with their use [1]. Recently, key 
serine proteases of the blood coagulation cascade, such as thrombin (thr) and factor 
Xa (fXa), have emerged as promising targets for anticoagulants, and indeed several 
direct inhibitors of thr (e.g., argatroban, dabigatran) and fXa (e.g., rivaroxaban, 
apixaban) have been introduced in therapy or in advanced clinical trials [2,3]. 
Some years ago we investigated the isonipecotanilide scaffold for new thr/fXa 
inhibitors [4]. Further optimization studies led us to develop new benzyloxy 
derivatives of N-(phenyl)-1-(pyridin-4-yl)piperidine-4-carboxamide, one of them 
(i.e., the 3-F analog, see below) showing low nanomolar Ki (thr) value, high 
selectivity against other serine proteases and good anticoagulant activity as 
measured by the activated partial thromboplastin time (aPTT) test. 
 
 
 
 
 
 
 
 
 
 
Physicochemical profiles of the newly synthesized compounds were assessed and 
their potential oral bioavailability estimated, by measuring effective permeability 
coefficients using PAMPA (Parallel Artificial Membrane Permeability Assay). 
 
[1] Mackman, N. Nature 2008, 451, 914-918. 
[2] Pinto, D.J.; Smallheer, J.M.; Cheney, D.L.; Knabb, R.M.; Wexler, R.R. J. Med. Chem. 2010, 
53,6243-6274. 
[3] de Candia, M.; Lopopolo, G.; Altomare, C. Exp. Opin. Ther. Patents 2009, 19, 1535-1580. 
de Candia, M.; Liantonio, F.; Altomare, C. et al. J Med. Chem. 2009, 52, 1018-1028. 
Ki (thr) = 6 nM 
Ki (fXa)= 5640 nM 
aPTT2 (in vitro) = 6.60 M 
N
N
N
H
O
O
F
 401 
 
FAR-PO-29 Novel Bifunctional Compounds Targeting 
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Future therapies for diseases associated with altered dopaminergic signaling, 
including Parkinson’s disease, schizophrenia and drug addiction or drug 
dependence, may be substantially built on the existence of intramembrane receptor-
receptor interactions within receptor mosaics where it is believed that the D2 
receptor may operate as the “hub receptor” [1]. In particular, it has been proposed 
that striatal dopaminergic neurotransmission could be under the control of  receptor 
heteromers containing D2 autoreceptors and non-7 nicotinic acetylcholine 
heteroreceptors [2]. 
In an attempt to investigate the biochemical and functional interactions 
between dopaminergic autoreceptors and nAChRs containing the 2 subunit, we 
designed and prepared a group of potential bifunctional derivatives incorporating a 
D2/D3 agonist moiety and a nicotinic 42 antagonist fragment, linked by 
polymethylene spacers of different length. 
 
 
 
The new compounds have been biologically characterized for their 
affinity/specificity/functional profile at the target nACh and D2 receptor subtypes. 
The synthesis of the designed derivatives and the results of their pharmacological 
investigation will be presented and discussed. 
 
[1] K.Fuxe, D.Marcellino, A.Rivera, Z.Diaz-Cabiale, M.Filip, B.Gago, D.C.S.Roberts, 
U.Langel, S.Genedani, L.Ferraro, A.de la Calle, J.Narvaez, S.Tanganelli, 
A.Woods, L.F.Agnati, Brain Res.Rev., 58, 2008, 415-452. 
[2] D.Quarta, F.Ciruela, K.Patkar, J.Borycz, M.Solinas, C.Lluis, R.Franco, R.A.Wise, 
S.R.Goldberg, B.T.Hope, A.Woods, S.Ferré,  Neuropsychopharmacol., 32, 2007, 35-42. 
D2/D3 agonist 42 antagonist 
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thiophene-pyridine based alpha helix mimetics. 
 
Marcella De Giorgi,1,2 A.S. Voisin-Chiret, 1 J. Sopková-de Oliveira Santos, 1 M. 
Muraglia, 2 F. Corbo, 2 C. Franchini, 2 S. Rault1  
 
1Université de Caen Basse-Normandie, U.F.R. des Sciences Pharmaceutiques, 
CERMN, UPRES EA-4258, FR CNRS INC3M, Bd Becquerel, 14032 CAEN 
Cedex, France.  
2Dipartimento Farmaco-chimico dell’Università degli Studi di Bari Aldo Moro, Via 
Orabona 4, 70125, BARI, Italia. 
marcella.degiorgi@farmchim.uniba.it or marcella.degiorgi@unicaen.fr 
 
Protein-protein interactions (PPIs) are attractive targets because they control 
numerous cellular processes. Consequently their misregulation can result in 
numerous disease states.1 In particular, in oncology, among these PPIs, several 
approaches have been developed to target Bcl-2 family proteins and numerous 
strategies of non-peptidic small molecules, structurally and functionally alpha helix 
mimetics have been presented in the literature.2  
 
 
 
 
 
 
 
 
 
 
          Figure 1 
 
Synthetic aspects, molecular modeling studies and preliminary biological 
evaluation will be reported in the poster presentation. 
 
[1]. Davis, J. M.; Tsou, L. K.; Hamilton, A. D. Chem. Soc. Rev. 2007, 36, 326-334. 
[2]. Ross, N. T.; Katt, W. P.; Hamilton A. D. Phil. Trans. R. Soc. A 2010, 368, 989-1008 
[3] a) Voisin-Chiret, A. S.; Bouillon, A.; Burzicki, G.; Célant, M.; Legay, R.; El-Kashef, 
H.; Rault, S., Tetrahedron 2009, 65, 607-612; (b) Burzicki, G.; Voisin-Chiret, A. S.; 
Sopkovà-de Oliveira Santos, J.; Rault, S., Tetrahedron 2009, 65, 5413-5417; (c) Burzicki, 
G.; Voisin-Chiret, A. S.; Sopkovà de Oliveira Santos, J.; Rault, S. Synthesis 2010, 16, 
2804-2810; (d) Voisin-Chiret, A. S.; Muraglia, M.; Burzicki, G.; Perato, S.; Corbo, F.; 
Sopkovà de Oliveira Santos, J.; Franchini, C.; Rault, S., Tetrahedron  2010, 66, 8000-8005; 
(e) De Giorgi, M.; Voisin-Chiret, A. S.; Sopkovà de Oliveira Santos, J.; Corbo, F; 
Franchini, C.; Rault, S., 2011, submitted. 
The research program of our laboratory consists the design 
and synthesis of small to medium sized oligo(het)aryl 
scaffolds based on a new methodology using iterative 
Suzuki cross-coupling reactions named Garlanding 
concept.3 In particular, this work is focused on the change 
of the nature of (het)aromatic units with the aim to obtain 
new less hydrophobic thienyl pyridyl scaffolds (Figure 1). 
Further, in the case of the peculiar interaction of Bcl-XL and 
the BH3 domain the length and the size of these 
oligopyridines were guided by our molecular modeling 
studies on bi-, ter- and quater-pyridines in according with 
Hamilton’s work. 
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Temozolomide is a 3-methyl-imidazotetrazine currently in the market with trade name 
Temodal® and is used in the treatment of melanoma, mycosis fungoides, and brain tumors 
[1-4]. Temozolomide itself is a prodrug, spontaneously hydrolyzing at physiologic pH  into 
MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide) and a methyldiazonium ion. This 
latter acts as a DNA methylating agent mainly at the N7 position of guanine [5-7].  We 
synthesized pyrrolo[2,1-d][1,2,3,5]tetrazinones that hold the deaza skeleton of 
temozolomide. Surprisingly the 3-methyl derivatives were the least active whereas the 3-
aryl compounds had remarkable antineoplastic activity having GI50 values from the low 
micromolar-nanomolar range. Pyrrolotetrazinones showed a mechanism of action different 
from that observed by temozolomide. Infact they inhibit microtubule polymerization, 
induce G2/M arrest of cell cycle and cause apoptosis through the mitochondrial pathway. 
Considering the previous results we synthesised new 3-chloroethyl-pyrrolotetrazinones to 
verify whether the mode of action would resemble to that of temozolomide or to that of the 
deaza-analogues. Cytotoxicity was evaluated 72 h after incubation with compounds in 
several human cell lines. Generally compounds were cytotoxic in Jurkat cells, whereas one 
of them presents an antiproliferative activity in all cell lines with GI50 20-0.6 μM. 
Moreover, since the resistance onset is one of the main problems for classical anticancer 
drugs, the cytotoxicity of this latter compound was also studied in a P-glycoprotein over-
expressing cell line and its antiproliferative effect was maintained. We also performed cell 
cycle analysis to investigate the kind of cellular death (necrosis or apoptosis) and it 
resulted that compounds induced cell death by apoptosis. However, no clear block in some 
specific phase was detected. Other studies were also carried out to check the involvement 
of mitochondria in the apoptotic process after JC-1 cell staining.  Other experiments to 
identify their mechanism of action are now in the pipeline; in particular since 
temozolomide is a DNA alkylator, DNA will be considered as the possible target for these 
new compounds. 
 
[1] Bleehen NM, et al  J  Clin Oncol 1995, 13:910–913; [2] O’Reilly SM, et al Eur J Cancer 1993, 
29A:940–942; [3] Newlands ES, et al Br J Cancer 1992, 65:287–291; [4] Newlands ES, et al 
Cancer Treat Rep 1997, 23:35–61; [5] Catapano CV, et al Cancer Res 1987, 47:4884–4889; [6] 
Denny BJ, et al Biochem.1994, 33:9045–9051; [7] Curtin NJ, et al A Clin Cancer Res 2004, 10:881–
889. 
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A new generation of selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) was 
developed to circumvent the major side effects of cyclooxygenase-1 (COX-1) and 
COX-2 inhibitors (stomach ulceration and nephrotoxicity).1Structural features of 
known selective cyclooxygenase-2 inhibitors and of COX isozymes led our 
research group to synthesize the novel class of 1,5-diarylpyrrole derivatives.A 
series of previously patented 1,5-diarylpyrrol-3-acetic esters and 1,5-diarylpyrrole-
3-alkoxyethyl ethers proved to be potent and selective COX-2 inhibitors in in vitro 
cell culture assay.1,2 The potential anti-inflammatory and antinociceptive activities 
of these compounds were evaluated in vivo, where they showed a very good 
activity against both carrageenan-induced hyperalgesia and edema in the rat paw 
test. In particular, compounds 1 and 2  appear to be equipotent with rofecoxib. In 
the Human Whole Blood (HWB) test, compound 2 demonstrated to be as selective 
as valdecoxib. The potential anti-inflammatory and antinociceptive activities of 
compounds 1 and 2 were evaluated in vivo, where they showed a very good activity 
against both carrageenan induced hyperalgesia and carrageenan induced oedema in 
the rat paw, with a complete remission 1 hour after the administration.2,3 
Compound 2 was  then selected for a preliminary pharmacokinetic analysis in male 
Sprague−Dawley rats. Unfortunately, plasma levels of this compound showed a 
low oral bioavailability, probably due to a rapid first-pass metabolism (Fig. 1). So a 
new series of fluorinated derivatives, 4 and 5, was synthetized in order to obtain an 
improved parmacokinetic profile: substitution of the 4’-H by the fluorine atom  can 
profoundly change the conformational preferences of a small molecule because of 
size and stereoelectronic effects4 along with the possibility for 4’-F to exert an 
advantageous metabolic obstruction.  
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Compounds 3 and 6 were also synthesized and evaluated as candidate ligands for 
Positron Emission Tomography (PET) to characterize their pharmacokinetic and 
distribution properties. 
 
[1]Biava, M. et al. Cyclooxygenase-2 Inhibitors. 1,5-Diarylpyrrol-3-acetic Esters with Enhanced Inhibitory 
Activity toward Cyclooxygenase-2 and Improved Cyclooxygenase-2/Cyclooxygenase-1 Selectivity J. Med. 
Chem. 2007, 50, 5403-5411[2]Anzini, M. Biava, M. et al. Synthesis, Biological Evaluation, and Enzyme Docking 
Simulations of 1,5-Diaryl pyrrole-3-alcoxyethyl Ethers as Highly Selective COX-2 Inhibitors Endowed with 
Anti-inflammatory and AntinociceptiveActivity J. Med. Chem., 2008, 51, 4476-4481.[3] Cappelli, A.; Anzini, 
M.; Caselli, G.; Giordani, A.; Makovec, F.; Rovati, L.C.; Biava, M. 3-Substituted-1,5-diarly-2-alkyl-pyrroles 
Highly Selective and Orally Effective COX-2 Inhibitors. WO/2008/014821.[4]Müller, K.; Faeh, C.; Diederich, 
F.; Fluorine in Pharmaceuticals: Looking Beyond Intuition. Science, 2007,Vol 317, 1881-1886. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Profilo della Concentrazione Plasmatica del 2 dopo singola smministrazione
orale (10 mg/Kg) e intravenosa (10mg/Kg) in ratti maschi "Sprague-Dawley".  
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 Nonsteroidal antinflammatory drugs (NSAIDs) inhibit the 
cyclooxygenase enzymes (COXs), and are widely used for the treatment of 
inflammation, pain, and cancers. A selective inhibition of the COX-2 
isoform is desirable, as this is overexpressed during inflammatory events.1 
Therefore, many efforts have been directed towards the development of 
COX-2 selective inhibitors. Unfortunately, most of these inhibitors have 
been found to be highly cardiotoxic, as they produce a strong 
prostacyclin/thromboxane imbalance.2 Therefore, a deep understanding of 
the molecular bases of COXs selective inhibition is of great demand. 
Recently, we have successfully used metadynamics1 to study the binding 
behavior of a highly potent COX-2 selective inhibitor, SC-558, in both 
COX-1 and COX-2 isoforms.2 Following the line traced in our previous 
work, we have here extended the metadynamics studies on a series of potent 
COXs inhibitors endowed with different selectivity profiles. Our results 
provide useful computational tools to design small organic molecules with 
fine-tuned COX-1/COX-2 potency and selectivity. Furthermore, these results 
can be of paramount importance in the design of less toxic novel anti-
inflammatory drug candidates. 
[1] G. D. Anderson, S. D. Hauser, K. L. McGarity, M. E. Bremer, P. C. Isakson and S. A. 
Gregory, J. Clin. Invest., 97, 1996, 2672. 
[2] L.-C. Chen and D. M Ashcroft, Pharmacoepidemiology and Drug Safety, 16, 2007, 
762. 
[3] A. Laio and M. Parrinello, Proc. Natl. Acad. Sci. U.S.A., 99, 2002, 12562. 
[4] V. Limongelli, M. Bonomi, L. Marinelli, F. L. Gervasio, A. Cavalli, E. Novellino and M. 
Parrinello, Proc. Natl. Acad. Sci. U.S.A., 107, 2010, 5411. 
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It is well known that adenosine interacts with G-protein coupled receptors 
that were classified in four receptors subtypes: A1, A2A, A2B and A3 adenosine 
receptors (AR). Adenosine receptor antagonists have several potential therapeutic 
applications. In particular, A1 antagonists are diuretic. Because antagonism towards 
A2A AR gave neuroprotection, antagonists for this receptor subtype are useful in 
neurodegenerative diseases, in particular for the treatment of Parkinson's disease. 
A2B AR antagonists could be used in asthma and diabetes, while A3 antagonism is 
useful in glaucoma, moreover, due to the fact that A3AR is widely expressed in 
some cancer cells, A3AR antagonists could be used for tumoral diagnosis.[1] 
It was demonstrated by several studies that pyrazolo-triazolo-pyrimidine 
(PTP) core is a good template to obtain potent and selective adenosine receptor 
antagonists.[2] Until now all the PTP derivatives substituted at the 5 position bear 
phenylureidic or phenylacetamidic moieties, with a very poor variability.[3] So we 
have synthesized a novel class of 5-alkylamino-pyrazolo[4,3-e]1,2,4-triazolo[1,5-
c]pyrimidines. This kind of substitution allows the introduction of several different 
amines, such as alkyl, cycloalkyl and benzyl amines, but also disubstituted-amines 
and hydroxylamines, which enabling the investigation of both the volume and 
nature of the receptor binding cavity.  
Good results were obtained towards the A3 adenosine receptor subtype, in 
particular when a 5-bulky substituent, such as a benzhydrylamine, was present 
(KihA3=0.83 nM). Moreover a stereoselectivity by the binding pocket was 
observed for the derivatives substituted with a 1-phenyl-ethylamine, where the S 
isomer was 12-fold more potent than the R isomer at the A3 AR. 
[1] K.A.Jacobson, Z.-G.Gao. Nature Rev.DrugDisc., 5, 2006, 247.  
[2] S.Moro, Z.-G.Gao, K.A.Jacobson, G.Spalluto. Med.Res.Rev., 26, 2006, 131. 
[3] S.L.Cheong, G.Venkatesan, P.Paira, R.Jothibasu, A.L.Mandel, S.Federico,     
G.Spalluto, and G.Pastorin. Int.J.Med.Chem. In press: doi:10.1155/2011/480652 
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Continuing our research on synthesis and study of biologically active compounds, a 
series of 3-phenyl-pyrrolo[3,2-f]quinazolin-1-one derivatives was synthesized 
starting from 5-amino-indoles via a condensation with N-
ethoxycarbonylthiobezamides and next thermal cyclisation. . The newly 
synthesized compounds showed the absence of cytotoxic activity on human cell 
lines in vitro up to 50-100 µM concentrations. On the basis of their structural 
analogy with anti-thrombin pyrroloquinazolines reported in Literature [1-4], some 
of them were chosen to evaluate their inhibitory effect on platelet activation and 
aggregation. The most active compound 18 inhibited collagen- and thrombin-
induced platelet aggregation in concentration dependent manner causing a 
complete inhibition at a concentration of about 4 µM. Other experiments, 
performed with compound 18, addressed to study the action-mechanism of these 
pyrroloquinazolinones, suggest that they act at least at two sites: one preceding the 
agonist-induced increase of cytosolic [Ca2+], deriving from the endoplasmic 
reticulum, and protein-kinase activation, and one following these events in the 
platelet activation cascade leading to aggregation. Synthesis of new compounds 18-
23 (Fig. 1) and results from a preliminary biological activity evaluation will be 
reported. 
 
 
 
 
Figure 1. Structures of phenyl-pyrroloquinazolinones synthesized and screened for 
their platelet aggregation inhibitory activity. 
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[1] Dixit, A., Kashaw, S.K., Gaur, S., Saxena, A.K. Bioorg. Med. Chem., 2004, 12, 
3591-3598. 
[2] Ahn H.S., Arik L., Boykow G., Burnett D.A., Caplen M.A., Czarniecki M., 
Domalski M.S.,  
     Foster C., Manna M., Stamford A.W., Wu Y. Bioorg. Med. Chem. Lett. 1999, 9, 
2073-2078.  
[3] Huang, L-J.; Hsieh, M-C.; Teng, C-M.; Lee, K-H.; Kuo, S-C. Bioorg. Med. 
Chem. 1998, 6,   
     1657-1662. 
[4] Verstraete M., Zoldhely P. Drugs 1995; 49, 856–884. 
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Ageing affects many cellular processes which favor chronic 
neurodegenerative diseases, among them Alzheimer’s disease (AD). AD is a 
complex pathology which involves more than 20 million individuals in the 
world.[1] AD is characterized by memory loss and other cognitive deficiencies, by 
the progressive dissolution of the personality as well as of the intellectual 
capacities. AD is accompanied by damages to brain capillaries, impairment of 
cholinergic transmission in both the hippocampus and the cerebral cortex as well as 
by extracellular accumulation of -amyloid (A plaques and intracellular tau 
protein aggregates in different area of the brain. In addition, it has been shown that 
oxidative stress, related to an abnormal production of reactive oxygen species 
(ROS) and nitrogen species (RNS) and/or depletion of the antioxidant defences, is 
an important early event in AD.[2] An increasing amount of experimental data 
suggests that AD is a cerebral microvascular disorder with neurodegenerative 
consequences, rather than the opposite. Microvascular disorders occurring in 
advanced ageing or in the presence of increased oxidative stress are consequent to 
the endothelial dysfunction, namely to a reduced capacity of the endothelial cells to 
produce nitric oxide (NO).[3] 
On this basis we designed new 
“multifunctional” molecules 
potentially useful in modifying 
the development and the progress of AD. These products were obtained by 
combining the structure of L-carnosine, a natural dipeptide endowed with a 
complex and multifactorial antioxidant action, with nitrooxy NO-donor moieties. 
These two pharmacophores were joined through an amide bond which, in a 
previous work, allowed us to obtain compounds stable in human serum, 
overcoming the major drawback of carnosine, while preserving its beneficial 
properties.[4] Synthesis, serum stability, vasodilating properties, antioxidant 
activity, ability to scavenge reactive carbonyl species (RCS) as well as copper (II) 
chelating properties of the obtained models are reported. 
[1] C.P. Ferri et al., Lancet, 366, 2005, 2112. 
[2] A. Nunomura, et al., J. Neuropath. Exp. Neur., 65, 2006, 631. 
[3] J.C. de la Torre, G.B. Stefano, in Biomedical Significance of Nitric Oxide. 
G.B. Stefano, Ed. Medical Science International: Warsaw-New York, 2003, 213. 
[4] M. Bertinaria et al. J. Med. Chem., 54, 2011, 611. 
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Recently, the drug discovery process has been frequently focused on the screening 
of plant extracts commonly used in traditional medicines as source of novel 
therapeutic agents. In this context, the object of the present study was to evaluate 
the folk claims of Eremurus persicus. Genus Eremurus (Asphodelaceae), with its 
45 species, is distributed over large area in Central Asia [1].  Eremurus persicus 
(Jaub. & Spach) Boiss is a medicinal plant of Kurdistan; its root extracts are used 
by native people as folk remedies for managing wounds, inflammatory and skin 
diseases. Basing on our previous experience [2] several extracts were prepared by 
varying either the solvent mixture or the extraction procedure. All prepared extracts 
were tested in vitro to evaluate anti-tyrosinase and free radical scavenging 
properties, since these are relevant bioactivities related to skin disorders and 
inflammation [3]. The ethanolic extract obtained from maceration of plant material 
pre-treated with petroleum ether gave rise to the most interesting antiradical and 
antityrosinase effect, therefore it has been selected as the hit extract. The 
phytochemical fingerprint of the hit extract was investigated by HPLC-UV-PAD 
coupled by either CD or MS detector and herein presented together with the 
preliminary biological results reached till now. 
 
 
[1] K. N. Safar et al, Iran. J. Bot., 15, 2009 
[2] R. Gaggeri et al, The Open Natural Products Journal, 3, 2010 
[3] I. Süntar et al, J. of Ethnopharmacol., 135, 2011 
 
The Authors would like to thank Regione Lombardia (PROKURDUP Project) for 
financial support 
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   Malaria is a global health problem and a major cause of morbidity and mortality 
worldwide, especially in SubSahara Africa. The extensive and often suboptimal use 
of common antimalarial drugs led to the rapid spread of drug resistant strains of 
Plasmodium falciparum, the cause of the most severe form of the disease. To 
overcome resistance, new antimalarial agents with innovative structure are 
necessary. 
   Due to the consolidated experience of our research group on the synthesis of 
diazabicyclo compounds [1] and the evidence that some diaryl substituted 
azabicyclo nonanes show antimalarial activity [2], we designed and synthesized a 
series of novel 3,9-diaza-bicyclo[3.3.1] 
nonane derivatives (I), as new scaffolds for 
potential antimalarial agents. The compounds 
present a benzyl group at position 3,  and 
different substituents of variable dimension, 
lipophilicity and electronic features at 
position 9. Synthesis, molecular modeling 
studies and in vitro activity against both chloroquine sensitive or resistant strains of 
P. falciparum strains will be presented. 
 
 
[ 1]       G. Pinna et al., Synthesis, modelling and µoppioid receptor affinity of 
       N-3(9)-arylpropenyl-N-9(3)-3,9-propionyl-3,9-diazabicyclo[3.3.1]nonanes 
      Il Farmaco, 55, 2000, 553                                                 
       H. Berger et al. Novel azabicyclo[3.2.2]nonane derivatives and their activities 
against Plasmodium falciparum K1 and Tripanosoma brucei rhodensiense, Bioorg. 
Med. Chem., 16, 2008, 6371 
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The psoralen tricyclic moiety constitutes the basic chromophore from which the 
drugs employed in the PUVA therapy (psoralen plus UVA light) were developed. 
Nevertheless, this treatment presents some drawbacks, both short-term (erythema, 
hyperpigmentation) and long-term (premalignant keratoses, skin cancers)[1-2]. 
Within the attempt to obtain promising new photochemotherapeutic drugs, two 
strategies were developed: fusing the furan ring to the coumarin moiety in [2,3-h] 
or [2,3-f] to obtain angular furocoumarin, angelicins or allopsoralens, respectively. 
A further interesting approach led to tetracyclic derivatives, characterized by the 
condensation of a fourth nucleus to the tricyclic furocoumarin chromophore and by 
a protonable side chain to increase the solubility in aqueous media [3-4].
In this connection we prepared and 
studied a structure characterized by 
the condensation of a cyclohexenylic 
ring at the 4,5-double bond of the 
angelicin nucleus and a 
dimethylaminopropoxy side chain 
inserted in position 5 (1). The 
photoantiproliferative activity on 
human tumor cell lines along with the 
interaction with DNA was studied 
both in the dark and after UVA 
irradiation in comparison with the 
analogue benzoderivative (2) [3].  
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The isolation and characterization of the furan side photoadduct with the 
pyrimidine base thymine is also reported. Finally, the ability to interact with 
topoisomerase II in the dark was investigated. 
 
[1] N. J. Lowe, V. Chizhevsky, and H. Gabriel, Clin. Dermatol., 15, 1997, 745. 
[2] R. S. Stern, J. Am. Acad. Dermatol., 44, 2001, 755. 
[3] L. Santana, E. Uriarte, L. Dalla Via, and O. Gia, Bioorg. Med. Chem. Lett., 
 10, 2000, 135. 
[4] L. Dalla Via, S. Mammi, E. Uriarte, L. Santana, I. Lampronti, R. Gambari, 
 and O. Gia, J. Med. Chem., 49, 2006, 4317. 
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Matrix Metalloproteinases (MMPs) represent a family of proteolytic enzymes 
involved in a variety of important physiological and pathological processes. [1] In 
the present study, 104 structurally-solved MMPs were examined to gain insights 
into the structural features governing molecular recognition and underlying distinct 
biological activities. Protein electrostatic similarity was, for the first time, analyzed 
through the Chaotic Map Clustering (CMC), an algorithm successfully used in 
other fields of applied sciences. [2] The investigation was conducted on the entire 
MMP structures as well as on the protein binding sites. Interestingly, CMC 
provided a reliable and comprehensive representation of the structural and 
functional relationships existing among MMPs enlarging and complementing the 
current knowledge in the field. [3]  
Based on the variation of the electrostatic potentials, CMC was successful in 
analysing MMP target family landscape and their different subsites. The first 
investigation resulted a rational figure interpreting both the domain organization as 
well as the substrate specificity classifications. The second enabled to discriminate 
the diverse MMP classes related to the high specificity of the S1′ pocket, to detect 
both the occurrence of punctual mutation of ionisable residues and different side 
chain conformation accounting for likely induced fit phenomena. In addition, CMC 
was successful even for standard pairwise analyses of protein sequences. Finally, 
the CMC algorithm was used to properly explain the complementarity existing 
between the ligand molecular shapes and the accessible MMP void volumes. [4] 
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We have previously demonstrated that 2-adrenergic (2-AR) molecules, related to 
the non-subtype selective antagonist 1, displayed different activity at 2A-, 2B- and 
2C-AR subtypes, depending on the peculiar nature of the ortho substituent in the 
Ar ring. For example, phenyl and thienyl groups converted 1 into the efficacious 
agonists 2 (biphenyline) and 3, respectively, activating 2A- and 2C-subtypes. 
Allyl or cyclopropyl groups of lower steric bulk turned the biological profile of the 
antagonist 1 only at 2C-subtype: 4 (allyphenyline) and 5 were potent 2C-agonists, 
whereas efficiently antagonized 2A-AR. From in vivo study 4 significantly 
enhanced morphine analgesia (due to 2C-AR agonism), was devoid of sedative 
side effects (due to 2A-AR antagonism) as well as prevented and contrasted 
morphine tolerance and dependence at very low dose (0.05 mg/Kg) [1]. 
Encouraged by these results, we prepared and studied compounds 6-12 inspired by 
4. They were characterized by ortho substituents of moderate steric bulk and 
positive or negative  and  contributions in all the combinations. A molecular 
modeling study performed on 2-12 highlighted that the desired 2C-agonism/2A-
antagonism combination was displayed by ligands having favoured extended 
conformation (i.e. 4 and 5). In contrast, the activation of both 2A- and 2C-
subtypes was produced by ligands endowed with favoured folded conformation 
(i.e. 2 and 3). 
 
2 3 4 5  
 
This work was supported by the Monte dei Paschi di Siena Foundation Award. 
 
[1]    F. Del Bello et al. J. Med. Chem. 53, 2010, 7825-7835 and references therein. 
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The ubiquitin-proteasome pathway is the major proteolytic system of all 
eukaryotic cells and plays a very important role in the degradation of many proteins 
critical for cell division, growth activation, signaling and transcription. A 
deregulation of this system could lead to an anarchic cell proliferation and to a 
tumor development [1]. For these reasons, ubiquitin/proteasome inhibition has 
become a new and significant strategy for the drug development in cancer 
treatment. 
Within the present work, the strategy targeting proteasome has been 
delineated with the aim of developing efficacious antitumor agents. This approach 
was based on the design of conformationally constrained peptidomimetics by 
reducing the peptidic character of the tripeptide boronate Z-Leu-Leu-Leu-B(OH)2 
(MG262, Ki=18 pM, Figure 1), reversible inhibitor of the chymotrypsin-like 
activity of the 20S proteasome. This strategy has been accomplished by bioisosteric 
replacement of the P3 Leu residue with a 2-pyridone nucleus [2]. This structural 
modification could ensure stability towards degradation by enzymes, enhancement 
of oral bioavailability, reduction of conformational freedom of peptides, 
improvement of the selectivity towards the target enzyme. 
Further modifications of new conformationally constrained 
peptidomimetics involved the P2 site according to the features of the dipeptide 
boronate bortezomib (Velcade®, Figure 1), the first proteasome inhibitor approved 
by FDA for the treatment of haematological malignancies such as multiple 
myeloma and mantle cell lymphoma. In this context we introduced bulky 
substituents at the P2 site (i.e. Phe residue, Figure 1), whereas the P1 site was kept 
constant because of its importance for substrate specificity. Additional changes 
involving the N-terminal protective group have been realized in order to improve 
the binding properties of the new inhibitors (Figure 1). 
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The synthesized peptidomimetic boronates are currently under screening to 
evaluate their inhibitory properties against the chimotripsyn-like, trypsin-like and 
peptidyl-glutamyl peptide hydrolase proteasome activities. Selectivity towards the 
target enzyme will be also evaluated by testing them against bovine pancreatic α-
chymotrypsin. The results of such investigation will be presented and discussed. 
 
[1] G. De Martino, T. Gilette, Cell, 129, 2007, 659. 
R. Ettari, C. Bonaccorso, N. Micale,T. Schirmeister, M.L. Calabrò, S.Grasso, 
M.Zappalà, ChemMedChem, DOI: 10.1002/cmdc.20110093. 
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Today around 200 million people worldwide are parasitized by several 
species of Schistosoma and in particular S. mansoni, and more than 200 000 people 
die every year from this neglected disease. Praziquantel (PZQ) is the only drug 
currently administered. The mechanism of action of this drug has not been 
elucidated; however, inhibition of calcium channels and inhibition of adenosine 
uptake have been suggested to be involved in PZQ activity. Since PZQ-resistant 
worms have been identified, the development of new anti-schistosomiasis drugs is 
urgently needed [1]. 
Recently, several furoxans (1,2,5-oxadiazole 2-oxides) have been shown to 
be endowed with good activity against S. mansoni. The proposed mechanism of 
action consists in the inhibition of thioredoxin glutathione reductase (TGR), an 
essential enzyme for parasite redox balance, through nitrosylation of cysteine 
and/or selenocysteine residues of the protein. This reaction takes place as a 
consequence of the interaction of the compounds with the enzyme and subsequent 
NO release [2]. 
On this basis we decided to conjugate PZQ and furoxan pharmacophores in 
a single molecule in order to obtain dual drugs exploiting antischistosomal 
properties through two different mechanisms of action. Through slight 
modifications of an inexpensive and straightforward synthesis [3], six novel PZQ 
derivatives were prepared, three of them bearing furoxan moieties with the 
remainder bearing the corresponding furazan (1,2,5-oxadiazole) moieties and 
devoid of NO-donor properties. 
All the compounds have been subjected to structural and pharmacological 
characterization for their activity against adult ex vivo worms and their capability to 
inhibit TGR activity. Moreover in vivo studies are in progress in order to evaluate 
whether the compounds are able to decrease worm burdens in infected mice. 
 
[1] A. Dömling and K. Khoury, ChemMedChem, 5, 2010, 1420. 
[2] A. Simeonov et al, PLoS NTDs, 2, 2008, e127; A. Sayed et al., Nature Med., 14, 2008, 407; 
G. Rai et al, J. Med. Chem., 52, 2009, 6474. 
[3] J. H. Kim et al, Tetrahedron, 54, 1998, 7395. 
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In our ongoing researches of cytotoxic natural compounds[1,2], we isolated 
sixteen daucane esters (116) from plants of the genera Ferula and Ferulago, in 
which two of the daucane derivatives (3 and 4) are new natural compounds. The 
daucane derivatives can be considered as attractive compounds especially as 
potential antiproliferative and anticancer compounds [3,4]. 
The cytotoxic activity of the isolated compounds was evaluated against a 
panel of seven human tumor cell lines. Fourteen of the daucane derivatives showed 
antiproliferative activity at least against one of the human tumor cell lines tested, 
four compounds (5, 8, 11 and 16) were active against all the tested cell lines. 
Preliminary structure activity relationships suggests that the most active 
compounds in the daucane series present the trans fusion of the penta- and hepta- 
atomic cycles, and lipophylic ester groups linked to position 6. Isomeric derivatives 
such as 8 and 9 or 3, 4 and 5 exhibited significant differences in their IC50 
supporting that the  orientation for the ester group in the position 2 enhances the 
cytotoxic activity. Furthermore, the pro-apoptotic effect of the most active 
compounds (8 and 11) evaluated in Jurkat cell line showed that these compounds 
are able to induce apoptosis in a time and concentration-dependent manner.  
Our findings suggest the potential role of daucane derivatives as models for 
the development of proapoptotic compounds. 
  
[1] S.Dall'Acqua, G.Viola, S.Piacente, E.M.Cappelletti and G.Innocenti, J. Nat.Prod., 67, 2004, 
1588. 
[2] S.Dall'Acqua, G.Viola, M.Giorgetti, M.C.Loi and G.Innocenti, Chem. Pharm. Bull., 54, 2006, 
1187.  
[3] F.Poli, G.Appendino, G.Sacchetti, M.Ballero, N.Maggiano and F.O.Ranelletti, Phytother. Res., 
19, 2005, 152.  
[4] A.M.Gamal-Eldeen and M.F.Hegazy, Nat. Prod. Res. 24, 2010, 246.  
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A HPLC method for the simultaneous determination of three widely used 
antihistaminic drugs, diphenhydramine (DIP), oxatomide (OXA) and promethazine 
(PRO), in surface waters and a toxicological assay using the bioluminescent 
bacterium Vibrio fischeri were developed. The analytical procedure was extended 
to the by-products from PRO photodegradation. The method involved pre-
concentration and clean-up by SPE and HPLC analysis with diode array detection.  
 
 
 
 
 
 
 
 
 
 
Validation of the method was performed on synthetic mixtures and surface 
water samples spiked with the drugs, showing mean recoveries ranging from 93 
and 107%, with RSD below 5.5%. Limits of detection in surface waters, calculated 
on 1.0 L of sampled waters, were in the range 0.6 – 0.8 g/L.  
The Vibrio fischeri test demonstrated toxicity due to PRO at a concentration of 
just 3.94 g/mL while the other antihistamines showed no significant toxicity until 
to 50.0 g/mL. However, toxicity of drug 
mixtures was greater than the sum of the 
values from single component samples. The 
presence of the studied drugs was monitored 
in two rivers in Calabria (Italy), collected 
along a period of seven months. DIP and 
OXA were not detected in any samples. On 
the contrary, PRO was found in two samples 
taken in July at a concentration of 1.98 and 
2.31 g/L, both significantly below the 
values causing toxicity. 
 
HPLC chromatogram 
from analysis of a surface 
water sample spiked with 
DIP, OXA and PRO at a 
concentration of 10, 20 
and 10 g/L, respectively. 
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Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear 
receptor superfamily of ligand-activated transcription factors.[1] The combination 
therapy with drugs acting on both PPARα and PPARγ isotypes may have 
synergistic and wider therapeutic effects improving both glucose and lipid 
metabolism and could be a new strategy in the treatment of metabolic syndrome. 
[1–4] In the recent past we have synthesized and reported the effects on human 
PPARα and PPARγ of chiral clofibric acid analogues, identifying MS39 as a lead 
compound.[2–4] With the aim to investigate the possibility to fine-tune the activity 
of this ligand, a new series of its analogs were synthesized in which fluorine atom 
or trifluoromethyl group were introduced on the aromatic rings in place of chlorine 
or as additional substituents (Figure 1). Fluoro or trifluoromethyl substituents 
generally have a profound effect on the physical and/or biological properties of the 
target molecule. Their introduction, in fact, beyond improving metabolic stability 
by blocking metabolically labile sites, can modulate physicochemical properties, 
such as lipophilicity or acidity, change molecular conformation, and increase 
binding affinity by exploiting specific interactions of F with the target protein.[5]
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Figure 1 
 
The biological activity on PPAR isoforms of all new synthesized derivatives was 
evaluated by the transactivation assay, a powerful and widely used assay whose 
good correlation with in vivo activity is generally accepted. [2–4] 
 
[1] Kliewer S.A. et al. Recent Prog. Horm. Res. 56, 2001, 239. 
[2] Pinelli A. et al., J Med Chem. 2005, 48, 5509. 
[3] Fracchiolla G. et al., ChemMedChem. 2007, 2, 641. 
[4] Fracchiolla G. et al., J Med Chem. 2009, 52, 6382. 
[5] Böhm H.-J. et al., ChemBioChem. 2004, 5, 637. 
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Sigma () receptors are involved in several functions such as modulation and 
biosynthesis of several neurotransmitters, motor control, cell growth and 
proliferation[1]. Several classes of structurally unrelated compounds interact with σ 
receptors, but only few σ ligands are gifted 
with affinity and selectivity against a specific 
receptor subtypes.  
The interest in  ligands stems from the 
possibility to develop clinical agents for the 
treatment of  several CNS diseases, for 
neuroprotection, tumour treatment and 
diagnosis[2]. Therefore  1 receptor ligands 
could be involved in treatment for 
schizophrenia, depression, lack of 
memorization skill, difficulty of learning and increase of analgesic action. 
Recently, we developed a 3D pharmacophore model for 1 receptor (Figure1) [3], 
that we exploited to design a series of piperidin-4-carboxamide derivatives 1. All 
molecules are provided with good affinity and, above all, high selectivity.  
With the aim to increase the skill of these compounds to bind 1 receptor, we 
synthesized a new series of piperidin-4-carboxamide derivatives 2. Maintaining the 
main scaffold, we changed the N-benzyl portion of the amide groups with an 
aliphatic or arylaliphatic moiety in order to evaluate the effect on  binding. All the 
synthesized compounds have been tested to estimate their affinity and selectivity 
toward 1 receptor. Despite the work is in progress, the achieved results seem 
positive since the new derivatives showed a good affinity against 1 receptors in 
the range of 1.98-350 nM and they gifted with a fairly good selectivity toward 1 
receptor.    
 
[1] G. Ronsisvalle, O. Prezzavento, A. Marrazzo, F. Vittorio, E. Bousquet, R. Di Toro, S. 
Spampinato, Eur. JPS., 12 (2001) 277-284. 
[2] K. W. Crawford,  A.Coop, W.D.Bowen, Eur. J. Pharmacol., 443 (2002) 207-209 
[3] Zampieri D, Mamolo MG, Laurini E, Florio C, Zanette C, Fermeglia M, Posocco P, Paneni MS, 
Pricl S, Vio L., J Med Chem. 2009; 52, 5380-93. 
 
Figure 2 
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The cell division cycle 25 (Cdc25) family of proteins are highly conserved dual 
specificity phosphatases that regulate cyclin-dependent kinases, the main 
gatekeepers of the eukaryotic cell division 
cycle. The three isoforms of Cdc25, 
including Cdc25A, Cdc25B and Cdc25C, 
appear to act on different cyclin-dependent 
kinase/cyclin complexes at different stages 
of the cell cycle. Overexpression of Cdc25A 
and/or Cdc25B, but not Cdc25C, has been 
detected in numerous cancers and is often 
correlated with a poor clinical prognosis; 
Thus, the inhibition of these phosphatases 
may represent a promising therapeutic 
approach in oncology [1-2]. So, a computer-
aided drug design protocol involving virtual screening was performed on Cdc25B 
crystal structure (Figure 1) [3] in order to identify novel classes of inhibitors. In 
vitro experiments carried out on a selected list of 30 molecules led to the discovery 
of 4 compounds able to inhibit Cdc25A and B activity at low micromolar 
concentrations and to the significant inhibition of the MCF-7 breast cancer cell 
proliferation. All selected compounds also affected MCF-7 cell cycle progression. 
Furthermore, kinetics studies were realised on the phosphatase activity catalysed by 
Cdc25B in the presence of the above-mentioned compounds, in order to establish 
type and power of inhibition. 
 
[1] Lavecchia A, Di Giovanni C, Novellino E. Inhibitors of Cdc25 phosphatases as anticancer 
agents: a patent review. Expert Opin. Ther. Pat. 20, 2010, 405. 
[2] Lavecchia, A.; Di Giovanni, C.; Novellino, E. Cdc25A and B Dual-Specificity Phosphatase 
Inhibitors: Potential Agents for Cancer Therapy. Curr. Med. Chem. 16, 2009, 1831. 
[3] Reynolds, R.A.; Yem, A.W.; Wolfe, C.L.; Deibel, J.; Chidester, C.G., Watenpaugh, K.D. Crystal 
structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J. 
Mol. Biol. 293, 1999, 559. 
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In the last decade, drug repositioning (drug repurposing or indication switch) 
strategies have become more and more attracting as useful ways for drug discovery 
[15], and promiscuous ligands let envisage the way toward a new generation of 
efficacious drugs [6]. 
Calmodulin (CaM) ligands are a chemically heterogeneous class of 
biologically active compounds, many of which behave as anthypertensive and 
antianginous, neuroleptic, anxiolytic, antidepressant, antiarrhythmic, antiestrogen, 
and antineoplastic agents. Several CaM ligands display polypharmacology. Thus, 
this class of compounds might be mined to detect leads for repositioning: both new 
and clinically established CaM ligands might prove useful in some of the above 
mentioned therapeutic areas. 
Here we propose a label-free, reagentless, straightforward affinity capillary 
electrophoretic (ACE) method to screen compounds as CaM ligands. Apparent 
dissociation constants between bovine brain CaM and various small ligands were 
found in good agreement with those reported in the literature. The method was 
successfully used to demonstrate that lubeluzole―a well-known neuroprotective 
agent―is a high-affinity CaM ligand.  
 
[6] Wermuth C. G. Med. Chem. Res. 2001, 10, 431–439. 
[7] Wermuth C. G. J. Med. Chem. 2004, 47, 1303–1314. 
[8] Dueñas-González A., García-López P., Alonso Herrera L., Medina-Franco J. 
L., González-Fierro A., Candelaria M.  Mol. Cancer 2008, 7, 82. 
[9] Riveiro M. E., De Kimpe N., Moglioni A., Vázquez R., Monczor F., Shayo C., 
Davio C. Curr. Med. Chem. 2010, 17, 13251338. 
[10] Gan F., Cao B., Wu D., Chen Z., Hou T., Mao X. Curr. Med. Chem. 2011, 18, 
15091514. 
Hopkins A. L., Mason J. S., Overington J. P.  Curr. Opin. Struc. Biol. 2006, 16, 
127136. 
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The farnesoid X receptor (FXR) is a nuclear hormone receptor expressed in the 
liver, kidney and intestine that is activated by bile acids, such as chenodeoxycholic 
acid (CDCA) and cholic acid (CA). Upon activation, FXR binds to DNA as a 
heterodimer with the retinoid X receptor (RXR), thus regulating the expression of 
various genes and proteins involved in bile acid and cholesterol homeostasis 
(CYP7A1, SHP, IBABP, BSEP, and ApoA-I), triglyceride synthesis, and 
lipogenesis (SREBP-1c, and ApoC-III). Furthermore, bile acids-mediated FXR 
activation has been recently recognized as a major pathway for energy homeostasis 
and glucose metabolism. All these evidences make FXR a promising potential 
target for the treatment of a variety of metabolic disorders, including 
hyperlipidemia, cholelithiasis, cholestasis, and diabetes mellitus.[1] Over the past 
few years, many efforts have been dedicated by our group to the search of highly 
potent steroidal FXR modulators by rational structural modification of CDCA. 
Following this approach, we discovered in 2002, the highly potent and orally 
bioavailable FXR full agonist, 6α-ethylchenodeoxycholic acid (6ECDCA, INT-
747),[2] that has positively completed phase II clinical trials for primary biliary 
cirrhosis and type 2 diabetes. More recently starting from a virtual screening 
protocol we were successful in the identification of a novel class of non- steroidal 
FXR agonists, structurally characterized by 4,8-dihydro-1H-pyrazole[3,4-
e][1,4]thiazepin-7-one scaffold (I). The synthesis and the preliminary structure-
activity relationships of this class of non-steroidal FXR agonists will be presented.  
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[1] Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Nat. Rev. Drug 
Discov. 2008, 7, 678. 
[2] Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P.R.; 
Morelli, A.; Parks, D.J.; Willson, T.M. J. Med. Chem. 2002, 45, 3569-3572. 
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An emerging class of macromolecules acting on thrombin is represented by 
oligonucleotide aptamers, short DNA/RNA sequences which recognize a target 
with an high specificity and affinity. A peculiar feature of these molecules is their 
structural flexibility which allows them to assume distinct foldings depending upon 
their sequence and/or environment. 
Leading examples are represented by the Thrombin Binding Aptamers (TBAs), 
which comprise a 15-mer DNA (15fTBA) selected by its high affinity for the 
exosite I (fibrinogen binding site) and a 29-mer DNA (29hTBA) selective for the 
exosite II (heparin binding exosite) of the coagulation factor. 
The 29hTBA structure consists in a 15-mer quadruplex core with the two 5’ and 3’ 
portions that can partially pair producing a mixed quadruplex/duplex dual structure. 
The structured core shares a 
close similarity with the 
15fTBA; the major loop 
sequence (GCA that replaces 
TGT) and a single T-A 
nucleotide mutation in one 
minor loop are sufficient to 
drive the sequence to a 
distinct epitope.[1] 
Considering the complexity 
of the TBAs’ topology some 
questions raised. Which 
structural motif the sequences 
adopt? How are they involved in defining the thermodynamic stability and/or the 
thrombin affinity? 
Here, we studied and compared a series of DNA sequences derived by rational 
modifications of 29hTBA sequence, selected to dissect the role of the different 
structural elements in these processes.[2] 
Early results suggest that the bulge domain largely impairs the thermal stability 
and modulates the folding kinetic of the G-quadruplex core. 
G                           G
G                          G
5’ 3’
G                          G
Structural element 3 
(G-quadruplex core)
Structural element 1 
(Double strand Portion)
Structural element 2 
(Buldge loop Portion)
G                           G
X-ray structure human thrombin  
(pdb code: 1HUT)) 
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Similarly, the length of the double strand portion, does not seem to influence 
protein binding affinity although it plays a significant role in defining the folded 
DNA thermal stability. 
Finally we designed and characterized an ExositeI/Exosite II DNA binder that 
merges 15fTBA structural elements in the 29hTBA general structure. 
Our work is aimed to define the minimal structural motifs required to preserve the 
target affinity, to finally translate them to not-oligonucleotide molecules (e.g. 
PNA) characterized by better drug-like properties. 
 
[1] I., Smirnov, Effect of Loop Sequence and Size on DNA Aptamer Stability. 
Biochemistry, 39, 2000, 1462-1468. 
 
[2] F., Macaya, Structural and functional characterization of potent antithrombotic 
oligonucleotides possessing both quadruplex and duplex motif. Biochemistry, 34, 
1995, 4478-4492. 
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In recent years, besides the main field of nonsteroidal anti-inflammatory agents, the 
interest towards pyrazolone derivatives has been renewed because of their wide 
biological and pharmacological applications [1]. Currently, particular attention is 
focused on such a class of compounds due to the affinity with sigma receptor and 
their relationship with cancer [2].To these purposes we planned to design, 
synthesize and evaluate the antiproliferative activity (MTS assays) of a new series 
of 3-methyl-2-(1-R-naphthalen-2-yl)-1,2-dihydropyrazol-3-one derivatives 1 
against HeLa, MCF-7, LAN-5, Caco2 in order to explore their anticancer potential. 
Additionally, further elaboration of the amino derivative 1 led to the tetracycle 2, 
possessing a reactive tetrazinone core which conferred valuable antiproliferative 
activity as previously reported [3]. Synthesis and biological results will be 
presented. 
NH
N
O
1a;  R = H 
1b;  R= Cl 
1c;  R= NO2
1d;  R= NH2
1e;  R= N3
R
N
N
O
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N
1 2  
 
[1]    G. Mariappan, B.P. Saha, L. Sutharson, Anki, S. Garg, L. Pandey, D. 
Kumar,  J.    Pharm. Res., 2010, 3(12), 2856. 
[2]  E. Aydar, C.P. Palmer, M. B. A. Djamoz, Cancer Res., 2004, 64, 5029.  
[3] A.M., Almerico, F. Mingoia, P. Diana, P. Barraja, A. Lauria, A. 
Montalbano, G Cirrincione, G. Dattolo, J. Med. Chem., 2005, 48, 2859. 
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G protein coupled receptors (GPCRs), recognizing adenosine and purine and 
pyrimidine nucleotides as extracellular messengers, have been characterized and 
classified as purinergic P1 and P2 receptors, respectively. However, some 
experimental data suggest that other nucleosides as guanosine, inosine and 
hypoxanthine can also act as signalling molecules via the activation of specific 
membrane receptors [1]. In particular, extracellular guanosine seems to possess 
many trophic effects, including promotion, division, and growth of astrocytes and 
other neuron-like cells. Binding studies, performed on rat brain membranes using 
[3H]guanosine, have shown that the compound interacts with binding sites, which 
are distinct from the well-characterized ATP and adenosine receptors. Furthermore, 
guanosine itself and 6-thioguanosine are equally effective in displacing 
[3H]guanosine from rat brain membranes [2]. Hence, potent and selective agonists 
and antagonists are highly needed for the characterization of the physiopathological 
profile of the new putative guanosine receptor. Starting from these observations 
and aimed at developing a new assay that allows to evaluate the potency of ligands 
at the putative guanosine receptor, Eu-GTP assay was performed in rat brain. This 
technique, using the principle of the [35S]GTPγS binding assay, replaces the 
radioactive material with Eu-GTP and exploits the unique fluorescence properties 
of Europium lanthanide chelate. New molecules, prepared by modifying the purine 
and sugar moieties of guanosine at the 6- and 5’-positions, were tested using Eu-
GTP assay. Results showed that the new compounds are able to activate the 
putative guanosine receptor more than guanosine itself. On the other hand, this 
functional assay seems to demonstrate that a GPCR activated by guanosine is 
present in rat brain [3]. 
 
[1] F. Caciagli, P.  Illes, Purinergic Signalling, 1, 2005, 297.   
[2] U. Traversa, G. Bombi, E. Camaioni, A. Macchiarulo, G. Costantino, C. 
Palmieri, F. Caciagli, R. Pellicciari, Bioorg. Med. Chem.,11(24), 2003, 
5417.  
[3] R. Volpini, G. Marucci, M. Buccioni, D. Dal Ben, C. Lambertucci, C. 
Lammi, R.C. Mishra, A. Thomas, G. Cristalli, ChemMedChem., DOI: 
10.1002/cmdc.201100100, VIP (the paper was judged to be very important 
by the referees). 
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ribonuclease HIV-1 RT associated function 
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Ospedale 72, Cagliari, 09124, Italy. rita.meleddu@unica.it 
2) Department di Scienze Applicate ai Biosistemi, University of Cagliari, 
Cittadella Universitaria di Monserrato, 09042, Monserrato, Cagliari, Italy.  
3) Department di Scienze Farmacobiologiche, Università degli Studi di Catanzaro 
"Magna Graecia", 88021, Roccelletta di Borgia (CZ), Italy. 
RT is an essential enzyme for viral replication which has two associated catalytic 
functions: a DNA or RNA dependent polymerase activity and a ribonuclease H 
(RNase H) activity.[1-2] 
The two catalytic sites are distinc but inter-dependent and mutations in the 
polymerase domain affect the RNase H activity, and vice versa. Furthermore, both 
RT associated activites are essential for virus replication. Thus, both enzyme 
functions are attractive targets for drug development. 
Aiming to identify new scaffolds capable to combine inhibitory activity on both 
enzymatic functions, some of us performed a combined shape-, 2D-fingerprint-, 
and pharmacophore-based virtual screening and identified a 3-substituted-2-
indolinone derivative as a promising dual inhibitor of both RT functions.[3] 
2-indolinone derivatives are of biological interest and their biological properties 
have been recently investigated.[4-6] However their activity on HIV-1 RT has never 
been investigated. Prompted by the virtual screening results we have synthesised a 
series of 3-[2-(4-aryl-1,3-thiazol-2-yl)hydrazin-1-ylidene]-1H-indol-2-ones and 
evaluate their biological activity as potential dual inhibitors of the Human 
Immunodeficiency virus-1 (HIV-1) Reverse Transcriptase (RT). Furthermore we 
have investigated on the site of interaction on the HIV-1 RT. 
In this presentation we wish to report on our first approach dedicated to the 
synthesis and the biological behaviour investigation of new rationally designed 
RNase H and RDDP dual inhibitors. 
 
[1] Telesnitsky, A.; et al, In Retroviruses, Cold Spring Harbor Laboratory Press: 
1997; pp 121-160. 
[2] Hughes, S. H.; et al, In Ribonucleases H, Editions Inserm: Paris, 1998; pp 195-
224. 
[3] Distinto, S.; et al, (submitted for publication). 
[4] Roth G. J.; et al,; J. Med. Chem., 2010, 53, 7287–7295. 
[5]. Andreani A.; et al,  J. Med. Chem., 2008, 51, 7508–7513. 
[6] Kilian H.; et al, J. Med. Chem., 2010, 53, 1383–1386. 
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 The class III family of histone deacetylases also called sirtuins (Sirt1-7), is 
characterized by a conserved 270 amino acid catalytic core domain and requires 
NAD+  as cofactor1 to catalyze the removal of acetyl groups from acetyl-lysine 
residues on protein substrates (i.e.FOXO1,4, NF-kB, p53, p73, p300, tubulin etc.) 
including histones (H1,3,4). Sirt1-7 also possess mono-ADP-ribosyl transferase 
activity and have pathophysiological relevance in many diseases such as cancer, 
obesity, muscle differentiation, inflammation and neurodegeneration. 
        Sirt1 inhibition causes hyperacetilation of p53, a major tumor suppressor, and 
activates this protein through the use of nongenotoxic compounds which may result 
in new therapeutically useful tools in cancer therapy2. Furthermore, the inhibition 
of NAD+ consumption by sirtuin inhibitors can increase its availability for cellular 
metabolic function.   
        The observation that EX-527, the most potent Sirt1 
inhibitor, and carprofen (an anti-inflamatory drug) presented 
a good overlay in the carbazole core,  suggested us to design 
a carpofen amide derivatives (Fig.1), to be evaluated as SIRT 
inhibitors. All the derivatives are active against Sirt1 using a 
fluorimetric assay. In particular one of them (STP16) is a powerful inhibitor of 
Sirt1 showing an IC50 of 7,95µM.  
[1]. Josè L. Avalos, Katherine M. Bever, and Cynthia Woolberger. Molecular Cell, 
2005, 17, 855-868. 
[2]. Susanne Voelter-Mahlknecht, Ulrich Mahlknecht. Clin Epigenet, 2010, 1, 71-
83.VC is a post-doctoral fellow of the APOSYS EU project (contract n° 200767); 
this study was funded by the Italian association against cancer (AIRC) and by the 
APOSYS EU project (contract n° 200767). 
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directed ligand as potential therapeutic agent for Alzheimer’s 
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Alzheimer’s disease (AD) is the most common cause of dementia, clinically 
characterized by loss of memory and progressive deficits in different cognitive 
domains due to a pronounced degradation of the cholinergic system and alteration 
in other neurotransmitter systems such as the glutamatergic and serotoninergic 
ones. From a neuropathological point of view, the hallmarks of AD are represented 
by senile plaques, which are insoluble deposits of amyloid-beta (βA) protein, and 
neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein. These 
pathological lesions have been considered to be the causative features of AD, 
giving rise to several theories about AD pathogenesis mainly including the 
cholinergic hypothesis, the amyloid cascade hypothesis, oxidative stress and free 
radicals formation. Actually the AD therapy is mainly bolstered on 
acetylcholinesterase inhibitors (AChEIs) able to increase the acetylcholine (ACh) 
levels in the cholinergic synapses but their clinical effectiveness is still under 
debate. A more appropriate approach to face the multifactorial nature of AD may 
be represented by the development of Multi-Target Directed Ligands (MTDLs) 
which is based on the assumption that a single compound may simultaneously 
modulate different targets involved in the neurodegenerative AD cascade [1]. The 
structure of tacrine (1) [2], one of the most known AChEIs, and, in particular, its 
dimer bis(7)tacrine (2) [3], have been widely used as scaffolds to design novel 
MTDLs against AD. 2 exhibited a 1000 times higher AChE inhibition, a double 
interaction with active and peripheral sites of AChE and a better pharmacological 
profile consisting on the inhibition of the AChE-induced Aβ aggregation through 
its peripheral site, and neuroprotective effects due to the interaction with beta-
secretase enzyme, NMDA and GABAA receptors.  
Thus, in the search of new rationally 
designed MTDLs against AD, we 
replaced the heptamethylene linker of 
bis(7)tacrine with the structure of 
cystamine, leading to cystamine-
tacrine dimer characterized by a disulfide bridge. We focused our attention on 
N
NH2
N
HN
N
1 2
NH
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cystamine for its biological activities as antioxidant, cyto- and neuroprotective 
agent [4].  
In this study we demonstrated that the cystamine-tacrine dimer, in comparison to 
bis(7)tacrine, is endowed with a lower toxicity, it is able to inhibit AChE, BChE, 
self and AChE induced Aβ aggregation in the same range of the reference 
compound and to protect the neuroblastoma SH-SY5Y cell line against H2O2-
induced damage by activating the extracellular signal-regulated kinase 1 and 2 
(ERK1/2) and Akt/protein kinase B (PKB) pathways. 
 
(This research was supported by grants from MIUR, Rome (PRIN), and University 
of Bologna (RFO)) 
 
(1) Cavalli, A., Bolognesi, ML et al. J. Med. Chem., 51, 2008, 347. 
(2) Tumiatti, V., Minarini, A. et al. Curr. Med. Chem., 17, 2010, 1825. 
(3) Pang, Y. P., Quiram, P. et al. J. Biol. Chem., 271, 1996, 23646. 
(4) Wood, P. L., Khan, M. A. et al. Brain Research, 1158, 2007, 158. 
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The two most studied endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-
arachidonoylethanolamine (anandamide, AEA), are principally degraded by two 
enzymes from the serine hydrolase superfamily: monoacylglycerol lipase (MAGL) 
and fatty acid amide hydrolase (FAAH), respectively. Inhibitors of these enzymes 
can constitute important pharmacological tools to explore the endocannabinoid 
system and could also be developed as a new promising class of analgesic drugs.1 
Considering that MAGL and FAAH are both inhibited by carbamates bearing a N-
piperidine/piperazine group,2,3 we synthesized a series of compounds by using the 
benzotriazole moiety as the leaving group and by substituting the carbamic 
functional group for an urea. 
The compounds were tested on recombinant human MAGL and FAAH and, on 
the basis of the pharmacological evaluation, we found that these derivatives can be 
tuned for MAGL- or FAAH-selectivity as well as for dual MAGL-FAAH 
inhibition by attachment of appropriate groups on the piperazine ring nitrogen. As 
general trend, we observed that the phenyl piperazyl moiety is better for the FAAH 
inhibition, while the benzyl piperazyl ureas are more potent MAGL inhibitors. 
 
 
 
References 
[1] Petrosino S., Di Marzo V., Curr. Opin. Investig. Drugs. 2010, 1, 51-62. 
[2] Long J. Z., Jin X., Adibekian A., Li W., Cravatt B. F., J. Med. Chem. 2010, 
53, 1830–1842. 
[3] Sanofi Aventis, PCT Int. Appl. WO2008145843, 2008 
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Endocannabinoids are a class of signalling lipids such as N-arachidonoyl 
ethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG), which 
activate cannabinoid receptors CB1 and CB2 to modulate a range of effects 
including pain, inflammation, appetite, motility, sleep, and thermoregulation, 
cognitive and emotional states. AEA and related bioactive fatty acid amides are 
inactivated by the membrane-bound serine hydrolase fatty acid amide hydrolase 
(FAAH). The development of FAAH inhibitors represents an elegant alternative to 
CB receptor agonists. Accordingly, inactivation of FAAH may have beneficial 
effects on pain and anxiety without the side effects (hypomotility, hypothermia, 
and catalepsy). To preserve this lack of “cannabinoid side effects”, the inhibitors 
should not interfere with CB1 receptor, which is involved in most of the unwanted 
effects of exogenous cannabinoids.  
With the aim to discover new scaffolds for selective FAAH inhibition we identified 
a series of potent and selective FAAH inhibitors characterized by a phenyl-1- 
pyrrole structure bearing differently functionalized lateral chains to improve 
hydrophylic and pharmacokinetic properties. Some representative hits proved to be 
extremely potent and selective FAAH inhibitors, reversibly binding the enzyme.1 
 
 
 
[1] Walter Cabri, Patrizia Minetti, Giuseppe Campiani, Stefania Butini; "New 
carbamate derivatives as modulators of fatty Acid Amide Hydrolase (FAAH 
Inhibitors)"; EP09155528 
 
 
 
 
 
 438 
 
FAR-PO-59 The effect of the Cu(II) salt anion in a ligand 
exchange system operating with a chiral mobile phase 
 
Benedetto Natalini, Roccaldo Sardella, Andrea Carotti, Federica Ianni, Maria 
Eugenia García Rubiño, Antonio Macchiarulo, Roberto Pellicciari 
 
Dipartimento di Chimica e Tecnologia del Farmaco, Università degli Studi di 
Perugia, Via del Liceo 1, 06123, Perugia, Italy 
natalini@chimfarm.unipg.it 
 
With the use of a chiral ligand-exchange chromatography (CLEC) system operating 
with the O-benzyl-(S)-serine [(S)-OBS] [1,2] as the chiral mobile phase (CMP) 
additive to the eluent, the effect of the copper(II) anion type was evaluated on the 
thermodynamic parameters, retention (k) and separation () factors, by rationally 
changing the following experimental chromatographic conditions: column 
temperature, absolute configuration of the chiral selector, and salt concentration. 
The CLEC-CMP analysis was carried out on ten amino acidic racemates and with 
nine cupric salts. While the group of analytes comprised both aliphatic (leucine, 
isoleucine, nor-leucine, proline, valine, nor-valine, and -methyl-valine) and 
aromatic (1-aminoindan-1,5-dicarboxylic acid, phenylglycine, and tyrosine) 
species, representative organic (formate, methanesulphonate, and trifluoroacetate) 
and inorganic (bromide, chloride, fluoride, nitrate, perchlorate, and sulphate) Cu(II) 
salts were selected as the metal source into the eluent. This route of investigation 
was pursued with the aim of identifying analogies among the employed Cu(II) 
salts, by observing the profile of variation of the selected chromatographic 
parameters, upon a change of the above experimental conditions. All the data were 
collected and analyzed through a statistical approach (PCA and k-means clustering) 
that revealed the presence of two behavioural classes of cupric salts, sharing the 
same variation profile for k and  values. Interestingly, this clustering can be 
explained in terms of ESP (Electrostatic Surface Potential) balance values, obtained 
by an ab initio calculation operated on the cupric salts. 
 
[1] B.Natalini, R.Sardella, and R.Pellicciari, Curr.Anal.Chem., 1, 2005, 85. 
[2] B.Natalini, N.Giacchè, R.Sardella, F.Ianni, A.Macchiarulo, and 
R.Pellicciari, J.Chromatogr.A, 1217, 2010, 7523. 
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Fatty acid amide hydrolase (FAAH) is a serine hydrolase that catalyzes the deactivating 
hydrolysis of the fatty acid ethanolamide family of signaling lipids, which includes 
endogenous ligands for cannabinoid receptors such as anandamide (AEA). Endogenous 
FAAH substrates such as AEA serve key regulatory functions in the body and have been 
implicated in a variety of pathological conditions including pain, inflammation, sleep 
disorders, anxiety, depression, and vascular hypertension, thus there has been an increasing 
interest in the development of inhibitors of this enzyme. Furthermore the contribution of 
endocannabinoid system to Nonsteroidal anti-inflammatory drugs (NSAIDs) action has 
been demonstrated [1], although inhibition of prostaglandin production by cyclooxygenase 
(COX) is NSAIDs primary mechanism of action. Acidic NSAIDs like ibuprofen, inhibit 
the activity of FAAH and this effect is particularly noticeable at low pH, such as is seen in 
inflamed tissue. It is has been  reported that COX-2 is capable of utilising AEA as a 
substrate to produce prostaglandin E2 ethanolamide and that the other main 
endocannabinoid, 2-arachidonoylglycerol (2-AG) is also a substrate for COX-2. FAAH 
and COX inhibitors produce synergistic effects upon visceral nociception [2], this is of 
considerable potential importance, given the gastrointestinal and cardiovascular problems 
associated with NSAID use. One of the difficulties, however, associated with 
polypharmacy is patient compliance and the potential for pharmacokinetic interactions 
between the drugs used. For this reason, there has been increased interest in the design of 
compounds with effects upon several targets.  The findings led us to design and synthesis 
of new series of FAAH – COX dual inhibitors based on NSAID templates.  
 
 
In this communication we report synthetic pathways, FAAH, MGL and COX inhibition 
results and SAR studies on the new inhibitor series.  
 
[1] J. Guindon, A. De Léan, and P. Beaulieu, Pain, 121, 2006, 85-93.  
[2] P. Naidu, L. Booker, B. Cravatt, and A. Lichtman , J. Pharmacol. Exp. Ther., 329, 
2009, 48-56. 
[3] R. Morphy, and Z. Rankovic, J. Med. Chem., 48, 2005, 6523-6543. 
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COX-1 isoenzyme has been recently reconsidered as therapeutic target, due to its 
crucial role exerted in a variety of pathological conditions, such as atherosclerosis, 
endothelial dysfunction, neuroinflammation, pain processing, pre-term labor and 
some type of cancers. 
Hence, highly selective COX-1 inhibitors might be particularly relevant for the 
treatment of several diseases [1]. 3-(5-Chlorofuran-2-yl)-5-methyl-4-
phenylisoxazole, P6, a highly selective COX-1 inhibitor, recently uncovered by 
us[2], has been chosen as “lead compound” for structure-activity relationship 
studies [3].They assessed that the presence of the P6-furanyl group is crucial for 
COX-1 inhibitory potency and selectivity, as it is important the substituent size 
(bromine, chlorine or methyl group) on that furanyl. 
In addition, the replacement of a methyl by CF3-group at isoxazole C5 and the 
introduction of a substituent on the phenyl bonded to the isoxazole C4 still provide 
selective COX-1 inhibitors. 
Among the diarylheterocycle class of COX-1 inhibitors, the most studied COX-1 
inhibitor is the SC-560 that has a 
pyrazole as a core ring instead of an 
isoxazole [4]. Thus, to identify the P6 
and SC-560 common (if any) structural 
and/or electronic determinants 
responsible of the selective COX-1 
inhibition, a series of new pyrazole 
analogues of P6 have been prepared by 
substituting the P6-isoxazole core ring 
with a pyrazole. 
The results of this investigation will be presented. 
 
[1] M.G. Perrone, A. Scilimati, L. Simone, P. Vitale. Curr.Med.Chem. 17, 2010, 
3769. 
[2] L.Di Nunno, P. Vitale,A. Scilimati, S. Tacconelli, P. Patrignani, J.Med.Chem., 
47, 2004, 4881. 
[3] A. Scilimati, P. Vitale, L. Di Nunno, S. Tacconelli, P. Patrignani, M.L. Capone, 
(2008). Functionalized diarylisoxazoles inhibitors of cyclooxygenase. Patent USA 
No. 12/007,571. University of Bari and University of Chieti. 
[4] Penning, T.D. et al. J. Med. Chem., 97, 1997,1347-1365. 
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Anticancer platinum drugs represent one of the most successful groups of 
compounds clinically used. Their biological mechanism of action is referred to 
platination of nuclear DNA, preferentially at guanine sites: the formation of stable 
DNA adducts is recognized as a DNA damage event and can ultimately drive to the 
apoptotic cell death.  
From the discovery of their anticancer properties, research has been largely 
focused on the description of the DNA adduct formation by Pt drugs [1]. Although 
it was proposed that Pt-protein adducts could play an important role in modulating  
pharmacokinetics, resistance mechanisms, drug activity and side effects during this 
anticancer treatment, poor attention has been dedicated to characterize the 
interaction of platinum compounds with selected proteins [2].  
In order to investigate the nature of metallodrug-protein interaction, we 
monitored the reactivity of different platinum compounds, included the trans planar 
platinum ammines [3] with model proteins such as bovine α-lactalbumin and hen 
egg lysozyme. The reactions were performed for 24 hours at 37 °C using different 
protein-Pt compound molar ratios. The reaction mixtures, containing the putative 
protein-Pt adducts, were resolved by SDS-PAGE gel electrophoresis and identified 
by electrospray ionization mass spectrometry technique (ESI-MS), a powerful 
technique to investigate metallodrugs-proteins interactions [4].  
Our results clearly confirmed the formation of the metallodrug-protein adducts. 
In particular, we observed that the tested Pt compounds specifically react with each 
selected model protein according to different kinetics. Additionally, the structural 
features of Pt drugs have been shown to play a crucial role in promoting the 
reactivity and the selectivity toward tested proteic substrates.  
 
[1]  D. Wang, S.J. Lippard, Nat. Rev. Drug Discovery, 4, 2005, 307. 
[2] E. Espinosa, J. Feliu, P. Zamora, M. Gonzalez Baron, J.J Sanchez., A. 
Ordonez, and J.J. Espinosa, Lung Cancer,12, 1995, 67. 
[3] C. Musetti, A.A. Nazarov, N.P. Farrell, C. Sissi, ChemMedChem., 6, 2011, 
1283. 
[4] A.R. Timerbaev, C.G. Hartinger, S.S. Aleksenko, and B.K. Keppler, Chem. 
Rev., 106, 2006, 2224. 
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The endocannabinoid system is involved in pain, immunosuppression, vascular 
disease, appetite management and locomotor disorders [1]. The CB1 inverse agonist 
Rimonabant (1), launched for the treatment of overweight, obesity and associated 
cardiovascular and metabolic disorders, was withdrawn because of psychiatric 
adverse events. There is a need of effective drugs to treat obesity because of the: (i) 
rapid increase of overweight people in the developed countries, and (ii) restricted 
therapeutic potential displayed by the FDA approved drugs sibutramine and orlistat 
[2]. 
New 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides were synthesized 
as CB receptor ligands. Compound 11 (CB1 Ki = 2.3 nM, CB1 SI = 163.6) showed 
CB1 receptor affinity and selectivity superior to Rimonabant and AM251. Acute 
administration of 2 mg/kg 11 resulted in preferentially reduced intake of sucrose 
rather than intake of regular food in rats. On the other hand, compound 23 (CB2 Ki 
= 0.51 nM, CB2 SI = 30.0) showed signficant affinity and selectivity for the CB2 
receptor. The results presented here show that the 1-aryl-5-(1H-pyrrol-1-yl)-1H-
pyrazole-3-carboxamide may serve as an effective scaffold for the design of either 
CB1 or CB2 receptor ligands.  
 
[1] V. Di Marzo, Targeting the endocannabinoid system: to enhance or reduce? 
Nat. Rev. Drug Discov. 7, 2008, 438-455.  
[2] R.S. Padwal, S.R. Majumdar, Drug treatments for obesity: orlistat, sibutramine, 
and rimonabant, Lancet 369, 2007, 71-77. 
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Penicillamine (DL-2-amino-3-mercapto-3-methyl-butanoic acid) is a 
chelating agent derived from the hydrolysis of penicillin, lacking any antibiotic 
properties. The therapeutic form is D-penicillamine, while L-penicillamine is toxic. 
This drug is used  in the treatment of severe active rheumatoid arthritis and acts by 
reducing the number of T-lymphocytes, inhibiting macrophage function and 
preventing collagen from cross-linking. It is also used as a chelating agent in 
Wilson's disease (a rare genetic disorder of copper metabolism), in cystinuria and 
in the treatment of heavy metal poisoning [1]. 
Adverse effects are frequent and may include: membranous 
glomerulonephritis, antibody-mediated myasthenic syndrome, drug-induced 
systemic lupus erythematosus, toxic myopathies and elastosis perforans 
serpiginosa. This last one may persist even after the therapy withdrawal [2]. 
Thus, to evaluate toxic effects in clinical cases we are developing a method 
based on capillary electrophoresis coupled to laser induced fluorescence detection 
(CE-LIF) in specific biological matrices such as epithelium. 
The analysis is carried out in a fused silica capillary, using a carbonate buffer 
as the background electrolyte. Satisfactory sensitivity was obtained by exciting the 
molecule at 488 nm after a derivatisation step with 5-(iodoacetamido)fluorescein 
(IAF). Preliminary results are promising and the validation of the method is in 
progress. At the same time, we are developing another technique based on reversed 
phase liquid chromatography with amperometric detection to analyse penicillamine 
in epithelium samples. 
 
[1] S. Sweetman (Ed.), Martindale: The Complete Drug Reference Thirty-sixth 
 edition, The Pharmaceutical Press, London, 2009, 1456. 
[2]  L. Atzori, A.L. Pinna, M. Pau and N. Aste, D-penicillamine elastosis  
perforans serpiginosa: Description of two cases and review of the literature. 
Dermatol. Online J. 17, 2011, 3. 
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Piracetam is a nootropic compound which has been studied for more than four 
decades; this compound and some of its analogues are in use in several countries as 
drugs to control cognition impairment, to afford neuroprotection after stroke and to 
treat epilepsy [1]. We have previously reported about the cognition-enhancing 
properties of DM232 (unifiram), DM235 (sunifiram) and MN19 (Sapunifiram) in 
rodents [2]. DM232 shares some structural similarity with piracetam (the 2-
oxopirrolidine ring) but Unifiram, as well as its analogues DM235 and MN19, are 
3-4 orders of magnitude more potent than piracetam. These compounds are well 
tolerated in rodents, but their development has been impaired because their 
mechanism of action has not been clarified. In order to find substances with 
improved potency, and possibly to understand the mechanism of action of this class 
of compounds, we have prepared new derivatives of the lead compounds DM235 
and MN19. In a previous paper we reported that the enlargement of the piperazine 
ring of DM235 into a diazepane moiety gave derivatives displaying good 
antiamnesic and procognitive activity, with a potency similar to the parent 
compound [3]. As a continuation of this research, we have synthesized a series of 
analogues of MN19 where the piperidine ring has been contracted or enlarged into 
an azetidine, pirrolidine, azepane or azocane moiety. In addition, the piperazine 
ring of DM235 has been further expanded into a diazocane cycle. These 
compounds have been tested for their cognition-modulating activity in the mouse 
passive-avoidance test. Structure-activity relationships will be discussed in this 
presentation. 
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[1] Malykh, A. G.; Sadaie, M. R. Drugs  70, 287-312, 2010. 
[2] Romanelli M. N., et al CNS Drug Rev. 12, 39-52, 2006. 
[3] Martini E. et al. Bioorganic & Medicinal Chemistry 17,7606-7614, 2009. 
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The Embryonic Lethal Abnormal Vision (ELAV) proteins, in response to intra- and 
extra-cellular signals, preferentially interact with ARE (Adenine and Uracile-Rich 
Elements) sequences present in the 3’-untranslated region of a subset of mRNAs, 
increasing their cytoplasmatic stability and translation speed, and thus gene 
expression. The ELAV-mRNA cascade is involved in many physiological and 
pathological contexts [1-2]. Evidence in the literature indicates that the ARE-
dependent mRNA decay can be affected by the Protein Kinase C (PKC) pathway. 
Particularly, the involvement of PKC α isozyme in ELAV protein activation has 
been recently demonstrated by us [3].  
In our recent research we focused on PKC alpha ligands as positive modulators of 
ELAV-mRNA cascade. A small compounds library was designed taking into 
account the known PKC alpha ligands and  the synthetic feasibility. For all the 
synthesized compounds the ability to compete with phorbol ester for the C1 
domain of recombinant human PKC α  has been determined [4]. 
In this communication, we report on the analytical and preparative chiral 
chromatographic resolution of the most interesting compounds 1 and 2. The 
configurational assignment was then performed comparing the circular dichroism 
(CD) spectra of the pure enantiomers of 1 and 2 with (R)-Baclofen HCl spectrum.  
To gain an additional direct proof for the configuration assignment, the 
HPLC/PAD/CD analysis was also carried out using  Chirobiotic T.  
 
R
O
O
OH
1:   R=  4-benzyloxy      
2:   R= 3-benzyloxy
 
 
[1] A. Quattrone et al., Proc. Natl. Acad. Sci. USA,  98, 2001, 11668.  
[2] M. Amadio et al., J. Alzheimers Dis., 16, 2009, 409.  
[3] A. Pascale et al., Proc. Natl. Acad. Sci. U S A., 102, 2005, 12065. 
[4] A. Carnevale Baraglia et al., XX NMMC 2010, Abano Terme, Italy, Book of 
Abstracts, p88. 
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G protein-coupled receptor kinase 2 (GRK2) regulates cell signaling by promoting 
agonist-specific desensitization of several metabolism-related GPCRs, including 
the -adrenergic receptors, endothelin, and glucose-dependent insulinotropic 
polypeptides. Interestingly, GRK2 expression and function has been shown to be 
altered in several pathological conditions. Thus, the upregulation of GRK2 and 
corresponding desensitization of these metabolism-related GPCRs seem play an 
important role in the onset or progression of diseases such as heart failure, 
myocardial ischemia, hypertension and Type 2 diabetes. In these diseases, 
understanding of the molecular mechanisms leading to altered GRK2 levels, as 
well as the identification of GRK2 inhibitors is a very active field of research.  
In this communication we report the preliminary results obtained with a small 
libraries of short analogues of peptides KRX107 and  KRX124 derived from HJ loop 
of GRK2/3 [1]. 1 and 2 show a positive effect on glucose metabolism in animal 
models of Type 2 diabetes, increasing insuline sensitivity and improving glucose 
homeostasis and emerge as a valuable starting point for the development of a novel 
class of GRK2 inhibitors. 
 
 
 
 
[1] Anis Y. et al. Diabetologia, 2004, 47:1232–1244. 
 
 
 
 
 
 
 
 
 
1 KRX107 G L L R r H S 
2 KRX124 G L L R r H S I 
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Signal Transducer and Activator of Transcription 3 (STAT3) belongs to the STAT 
family of proteins, which are both signal transducers and transcription factors. 
Constitutively-active Stat 3 induces oncogenic processes, such as dysregulated 
growth, survival, angiogenesis, and immune modulation, and thereby contributes to 
malignant transformation and progression [1]. Thus,            Stat 3 is an attractive 
molecular target for the development  of novel cancer therapeutics.  
A recent study has shown that new4-thiazolidinones compounds bearing cumarin 
moiety inhibit STAT 3 pathway. 4-Thiazolidinone ring system is a core structure in 
various synthetic compounds displaying broad spectrum of biological activities, 
including an anticancer and antiproliferative effect[2].   
So in this context, drawing inspiration from literature data, we present the synthesis 
of new thiazolidinone derivatives and their biological evaluation.  
 
 
N
SO
R'R
 
 
 
 
 
[1] S. Farzana Hussain Cancer Res 2007, 67, 9630-9636 
[2]T. Tomašic and L.P. Mašic, Curr. Med. Chem. 2009, 16,1596–1629  
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Neuropeptide S (NPS) was identified as the endogenous ligand of an orphan 
receptor now referred to as NPSR. NPS injected supraspinally in rodents has been 
shown to modulate arousal, sleep-wakefulness cycle, anxiety-related behaviours 
and feeding. To identify novel NPSR ligands, structure-activity relationship studies 
were performed on the NPS sequence. In the context of such studies [D-Xaa5]NPS 
analogues were recognized as the first NPSR antagonists, among these molecules 
[tBu-D-Gly5]NPS was the most potent (pKB 7.06) [1].  
The presence of Asn4-Gly5 in the N-terminal region hints at the possibility 
for this domain to assume, in its bioactive conformation, a regular turn centered on 
Asn4-Gly5, in fact these residues are found with high frequency in position i+1 and 
i+2 respectively of many natural turns of globular proteins [2]. 
Thus, we designated NPS analogues in which Asn4 or Asn4-Gly5 was 
substituted in turn with Pro/D-Pro or Orn  in order to stabilize I, II or II’ beta turns 
centered in this position.  
The NPSR agonist and antagonist properties of these NPS analogues were 
investigated by measuring the intracellular calcium levels in response to NPS in 
cells expressing the recombinant murine receptor.  
 
[1] R. Guerrini, V. Camarda, C. Trapella, G. Caló, A. Rizzi, C. Ruzza, S. Fiorini, E. 
Marzola, R.K. Reinscheid, D. Regoli, S. Salvadori, J. Med. Chem. 52, 2009, 4068-
71. 
[2] E.G. Hutchinson, J.M. Thornton, Protein Sci. 3, 1994, 3207-16. 
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Monoamine oxidase (MAO) (EC 1.4.3.4) are a family of enzymes responsible for 
the deactivation of active monoamines such as epinephrine, norepinephrine, 
dopamine, and serotonin [1]. MAO exist as 2 isoenzymes, A and B, with different 
affinities for various amines as substrates. The activity of monoamine oxidase 
helps to maintain neuron firing rates throughout the body within homeostatic 
limits. Because of the vital role that MAO play in the inactivation of 
neurotransmitters, MAO dysfunction is thought to be responsible for a number of 
psychiatric and neurological disorders, and, as a result, MAO inhibitors (MAOi) 
are studied for the treatment of several psychiatric and neurological disorders. Part 
of the biochemical activity of monoamine oxidase generates hydroxyl radicals, 
very toxic members of the oxygen free radical group, that may be involved in 
neurodegenerative disorders such as Parkinson's disease. Therefore, MAO-B 
inhibitors are coadjutant in the treatment of Parkinson’s  diseases [2]. MAO-A 
inhibitors are used as antidepressant and anxiolytic drugs. Furthermore, the activity 
of MAO-B is enhanced by aging and in Alzheimer’s diseases patients [3]. 
Aiming at the identification of new leads for the selective inhibition of the B 
isoform of MAO, we have recently reported on the design, the synthesis, and the 
biological properties of a wide selection of differently substituted heterocyclic 
nuclei [4]. In this work we wish to present further studies on MAO inhibitors, 
particularly focusing on the structural modifications leading to an increase of 
MAO-B activity and selectivity. Thus the synthesis, the biological properties and 
the SARs of different series of 3-acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles 
and 3,5-diaryl-4,5-dihydroisoxazoles will be reported. Moreover the influence of 
stereochemistry on the activity and the selectivity towards the different enzymatic 
isoforms will be discussed. 
 
[1] Wouters, J., 1998, Curr. Med. Chem., 5, 137-162 
[2] Cesura, A.M., et al., 1992, Prog. Drug Res., 38, 171-297 
[3] Saura, J., et al., 1994, Neuroscience, 62, 15-30 
[4] Maccioni, E., et al., 2010, Eur.J.Med.Chem., 45, 4490-4498, and references 
therein cited. 
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The employment of flow chemistry [1] in the process optimization of the N-acyl 
amidation of natural and unnatural bile acids (BAs), has required the connection 
with an in-line analysis and validation method for the determination of the reaction 
yields as well as of purity grade of the synthesized glyco- and tauro-conjugated 
derivatives. In this framework, an unique HPLC method was successfully 
established and validated for chenodeoxycholic (CDCA), cholic (CA), deoxycholic 
(DCA), and ursodeoxycholic (UDCA) acids, as well as the corresponding glyco- 
and tauro-conjugated forms. Because of the shared absence of relevant 
chromophoric moieties in the sample structure, an Evaporative Light Scattering 
Detector (ELSD) [2] was profitably utilized for the analysis of such steroidal 
species. For each of the investigated compounds, all the runs were contemporarily 
carried out on the free and the two relative conjugated variants. The different ELSD 
response of the free and the corresponding conjugated BAs, imposed to build-up 
separate calibration curves. In all the cases, very good precision and accuracy 
(evaluated both in the short and long period) along with appreciably low LOD and 
LOQ values turned out.  
[1] S.V.Ley, and I.R.Baxendale, Nat.Rev.DrugDiscovery, 1, 2002, 573. 
[2] B.Natalini, R.Sardella, A.Gioiello, G.Carbone, M.Dawgul, and R.Pellicciari, 
J.Sep.Sci., 32, 2009, 2022. 
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Aldose Reductase (ALR2) is the first enzyme of the polyol pathway and catalyzes 
the NADPH-dependent reduction of glucose to sorbitol. Under hyperglycaemic 
conditions the activity of aldose reductase becomes important, triggering to the 
backlog of sorbitol. The resulting elevated concentration of this sugar increases 
cellular osmolarity and initiates a cascade of events resulting in the development of 
long term diabetic complications. ALR2 is also a key regulator of ROS signals 
induced by growth factors such as FGF, and PDGF, and cytokines such as TNF-. 
Therefore, it is clearly involved in additional pathologies such as inflammation and 
cancer. ALR2 is an excellent therapeutic target, and its inhibition represents a 
useful therapeutic tool in the treatment of different pathologies. [1, 2] 
The last class of Aldose Reductase Inhibitors (ARI) synthesized and tested in our 
laboratory is represented by a series of variously substituted benzoxadiazole 
derivatives, emerged from a virtual screening study whose lead compound is 
illustrated below. [3] 
In this communication synthesis and biological properties will be discussed. 
 
 
 
References 
[1] Ramana, K. V.; Tammali, R.; Srivastava, S. K. Mol. Cancer Ther. 2010, 9, 813-
824. [2] Ramana, K. V.; Srivastava, S. K. Int. J. Biochem. Cell. Biol. 2010, 42, 17-
20. [3] Cosconati, S.; Marinelli, L.; La Motta, C.; Sartini, S.; Da Settimo, F.; Olson, 
A. J.; Novellino, E. J. Med. Chem. 2009, 52, 5578-5581. 
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Medullary thyroid carcinoma (MTC) is a malignant endocrine tumour originating 
from parafollicular calcitonin-producing C cells. Mainly sporadic, it may be also 
present in an inherited form, accounting for up to 8% of thyroid cancers. At 
present, the treatment of choice for both forms of MTC relies in their complete 
surgical resection. However, disease can persist or recur, with local and distant 
metastases which are often fatal. The limited effectiveness of conventional 
cytotoxic agents in thyroid carcinomas suggests the need of novel therapeutic 
strategies. Recent advances in the knowledge of pathogenic mechanisms leading to 
MTC identified receptor tyrosine kinase RET as a new and promising target. ‘Gain 
of function' mutations and rearrangement of RET activate the kinase activity of the 
receptor, thus providing mitogenic and survival signals to calcitonin-producing C 
cells. As mutations of RET have been identified in about 98% of inherited MTC 
cases, at the germ-line level, and in 30% to 50% of the sporadic forms, at the 
somatic level, this protein represent a sound target for the molecular therapy of 
most people affected by MTC [1,2]. Different approaches have been considered to 
repress the kinase function of RET, the most pursued one being the use of small 
molecules able to compete with the ATP site of the catalytic domain of this 
receptor. Recently, we described a number of pyrazolo[3,4-d]pyrimidine 
derivatives as effective inhibitors of both RET and VEGFR2 [3,4]. Here we present 
the synthesis and the functional evaluation of novel compounds of the same series, 
characterized by suitable substituents in the positions 3 and 6 of the heterocyclic 
core. 
 
References 
[1] Schlumberger, M.; Carlomagno, F.; Baudin, E. et al. Nat. Clin. Pract. 
Endocrinol. Metab. 2008, 4, 22-32. [2] Santoro, M.; Carlomagno, F. Nat. Clin. 
Pract. Endocrinol. Metab. 2006, 2, 42-52. [3] Antonelli, A.; Bocci, G.; La Motta, 
C. et al. Clin. Endocrinol. Metab. 2011, 96, E288-296. [4] Bocci, G.; Fioravanti, 
A.; La Motta, C. et al. Biochem Pharmacol. 2011, 81, 1309-1316. 
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Among plants, the Lycopersicon esculentum (Solanaceae) is the most important for 
its beneficial effects on health. Several epidemiological studies have shown the 
benefits of tomato consumption in the cancer and cardiovascular disease 
prevention. 
In traditional medicine, also, the leaves of chopped tomatoes are used as a remedy 
for insect bites, against diarrhea, dysentery, gonorrhea, anal irritation and eyes 
infections. These properties could be ascribed to alpha-tomatine, contained only in 
the green part of the plant, with antibiotic, insecticide, insectifuge, fungicide and 
antibacterial properties.  
This study was aimed to evaluate the cytotoxic activity in vitro of Black Tomato 
leaves extracts (var. Paul Robenson) on human embryonic kidney (HEK-293), rat 
glioma (C6) and human breast cancer cells (MCF-7).  
Data obtained by the MTT test, showed that both hydrophilic and chloroform 
fractions exert a citotoxic activity comparable to that of cis-platinum (used as a 
reference drug) on C6 cell line. No significant activity was exerted by all three 
extracts on MCF-7 and HEK-293 cell lines. 
Regarding MCF-7, our data was in agreement with a previous study of Friedman et 
al. who demonstrate that these cells are insensitive to lower concentration of 
glycoalkaloid contained in tomato and that lower concentration of the extracts 
cause an initial increase in cell growth. Regarding HEK-293 the inactivity of our 
extract could be advantageous because these are human cell but not tumor cells. 
Further studies needed to explore these preliminary observations that indicate the 
involvement of the extracts of tomato leaves in the reduction of tumour cell 
proliferation. 
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Most anticancer drugs, both synthetic and natural, interact with DNA or its 
precursors, causing irreversible damage to DNA and inhibiting the synthesis of 
new genetic materials [1]. 9H-Carbazole is found in coal-tar creosote and exhibits a 
widespread range of applications. Several 9H-carbazole possess various 
pharmacological activities [2]. 
The aim of this work was the synthesis and the biological evaluation of a series of 
different-substituted carbazoles 2,3. Thus, the conventional methodology for 
carbazole ring construction was applied using the substituted indole 1 as a starting 
material [2]. Alkylation of the carbazole NH was gave the N-alkylated derivatives 
3 in good yields. 
The anti-proliferation activity of the carbazoles prepared was evaluated using MTT 
methodology. Thus, different concentrations of 0.1-, 1-, and 10 μM of carbazoles 2 
and 3 were tested against human breast adenocarcinoma (MCF-7) and human 
endometrial cancer Ishikawa (ISK) cell lines. 
The compounds under testing have reduced significantly the proliferation of both 
cell lines after 96h (for MCF-7 cells) and 24h (for ISK cells) treatments. 
These results indicate that these compounds could be used as a new therapeutic 
approach for the anti-proliferation treatment of the cancer. 
 
 
[1] M.K. Roy, et al., British Journal of Pharmacology 145, 2005, 145. 
[2] A. Caruso, et al., Tetrahedron 65, 2009, 10400. 
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b, Ada Popolob, Aldo Pinto b,Pasquale Longo a 
 
a Dipartimento di Chimica, Università di Salerno, Via Ponte don Melillo, 84084 
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Novel titanocene derivatives and  zirconium analogues, having cyclopentadienyl-
alcoxyde or sulfoxyde ligands, were synthesized [1,2] and fully characterized by 
NMR, FT-IR, and elemental analysis. Some of these complexes showed a good 
cytotoxic activity [3] on human breast cancer (MCF-7) cell lines and on HEK-293. 
Additionally,a study on the rate of hydrolysis of these compounds showed that the 
leaving groups significantly affect the rate of hydrolysis of cyclopentadienyl 
groups too. The different activity of synthesized compounds was tentatively related 
to the rate of hydrolysis. 
                
 
[1] H. Huang, Y. Qian, Synthesis (1987) 910-913. 
[2] A.A.H. Zeijden, C. Mattheis, R. Fröhlich, Organometallics 16 (1997) 2651-2658. 
[3] T. Mosmann, J. Immunol. Methods 65 (1983) 55-63. 
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Recently, the physiological function of hydrogen sulfide (H2S) has been discovered 
and a potential therapeutic use of this gas for the treatment of diseases 
characterized by its altered concentrations has been suggested. A possible approach 
for a therapeutic administration of H2S is represented by molecules able to release 
H2S in a controlled manner, mimicking what happens physiologically. 
Dithiolethiones have been found to behave as H2S donors in physiological 
conditions. 
N-Acetylcysteine (NAC) is under investigation as potential therapeutic agent 
against several different pathologies characterized by the occurrence of oxidative 
stress and a decrease in GSH although results deriving from large, multi-center, 
prospective clinical trials are on most case contradictory and inconclusive. It is 
possible that the scarce efficacy of NAC is due to its low oral bioavailability (about 
8%). 
We have recently observed that both dithiolethione containing molecules and the 
derivative of NAC, N-acetylcysteine ethylester (NACET) are able to significantly 
reduce circulating and tissue levels of hyperomocysteinemia (hCys), probably via 
an increase of the thiol to disulfide ratio in extracellular fluids. Mild hCys is 
considered an independent risk factor for cardiovascular and cerebrovascular 
disease. 
 Starting from these observations, we synthesized new dithiolethione–cysteine 
hybrids (ACS94, ACS96, ACS97) with the assumption that they could have 
synergic effect in reducing plasma hCys, as well (by tissue glutathione increase) 
correcting the redox imbalance process present in several diseases. 
The effects on thiols pool in different organs and in plasma, after iv or oral 
administration of  NAC (10mg/kg) or  equimolar ACS94 to healthy rats and  after 
ip administration of paracetamol (as a model of hepatic toxicity), have been 
investigated. 
The results clearly indicate that ACS94 protects from paracetamol induced hepatic 
toxicity better than NAC and that ACS94 prevents paracetamol induced thiol 
depletion in kidney and liver. In addition a more significant decrease of hCys 
compared to NAC, was observed in some rat target organs and in plasma. 
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Medicinal Chemistry, Saarland University & Helmholtz IPR, Saarland; D-66041 
Saarbrücken, Germany 
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Aromatase (AR, CYP19) is a cytochrome P450 enzyme targeted by drugs, such as 
exemestane, anastrozole and letrozole, largely used in the therapy of ER+ (estrogen 
dependent) breast cancer. Our contribution to the field was given with the design, 
synthesis, biological evaluation and modeling studies of a series of 4 (or 3)-
imidazolylmethyl-7-substituted coumarins as highly potent and selective AR 
inhibitors.[1]  
To evaluate the potential multitarget activity of our compounds of general structure 
I we decided to study their selectivity over other relevant CYPs involved in the 
biosynthesis of steroids. Representative compounds from our first reports (i.e., 
from the 7-benzyloxy and 7-aryloxy series) were selected and tested towards 
CYP11B1 (steroid 11β-hydroxylase) [2] and CYP11B2 (aldosterone synthase), [3] 
two interesting drug targets for Cushing’s syndrome or metabolic disease and for 
hyperaldosteronism, congestive heart failure and myocardial fibrosis, respectively. 
Inhibition data indicated that the lead of the benzyloxy series 
(R = OBn, R1 = H), was a strong inhibitor of both CYP19 
and CYP11B1 (IC50 = 0.150 and 0.072 µM, respectively) 
whereas a lower inhibition was observed for CYP11B2 and 
more so for CYP17 (IC50 = 0.289 µM and 3% at 2.5 µM, 
respectively).  
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N
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A similar trend was observed for most of the analyzed benzyloxy-substituted 
congeners, the most potent and selective CYP11B1 inhibitor being the 3'-
trifluoromethoxybenzyloxy derivative which exhibited an IC50 value of 5 nM. 
Preliminary structure-affinity and structure-selectivity relationships will be 
presented and discussed.  
 
[1]A. Stefanachi, A. D. Favia, O. Nicolotti, F. Leonetti, L. Pisani, Catto, M.; C. 
Zimmer, R. W. Hartmann, A. Carotti, J. Med. Chem., 54, 2011, 1613 and refs. 
therein. 
[2]U. E. Hille, C. Zimmer, C. A. Vock, R. W. Hartmann, ACS Med. Chem. Lett., 2, 
2011, 2. 
[3]M. Voets, I. Antes, C. Scherer, U. Muller-Vieira, K. Biemel, C. Barassin, S. 
Marchais-Oberwinkler, R. W. Hartmann, J. Med. Chem. 48, 2005, 6632. 
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aDipartimento di Scienze Farmaceutiche, Università degli Studi di Genova 
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*corresponding author: bruno.tasso@unige.it 
 
Recently, on the pattern of the potent and selective butyryl cholinesterase 
inhibitors ethopropazine and Astra 1397, sets of quinolizidinyl derivatives of bi- 
and mainly tricyclic systems were studied as dual or BChE selective inhibitors. All 
compounds exhibited activity against both cholinesterases, but inhibition of BChE 
was generally stronger with submicromolar IC50 values for most of them [1]. This 
study has now been extended to other cyclic structures characterized by the 
presence of a carbonyl function, as in compounds (I) or of a quinone system, as in 
naphto- (II) and anthraquinones (III): 
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These substances were studied for their inhibitory activity on both AChE and 
BChE. High selectivity against AChE was achieved in compound [II: R=Cl; 
X=(CH2)3] with IC50=12 nM, while the IC50 for BChE was 12 M. In tricyclic 
systems, either bearing to structure I or III, inhibition of BChE was prevailing. 
Most of these substances were also active in hampering the beta-amyloid 
aggregation, thus resulting endowed with a promising multitarget behaviour [2,3]. 
 
 
[1] Tasso, B.; Catto, M.; Nicolotti, O.; Novelli, F.; Tonelli, M.; Giangreco, I.; Pisani, L.;  
Sparatore, A.; Boido, V.; Carotti, A.; Sparatore, F. Quinolizidinyl derivatives of bi- and 
tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in 
Alzheimer’s disease. Eur. J. Med. Chem. 2011, 46, 2170-2184. 
[2] Pisani, L.; Catto, M.; Giangreco, I.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Cellamare, S.; 
Carotti, A. Design, Synthesis and Biological Evaluation of Coumarin Derivatives Tethered to 
an Edrophonium-like Fragment as Highly Potent and Selective Dual Binding Site 
Acetylcholinesterase Inhibitors.  ChemMedChem 2010, 5 (9), 1616-1630. 
[3] Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A.  
Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new 
drugs against neurodegenerative diseases. Submitted to Current Medicinal Chemistry. 
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Experimental data have increasingly suggested that cellular oxidative damage 
induced by reactive oxygen species (ROS) has a relevant pathophysiological role in 
several types of human diseases, such as atherosclerosis and cancer [1]. Foods, 
particularly fruits and vegetables, have an important role in maintaining 
physiological redox equilibrium. These foods supply several antioxidants, such as 
vitamin C and polyphenolic compounds, to the body. Grapes are rich in phenolic 
compounds, such as flavonoids and resveratrol, which are mainly found in red 
grape products [2]. It has been already reported that grape juice compounds can 
prevent: (i) platelet aggregation, (ii) LDL oxidation and oxidative damage to DNA, 
(iii) coronary diseases and atherosclerosis [3]. Data on the effects of thermal 
treatments and subsequent storage on polyphenolics in fruits and vegetables are 
limited. However, several studies reported that processing may result in significant 
alterations in antioxidant compounds [4], especially anthocyanins, which may 
deeply influence antioxidant capacity, color and nutritional quality of food and 
food products.  
The aim of the present study was to evaluate the polyphenolic profile and 
antioxidant activity of red grape juice before and after freeze-drying. Scientific data 
on the composition of individual polyphenols in grape juice are scarce.  
In this study the sample was compared with the best red wines in the market and 
then the antioxidant activity of red grape juice was tested by DPPH and FRAP 
assays and compared with authentic standard. The sample after lyophilization 
revealed to keep quite unchanged both the polyphenolic composition and the 
antioxidant capacity when compared with the fresh product. 
 
 
 
[1] C. Dani et al., Food and Chem. Toxicol., 45, 2007, 2574-2580. 
[2] T. Fuleki et al., J. Agric. Food Chem., 51, 2003, 640-646. 
[3] K.W. Singletary, J. Agric. Food Chem., 51, 2003, 7280-7286. 
[4] T.J. Hager et al., J. Agric. Food Chem., 56, 2008, 689-695. 
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Multidrug resistance (MDR) is one of the main obstacles in cancer therapy; it is 
due to overexpression of proteins such as ABCB1 (Pgp) and ABCC1 (MRP1) [1] 
that act as extrusion pumps causing a lower cell concentration of various anticancer 
drugs that usually are structurally and mechanistically unrelated [2]. 
Inhibition of the functions of Pgp and related proteins, is considered a suitable 
approach to circumvent MDR. This is the main reason prompting the design and 
synthesis of Pgp inhibitors to co-administrate with cytotoxic substrates of Pgp [3]. 
Recently, we have described a new family of MDR reverters, N,N-
bis(arylalkanol)amine aryl esters, endowed with fairly good potency [4]. Now we 
report an extension of structure-activity relationships and of pharmacological 
studies in this series of compounds characterized by the N,N-bis(arylalkanol)amine 
scaffold where the aromatic ester portions were suitably modulated. 
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The new compounds show good potency and efficacy and warrant further studies 
as MDR modulators. 
 
[1] A. Aszalos and D. D. Ross, Anticancer Res., 18, 1998, 2937-2944. 
[2] L.A. Mitcher, S.P. Pillai, E.J. Gentry, D.M. Shankel, Med. Res. Rev., 19,1999, 477-496. 
[3] E. Teodori, S. Dei, C. Martelli, S. Scapecchi, F. Gualtieri Curr. Drug Targets, 7, 2006, 893-909. 
[4] C. Martelli, M. Coronnello, S. Dei, D. Manetti, F. Orlandi, S. Scapecchi, M.N. Romanelli, M. 
Salerno, E. Mini, E. Teodori J. Med. Chem. 53, 2010, 1755-1762. 
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In last years nanoparticles have been generated a strong interest for their potential 
application as in vivo carriers of active principles [1]. Especially liposome display 
unique pharmacokinetic properties slowly releasing drugs loaded in the inner 
aqueous cavity. Recently we have developed supramolecular aggregates decorated 
by bioactive peptide able to recognize overexpressed receptors on tumour cells 
membrane [2]. Here we present the synthesis, the structure and the in vitro 
behaviour of liposomes obtained by co-aggregation of the DOPC phospholipid 
with a new synthetic amphiphilic molecule, NT4Lys(C18)2, which contains a lysine 
scaffold derivatized with a lipophilic moiety and a tetra-branched neurotensin 
(NT1-13) peptides or a truncated form (NT8–13). The liposome were filled with 
the cytotoxic drug doxorubicin (Doxo). The synthesis was carried out on solid 
phase following a Fmoc strategy. The size of liposome was determinated by 
Dynamic light scattering measurements which indicate a value for the 
hydrodynamic radius (RH) of 88.3 ± 4.4 nm. The selective internalization and 
cytotoxicity of liposomes as compared to pure DOPC liposomes, were tested in 
HT29 human colon adenocarcinoma and TE671 human rhabdomyosarcoma cells, 
both of which express neurotensin receptors. FACS analysis indicates an increase 
in fluorescence signal of the NT4-liposomes, in both cell lines and the cytotoxicity 
is increased four-fold with respect to DOPC. These effects could to be ascribed to 
the higher rate of internalization for DOPC-NT4Lys(C18)2-Doxo liposomes, due to 
stronger binding driven by a lower dissociation constant of the NT4-liposomes that 
bind the membrane onto a specific protein, in contrast to DOPC liposomes, which 
approach the plasma membrane unselectively. 
 
[1] Torchilin Nat Rev drug 4, 2005, 145.  
[2] A. Accardo, et al. Molecular Biosystems, 6, 2010,  878. 
 
 
 
 
 
 463 
 
FAR-PO-83 In vitro and in silico studies of polycondensed 
diazine systems as anti-infective agents  
 
M.Tutone1, A.Lauria1, A. Guarcello1, F. Mingoia2, A.M. Almerico1 
 
1Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari (STEMBIO) 
Sezione di Chimica Farmaceutica e Biologica  
Via Archirafi, 32 – 90123 Palermo  
2Istituto per lo Studio dei Materiali Nanostrutturati, CNR 
Via U. La Malfa 153  90146 Palermo 
e-mail:mtutone@unipa.it  
 
Infective diseases caused by protozoarian agents are still relevant today 
more than ever. In fact, they represent the first cause of death all over the world 
with seventeen millions victims every year. The development of drug resistance 
and the broad diffusion of these pathologies make actual the research of new 
molecules able to act as selective and effective anti-infective chemotherapics.[1]  
Recently several polycondensed 
diazine derivatives, by means 1,3-dipolar 
cycloaddition, reactions [2, 3] were 
synthesized.  
A broad selection of these 
compounds chosen with a wide pattern of 
substitutions were submitted to biological 
in vitro screening against Plasmodium 
falciparum, Leishmania Infantum, 
Trypanosoma brucei e Trypanosoma 
cruzi, and they resulted active at 
micromolar level. In order to identify 
molecular targets able to explain the 
mechanism of action of these compounds, 
we performed Induced Fit Docking/MM-GBSA modeling studies. The obtained 
results give interesting indications about the probable mechanism of action of the 
most active compounds. 
 
[1] M. Gonzaalez, H. Cerecetto, Expert Opinion on Therapeutic Patents, 21, 
2011, 699-715. 
[2] A. Lauria, A. Guarcello, G. Dattolo, A.M. Almerico, Tetrahedron Lett., 49, 
2008, 1847-1850. 
[3] A. Lauria, A. Guarcello, G. Macaluso, G. Dattolo, A.M. Almerico, 
Tetrahedron Lett., 50, 2009, 7333-7336. 
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FAR-PO-84 Development of an Efficient Continuous Flow 
Synthesis of Glyco- and Tauro-Conjugated Natural and Semi-
Synthetic Bile Acids 
Venturoni F., Gioiello A., Sardella R., Natalini, B., Pellicciari R. 
Dipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, Via del 
Liceo, 1, 06123 Perugia, Italy.  
frenz@chimfarm.unipg.it 
The successful application of flow microreactors in synthetic chemistry has soon 
attracted a considerable interest for both organic and medicinal chemists. Indeed, 
moving a reaction from batch to a continuous flow mode turns out to be asset in 
terms of yield, safety, purity, money, man power, time, scale-up and automation.[1]  
In the frame of our continuous interest in the development of new synthetic 
methodologies for the structural modification and functionalization of steroids,[2] 
we report our ongoing endeavours in the application of flow chemistry for the 
preparation of bile acid (BA) derivatives. In particular, we describe the results 
obtained with the employment of a modular flow set-up in the process optimization 
and experiment design of the N-acyl amidation of natural and unnatural BAs. After 
a microreactor assisted systematic screening of different reaction conditions, 
including solvent system, base, flow rate and temperature, the connection with an 
in-line purification method allowed us to obtain glyco- and tauro-conjugated BAs 
in high yield and purity.  
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Figure 1. Flow synthesis of conjugated BAs 
[1] (a) Microreactors in Organic Synthesis and Catalysis, Ed. T. Wirth, Wiley-
VCH: Weinheim, 2008. (b) Ley, S. V.; Baxendale, I. R. Nat. Rev. Drug Disc. 
2002, 1, 573  
[2] For recent works see: (a) Gioiello, A.; Sabbatini, P.; Rosatelli, E., 
Macchiarulo, A.; Pellicciari, R. Tetrahedron 2011, 67, 1924. (b) Sato, H.; 
Macchiarulo, A.; Thomas, C.; Gioiello, A.; Une, M.; Hofmann, A. F.; Saladin, R.; 
Schoonjans, K.; Pellicciari, R.; Auwerx, J. J. Med. Chem. 2008, 51, 1831. (c) 
Pellicciari, R.; Costantino, G.; Camaioni, E.; Sadeghpour, B. M.; Entrena, A.; 
Willson, T. M.; Fiorucci, S.; Clerici, C.; Gioiello, A. J. Med. Chem. 2004, 47, 4559. 
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PTPRJ (a receptor-type protein tyrosine phosphatase also named DEP-1, HPTPeta, 
or CD148) is of particular interest for its role in human and experimental 
tumorigenesis.  After its discovery, a consistent body of literature  showed the 
inhibiting effect of the PTPRJ on several players of the mitogenic signal in both 
normal and cancer cells. In fact, PTPRJ is able to interact and dephosphorylate 
numerous receptor tyrosine kinases (RTKs) such as PDGFR, HGFR, RET, and 
EGFR  whose aberration or overexpression in cancer cells is responsible of self-
sufficiency cell growth. The role of PTPRJ on the inhibition of RTKs was also 
extended to VEGFR, whose activity is required for the formation of new vessels in 
tumor progression (angiogenesis).[1] These findings indicate a tumor suppressor 
activity for  PTPRJ and make it  an interesting candidate for the generation of novel 
therapeutic strategies.  
In a previous study, we described the isolation and characterization of synthetic 
PTPRJ binding peptides from a combinatorial phage display library. The cyclic 
peptides 1 and 2 induced dephosphorylation  of PTPRJ targets and moderate cell 
growth inhibition in HeLa and Huvec tumor cell lines. 
 
1 [Cys-His-His-Asn-Leu-Thr-His-Ala-Cys]-OH 
2 [Cys-Leu-His-His-Tyr-His-Gly-Ser-Cys]-OH 
In this communication, we present the synthesis, the biological activities and the 
structure-activity relationships of new analogues of peptides 1 and 2 which  we 
considered as a valuable starting point for the development of a novel class of 
PTPRJ agonists. 
 
 
[1] Takamune Takahashi  et al.,  Blood, 2006, Volume 108, Number 4. 
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Ca2+ /calmodulin (CaM)-dependent protein kinase is a multifunctional Ser/Thr 
protein kinase that plays an important role in many cellular function including cell 
division, differentiation, cardiac contraction and synaptic plasticity [1]. 
Over the past decade, several CaMKII inhibitors have been reported to study 
CaMKII function. Most of these compounds showed low potency and absence of 
highly specific inhibition. In the research of major selectivity the natural CaMKII 
inhibitor protein, CaM-KIIN, provides a promising alternative, because it potently 
inhibits CaMKII but not CaMKI, CaMKIV, PKA or PKC. In previous studies 
COOH-terminal truncations of CaM-KIIN indicated that its inhibitory potency and 
activities resided largely in a 27 aminoacid residues. This peptide, named CaM-
KNtide (KRPPKLGQIGR SKRVVIEDDRIDDVLK)  showed a similar IC50 value 
(50 nM) for both the total and the Ca2+-independent CaM-KII activities.  As part of 
our current interest in the study of CaMKII-dependent cell signaling that regulates 
some many physiological function, we directed our efforts toward the identification 
of a novel peptide CaMKII inhibitors. Here,  we present   synthesis, conformational 
studies and biological evaluation of different CaM-KNtide analogues.  
 
 
[1]Tsui, J.; Inagaki, M.; Schulman, H. J Biol Chem. 2005, Mar 11, 280(10), 9210-6.  
[2]Chang B.H., Mukherji S., Soderling T.R. Proc. Natl. Acad. Sci. USA 1998, 95, 10890-10895. 
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A bifunctional molecular device is a chemical species able to perform two specific 
works at a molecular level. [1.1.1]Cryptand [1a] falls into this definition because it 
is able 1) to change slowly, in an almost linear way,[2] the pH in a reaction 
medium, working as a molecular titrator, and 2) to measure it, as a molecular pH-
meter, making it possible to carry out automatic 1H NMR reaction monitoring for 
kinetic or thermodynamic investigation, without using physical devices like 
autoburette and pH-meter. The device performs this role by means of a mechanism 
[1b] where 1) a fast and reversible protonation followed by a slow, irreversible and 
highly specific entrapping of the hydrogen ion produce the increase of pH and 2) 
the partition between unreacted protonated and deprotonated species, in fast 
equilibrium with each other, produces an averaged CH2N chemical shift linked to 
the pH by the Henderson-Hasselbalch equation (Eqn. 1). 
This kinetic molecular device (KMD), used before for spectrophotometric 
automatic titrations,[3a] can be used to carry out unprecedented 1H NMR automatic 
titrations [3b] for the determination of the pKa of molecules of pharmaceutical 
interest. In this contribution it has been used to carry out, for the first time, a 
variable-pH kinetic experiment where the hydrolysis of aspirin, a classic pH-
sensitive reaction, has been followed by 1H NMR while the pH was changing in a 
controlled way. The kinetic profile obtained has been processed using a 
mathematical model (Eqn. 2; A = 1H NMR peak area of acetylsalicylic acid) to 
obtain the entire pH-rate profile of the drug in the range explored. 
 
  
pH  pKa  log ab        (1)  
 
  
-
1
A
dA
dt
 kobs[pH(t )]         (2)
 
 
 468 
 
The bifunctionality allows to obtain a variable-pH monitoring without using an 
added molecular pH-meter. In this way the device system takes only ca. 1 ppm of 
the entire spectrum and leaves all the rest available for the reaction monitoring. 
 
[1] a) J. Cheney, J. M. Lehn, J. Chem. Soc. Chem. Commun. 1972, 487–488; b) P. B. 
Smith, J. L. Dye, J. Cheney, J. M. Lehn, J. Am. Chem. Soc. 1981, 103, 6044–6048. 
[2] a) G. Alibrandi, Angew. Chem., Int. Ed., 47, 2008, 3026–3028; b) Alibrandi, G.; Lo 
Vecchio, C.; Lando, G. Angew. Chem., Int. Ed, 121, 2009, 6450–6452. 
[3] a) Alibrandi, G.; Lo Vecchio, C.; Villari, A; Villari, I. Chem. Eur. J., 16, 2010, 
7700–7703; b) Alibrandi, G.; Arena, G. C.; Lando, G.; Lo Vecchio, C.; Parisi, F. 
M. Chem. Eur. J., 17, 2011, 1419–1422. 
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Reactive carbonyl species (RCS) are involved in the pathogenesis of several human 
diseases. Hence RCS, beside to be considered a biomarker of oxidative damage, are 
also potential targets for the development of bioactive compounds acting as 
detoxifying agents of RCS (carbonyl quenching compounds) [1]. We found that the 
natural dipeptide carnosine (-alanyl-L-histidine) is a selective and potent RCS 
sequestering agent, even if its clinical application is limited due to the rapid 
hydrolysis in blood by a specific dipeptidase (carnosinase). Consequently, we 
developed a drug discovery approach aimed to design, synthesize and evaluate 
novel CAR peptidomimetics which, beside to maintain or improve the reactivity 
and selectivity of carnosine towards RCS, are recognized by hPepT1 and hence 
transported through an active transport but not recognized by carnosinase. The 
metabolic stability of the synthesized compounds was studied by incubating them 
with rat plasma and human serum as well as with rat and human liver fractions and 
reactivity (HNE as substrate) and selectivity (pyridoxal) studied in in vitro models. 
The pharmacokinetic profile for the most promising derivative (FL-926-A16) was 
then investigated in rats and its ability to quench HNE and to reduce protein 
carbonylation and tissue damage was demonstrated in different animal models 
(db/db mouse and nApoE null mice). 
 
[1] Aldini G, Orioli M, Rossoni G, Savi F, Braidotti P, Vistoli G, Yeum KJ, 
Negrisoli G, Carini M., J Cell Mol Med, 2010, Jun 1. [Epub ahead of print]. 
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A dualistic G protein coupled receptor named GPR17, which responds to 
nucleotides and cysteinyl leukotrienes, has been recently deorphanized. GPR17 is 
believed to represent a novel target for the development of new therapeutic 
approaches to human stroke and ischemic damage. Biological studies demonstrated 
that 2-phenylethynylATP behaves as a strong agonist (EC50 = 36 pM) of this 
receptor [1]. On the other hand, N6-methylATP and some purine nucleotide 
bisphosphates showed antagonist activity. On these bases, in the search for potent 
GPR17 ligands, 2-phenylethynylATP derivatives bearing a methyl or a cyclopentyl 
group in N6-position, 2-phenylethynyl bisphosphate derivative, and a stable 
analogue of 2-phenylethynylATP were synthesized (Figure 1). [35S]GTPγS binding 
assay, performed on transfected 1321N1 cells, showed that the new compounds 
 
 
 
behave as strong agonists of GPR17 with EC50 value in the low nanomolar or 
subnanomolar range, hence they could be efficacious tools for the further 
characterization of the receptor and to study its role in neurodegeneration processes. 
 
[1] E. Calleri, S. Ceruti, G. Cristalli, C. Martini, C. Temporini, C. Parravicini, 
R. Volpini, S. Daniele, G. Caccialanza, D. Lecca, C. Lambertucci, M.L. 
Trincavelli, G. Marucci, I.W. Wainer, G. Ranghino, P. Fantucci, M.P. Abbracchio, 
G. Massolini, J. Med. Chem., 53, 2010, 3489. 
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Photodynamic therapy (PDT) is a non-invasive therapeutic modality used in a 
various number of diseases and cancer. It involves the systemic or topic 
administration of a photosensitizer, followed by irradiation with light. The 
activated photosensitizer converts oxygen to singlet oxygen and/or reactive oxygen 
species (ROS) which lead to cell death and tissue necrosis. One aim of PDT 
research is the discovery of new photosensitizers possessing minimal dark 
cytotoxicity, high photodynamic properties, improved pharmacokinetics, 
preferential retention in diseased instead of healthy tissues, chemical stability and a 
good cellular uptake [1]. 
We recently focused our efforts on pheophorbide a (Pba), a chlorophyll derivative. 
Pba is characterized by a stronger absorption between 650-700 nm, in the tissue-
penetrating wavelength range. For in vivo applications the capacity of the 
photosensitiser to reach in the diseased tissues becomes critical, in particular when 
a large peritoneal area is interested as occurring in carcinomatosis and 
sarcomatosis. 
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To improve the pharmacokinetic and the activity of the photosensitizer we 
conjugated Pba to polyethylene glycol (PEG).  
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In vivo the pharmacokinetic analysis  performed on living female C57/BL6 mice 
bearing a subcutaneous melanoma mass, showed that injected mPEG-Pba 
distributes all over the body, with an higher uptake in the tumor respect to free Pba.  
Moreover, preliminary data suggest that PEG-Pba in mice bearing B78-H1 
amelanotic melanoma  reduces the tumor growth after light activation in 
comparison with Pba. 
 
[1] Josefsen, L.B. and Boyle, R.W., 2008. Photodynamic therapy and the 
development of metal-based photosensitisers. Met. Based Drugs, 276109-276133. 
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On the basis of some substituted benzylacetamide derivatives previously 
synthesized by us [1] and gifted with excellent  activity toward 1 receptor subtype 
(best 1Ki= 0,09 nM), we synthesized a new series (1 a-o) of alkylacetamide 
derivatives in order to establish the influence of an alkyl chain, rather than an aryl 
moiety, on  1 receptor affinity of the corresponding compounds and their 
selectivity over 2 receptor subtype. 
 
N
N
RO
R' R=CH3, CH2CH3,CH2CH2CH3,
     CH2CH2CH2CH3, cyclohexyl.
R'= H, 2,4-(Cl)2, 4-Cl.1 a-o  
These compounds were synthesized as follow: 
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The preliminary displacement percentage of the compounds tested over both 
receptor subtypes showed a remarcable affinity against sigma 1 receptor (average: 
78 %) which improves with the lengthening of the alkyl side chain. On the other 
hand, the results obtained over sigma 2 subtype indicate a constant, moderate 
affinity throughout all the series (average: 35 %). The Ki values of the entire series 
will be determined. 
 
[1] E. Laurini, D Zampieri, M.G. Mamolo, L. Vio, P. Posocco, M. Fermeglia, S. Pricl, C. Zanette, 
C. Florio, XX National Meeting on Medicinal Chemistry, Abano Terme (PD), 12-16/09/2010. 
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Malaria is currently endemic in 106 countries, with an estimated 225 
million clinical cases and nearly 781,000 deaths in 2009 [1]. To date resistance has 
emerged to all common antimalarial drugs, including recently artemisinins. In this 
context a new important target for antimalarial drug design is represented by 
falcipain-2 (FP-2), a hemoglobinase of P. falciparum food vacuole [2]. FP-2 is able 
also orchestrate selective proteolytic events during the release of malaria parasite 
from human red blood cells, because of its ability to cleavate the cytoskeletal 
proteins ankyrin and the band 4.1 protein.  
In this regard our research group actively worked in the last years on the 
development of novel peptidomimetic FP-2 inhibitors, containing a 1,4-
benzodiazepine (BDZ) scaffold [3] introduced into the dipeptide sequence D-Ser-
Gly. Among all the FP-2 inhibitors synthesized, the Michael acceptor vinyl ester 1 
[4] (Figure 1) has been shown to be the most potent and selective FP-2 inhibitor. In 
order to investigate the structure-activity relationship of the lead compound 1, 
novel vinyl ester derivatives have been designed (Figure 1) [5], by introducing 
different substituents on the fused benzene ring or at C-4’ of the phenyl substituent 
on the BDZ scaffold. Additionally the 4-chloro-2-trifluoromethylphenyl group, 
linked by means of a carbamoyl moiety to the side chain of the P3 site serine, has 
been replaced with other aromatic rings or with cyclo(alkyl)groups in such a way to 
investigate the ability of the P3 pocket to accommodate groups of different size. 
Lately the methyl substituent of the parent inhibitor 1 has been replaced with an 
ethyl and isobutyl or benzyl group in order to evaluate size and characteristics of 
the P1’ liphophilic pocket. In the present work we now report docking studies in 
order to explain the different degree of biological activity of synthesized inhibitors 
as well as their reversible or irreversible inhibition mode of FP-2.  
 
 476 
 
N
H
O
O
N
N
O
N
H
O
R''' COOR
R'
R''
N
H
O
O
N
N
O
N
H
O
Cl
CF3
COOCH3
1
R=Et, i-Bu, Bn
R'=H, Cl
R''=H, Br, OCH3
R''' =4-MeO-C6H4, 
1-naphthyl,
n-C4H9, c-C6H11
 
Figure 1 
 
[1] World Malaria Report 2010 
http://www.who.int/malaria/world_malaria_report_2010/en;  
[2] S.X. Wang, K.C. Pandey, J.R. Somoza, et al. Proc. Natl. Acad. Sci. U.S.A. 
103, 2006, 11503.  
[3] N. Micale, A. P. Kozikowski, R. Ettari, S. Grasso, M. Zappalà, A. Kumar, 
M. Hanspal, J.-J. Jeong, A. H. Chishti. J. Med. Chem., 49, 2006, 3064.  
[4] R. Ettari, N. Micale, T. Schirmeister, R. Vičík, E. Nizi, M. E. Di Francesco, 
S. Grasso, M. Zappalà, J. Med. Chem., 52, 2009, 2157. 
[5] F. Bova, R. Ettari, N. Micale C. Carnovale, T. Schirmeister, C. Gelhaus, M. 
Leippe, S. Grasso, M. Zappalà. Bioorg. Med. Chem., 18, 2010, 4928. 
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Hsp90 (heat shock protein 90) is a component of a molecular chaperone 
complex, involved in the folding, maturation and stabilisation of key signalling 
molecules which control cell proliferation, survival and transformation. It works by 
a modulation of a set of cancer-associated proteins collectively referred as 
‘‘clients’’. Inhibition of Hsp90 causes simultaneous destabilization and eventual 
degradation of client proteins that result in suppression of tumor growth. This 
observation led to the idea that Hsp90 is a potential target for a new strategy in 
human cancer therapy.1 Recently, investigations on 4,5-diarylisoxazoles generated 
an important new class of Hsp90 inhibitors, and VER-52296/NVP-AUY922 is 
currently in Phase II clinical trials.2 
Here we describe a 
novel class of Hsp90 
inhibitors structurally related 
to the 3,4-isoxazolediamide 
scaffold. We have found that 
compounds possessing a 
nitrogen atom directly 
attached to the C-4 
heterocycle ring possess in 
vitro Hsp90 inhibitory 
properties comparable, and 
for some aspects better, than the structurally related 4,5-diarylisoxazole derivatives. 
Remarkable compounds from this series of diamides combine potent binding and 
cell growth inhibitory activity in both series of alkyl and aryl or heteroaryl amides, 
with IC50 in the low nanomolar level. 
 
 [1] Whitesell, L. et al. HSP90 and the chaperoning of cancer. Nat Rev Cancer 
2005, 5, 761–772. 
[2] Brough, P. A. et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential 
therapeutic agents for the treatment of cancer. J. Med. Chem., 2008, 51, 196-218. 
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A. annua was usually used to prepare a tea and if it contains effective 
amounts of artemisinin, it might be used today as a self-reliant treatment of malaria 
[1]. Artemisia annua tea has proven itself to be a very effective treatment for 
malaria in various clinical trials, but to date, his efficacy has not been investigated 
in vitro. Therefore, we have carried out a study for the evaluation of effects of A. 
annua tea on Plasmodium falciparum cultures in vitro. We also determined the 
concentration of artemisinin in herbal tea preparation.  
The compound was tested against chloroquine-sensitive D10 and 
chloroquine-resistant W2 strains of P. falciparum using the parasite lactate 
dehydrogenase assay [2]. The quantification of artemisinin in the extract of leaves 
of A. annua was obtained using an 1H NMR method. 
The in vitro tests conducted in this study confirm the clinical efficacy 
demonstrated by the tea of A. annua in vivo on both chloroquine-sensitive D10 and 
chloroquine-resistant W2 strains. The concentration of artemisinin in A. annua tea 
is lower with respect to that of pure artemisinin responsible for the same 
antimalarial activity. The artemisinin present in the tea is probably co-solubilised 
with other ingredients, some of which may also have antimalarial activity and act 
synergistically with it. The presence of other active ingredients suggests that A. 
annua is a natural artemisinin combination therapy. These compounds also merit 
further research, to see whether their presence hinders the development of parasite 
resistance compared to pure artemisinin [3]. 
 
[1]  C.H.Blanke, G.B.Naisabha, M.B.Balema, G.M.Mbaruku, L.Heide and 
M.S.Muller, Trop. Doct., 38, 2008, 113–6.  
[2]  M.T.Makler, J.M.Ries, J.A.Williams, J.E.Bamcroft, R.C.Piper, 
B.L.Gibbins, et al, Am.J.Trop.Med.Hyg., 48(6), 1993, 739-41. 
[3]  Work supported by Regione Puglia Progetto Strategico PS70. 
